School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Suresh Ramalingam MD

  • EVPHA
    Exec Dir, Winship
  • (404) 778-5378
  • ssramal@emory.edu
Head shot of Suresh Ramalingam

Overview

Board certified in medical oncology, Suresh S. Ramalingam, MD, FACP, FASCO, is nationally recognized as an investigator and a physician in the area of small cell and non-small cell lung cancer.

Dr. Ramalingam serves as executive director of Winship Cancer Institute of Emory University and associate vice president for cancer of Woodruff Health Sciences Center. He is past-president of the Georgia Society of Oncology and a member of the board of Georgia CORE. He is a Fellow of the American Society of Clinical Oncology and a Georgia Cancer Coalition Distinguished Cancer Scholar.

Dr. Ramalingam holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, and International Association of Lung Cancer Study. He plays an active role in the ECOG-ACRIN Cancer Research Group as the Chair of the Thoracic Malignancies Committee and as the Deputy Chair of Therapeutics Programs. He serves on several international, national and institutional committees. He is a member of the Medical Oncology Board Exam Committee for American Board of Internal Medicine.

Dr. Ramalingam is a graduate of Kilpauk Medical College at the University of Madras in Madras, India. He completed his residency in internal medicine at Wayne State University in Detroit, Michigan, and his fellowship in hematology and medical oncology at the University of Pittsburgh Cancer Institute in Pittsburgh, Pennsylvania.

Dr. Ramalingam's present research involves developing immune checkpoint inhibitors and improving outcomes for patients with EGFR mutation. He has conducted several phase 1, 2 and 3 clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer.

Dr. Ramalingam has authored over 300 scientific publications. He serves as editor-in-chief of CANCER, a peer-reviewed journal of the American Cancer Society.

As a physician scientist, Dr. Ramalingam has received numerous peer-reviewed grants from the National Cancer Institute. He is also the recipient of several awards including the James Eckman Award for Excellence in Teaching at Emory, ECOG-ACRIN Young Investigator Award, and NCI Cancer Clinical Investigator Team Leadership Award. He has been consistently listed as one of Atlanta's "Top Doctors" by Atlanta Magazine since 2018.

Dr. Ramalingam has been named to the MilliPub Club, which recognizes current Emory University School of Medicine faculty who have published one or more individual papers throughout their careers that have garnered more than 1,000 citations.

Academic Appointment

  • Professor, Department of Hematology-Oncology, Emory University School of Medicine, Winship Cancer Institute

Education

Degrees

  • M.B., B.S from Kilpauk Medical College University of Madras

Research

Publications

  • EGFR mutation testing across the osimertinib clinical program.
    Lung Cancer Volume: 204 Page(s): 108549
    04/18/2025 Authors: Murat-Onana ML; Ramalingam SS; Jnne PA; Gray JE; Ahn M-J; John T; Yatabe Y; Huang X; Rukazenkov Y; Javey M
  • Induction of IL6/STAT3-dependent TRAIL expression that contributes to the therapeutic efficacy of osimertinib in EGFR mutant NSCLC cells.
    Oncogene
    04/17/2025 Authors: Oh Y-T; Chen Z; Wang D; Ramalingam SS; Sun S-Y
  • A Response to the Letter to the Editor: "Equipoise Is No Longer a Major Consideration in the Ethical Evaluation ofPhase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC".
    J Thorac Oncol Volume: 20 Page(s): e53
    04/01/2025 Authors: Carlisle JW; Pentz RD; Ramalingam SS
  • Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.
    Future Oncol Volume: 21 Page(s): 1033 - 1044
    04/01/2025 Authors: de Langen AJ; Johnson ML; Mazieres J; Dingemans A-MC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F
  • Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study.
    Lung Cancer Volume: 202 Page(s): 108417
    04/01/2025 Authors: Garassino MC; He Y; Ahn M-J; Orlov SV; Potter V; Kato T; Laskin J; Voon PJ; Reungwetwattana T; Ramalingam SS
  • Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial.
    Adv Ther Volume: 42 Page(s): 1950 - 1964
    04/01/2025 Authors: Hummel H-D; Ahn M-J; Blackhall F; Reck M; Akamatsu H; Ramalingam SS; Borghaei H; Johnson M; Dirnberger F; Cocks K
  • Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer.
    Oncologist Volume: 30
    03/10/2025 Authors: von Itzstein MS; Rashdan S; Dahlberg SE; Gerber DE; Sandler AB; Schiller JH; Johnson DH; Wang Y; Sun Z; Ramalingam SS
  • Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer.
    Nat Commun Volume: 16 Page(s): 2324
    03/08/2025 Authors: Shu C; Li J; Rui J; Fan D; Niu Q; Bai R; Cicka D; Doyle S; Wahafu A; Zheng X
  • Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT).
    Lung Cancer Volume: 201 Page(s): 108100
    03/01/2025 Authors: Gridelli C; Mok T; Jnne P; Passaro A; Felip E; Ramalingam SS; Attili I; de Marinis F
  • The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Oncologist Volume: 30
    02/06/2025 Authors: Sebastian NT; Stokes WA; Behera M; Jiang R; Gutman DA; Huang Z; Burns A; Sukhatme V; Lowe MC; Ramalingam SS
  • Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking.
    Lung Cancer Volume: 200 Page(s): 108101
    02/01/2025 Authors: Reuss JE; Zaemes J; Gandhi N; Walker P; Patel SP; Xiu J; Aggarwal C; Vanderwalde A; Ramalingam SS; Halmos B
  • The changing treatment landscape of EGFR-mutant non-small-cell lung cancer.
    Nat Rev Clin Oncol Volume: 22 Page(s): 95 - 116
    02/01/2025 Authors: Zhou F; Guo H; Xia Y; Le X; Tan DSW; Ramalingam SS; Zhou C
  • Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.
    J Thorac Oncol Volume: 20 Page(s): 94 - 108
    01/01/2025 Authors: Peters S; Paz-Ares LG; Reck M; Carbone DP; Brahmer JR; Borghaei H; Lu S; O'Byrne KJ; John T; Ciuleanu T-E
  • Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer.
    Oncologist Volume: 29 Page(s): 1079 - 1089
    12/06/2024 Authors: Shaw J; Pundole X; Balasubramanian A; Anderson ES; Pastel M; Bebb DG; Jiang T; Martinez P; Ramalingam SS; Borghaei H
  • The pro-oncogenic noncanonical activity of a RASGTP:RanGAP1 complex facilitates nuclear protein export.
    Nat Cancer Volume: 5 Page(s): 1902 - 1918
    12/01/2024 Authors: Tripathi BK; Hirsh NH; Qian X; Durkin ME; Wang D; Papageorge AG; Lake R; Evrard YA; Marcus AI; Ramalingam SS
  • Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.
    Future Oncol Volume: 20 Page(s): 3355 - 3364
    12/01/2024 Authors: Ahn M-J; Cho BC; Felip E; Korantzis I; Ohashi K; Majem M; Juan-Vidal O; Handzhiev S; Izumi H; Lee J-S
  • Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
    Ann Oncol Volume: 35 Page(s): 1116 - 1125
    12/01/2024 Authors: Lu S; Ahn M-J; Reungwetwattana T; zgrolu M; Kato T; Yang JC-H; Huang M; Fujiki F; Inoue T; Quang L-V
  • Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer.
    Cancer Res Volume: 84 Page(s): 3761 - 3771
    11/15/2024 Authors: Koo J; Seong C-S; Parker RE; Herrera A; Dwivedi B; Arthur RA; Dinasarapu AR; Johnston HR; Claussen H; Tucker-Burden C
  • Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer.
    J Exp Med Volume: 221
    11/04/2024 Authors: Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun S-Y
  • Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC.
    J Thorac Oncol Volume: 19 Page(s): 1509 - 1511
    11/01/2024 Authors: Carlisle JW; Pentz RD; Ramalingam SS
  • The MARIPOSA trials - implications for the treatment of EGFR-mutant NSCLC.
    Nat Rev Clin Oncol Volume: 21 Page(s): 767 - 768
    11/01/2024 Authors: Ardeshir-Larijani F; Ramalingam SS
  • Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections.
    Clin Lung Cancer Volume: 25 Page(s): 612 - 618
    11/01/2024 Authors: Somisetty M; Mack PC; Hsu C-Y; Huang Y; Gomez JE; Rodilla AM; Cagan J; Tavolacci SC; Carreo JM; Brody R
  • Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3.
    J Thorac Oncol Volume: 19 Page(s): 1525 - 1538
    11/01/2024 Authors: Gray JE; Markovets A; Reungwetwattana T; Majem M; Nogami N; Peled N; Lee J-S; Cho BC; Chewaskulyong B; John T
  • Spatially resolved subcellular protein-protein interactomics in drug-perturbed lung-cancer cultures and tissues.
    Nat Biomed Eng
    10/30/2024 Authors: Cai S; Hu T; Venkataraman A; Rivera Moctezuma FG; Ozturk E; Zhang N; Wang M; Zvidzai T; Das S; Pillai A
  • Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. Reply.
    N Engl J Med Volume: 391 Page(s): 1555 - 1556
    10/24/2024 Authors: Lu S; Ramalingam SS
  • Direct to Cancer: A new initiative to enhance the author experience.
    Cancer Volume: 130 Page(s): 3404 - 3405
    10/15/2024 Authors: Ramalingam SS; Gilman CA
  • Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
    Lung Cancer Volume: 196 Page(s): 107935
    10/01/2024 Authors: Marks JA; Gandhi N; Halmos B; Marmarelis ME; Yeon Kim S; Bazhenova L; Ramalingam SS; Xiu J; Walker P; Oberley MJ
  • Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer.
    Adv Sci (Weinh) Volume: 11 Page(s): e2310126
    09/01/2024 Authors: Chen Z; Vallega KA; Boda VK; Quan Z; Wang D; Fan S; Wang Q; Ramalingam SS; Li W; Sun S-Y
  • Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
    N Engl J Med Volume: 391 Page(s): 585 - 597
    08/15/2024 Authors: Lu S; Kato T; Dong X; Ahn M-J; Quang L-V; Soparattanapaisarn N; Inoue T; Wang C-L; Huang M; Yang JC-H
  • Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study.
    Lung Cancer Volume: 193 Page(s): 107819
    07/01/2024 Authors: Borghaei H; Pundole X; Sangar L; Anderson E; Bebb DG; Jiang T; Pastel M; Carrigan G; Balasubramanian A; Martinez P
  • Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial.
    JTO Clin Res Rep Volume: 5 Page(s): 100685
    07/01/2024 Authors: Solomon BJ; Dagogo-Jack I; Lee S-H; Boyer MJ; Ramalingam SS; Carcereny E; Felip E; Han J-Y; Hida T; Hughes BGM
  • Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best.
    Cancer Volume: 130 Page(s): 1910 - 1912
    06/01/2024 Authors: Leal TA; Ramalingam SS
  • Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having EGFR Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer-American Society of Clinical Oncology CancerLinQ Study.
    JTO Clin Res Rep Volume: 5 Page(s): 100592
    06/01/2024 Authors: Behera M; Jiang R; Huang Z; Bunn B; Wynes MW; Switchenko J; Scagliotti GV; Belani CP; Ramalingam SS
  • Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.
    Clin Cancer Res Volume: 30 Page(s): 1833 - 1845
    05/01/2024 Authors: Mariniello A; Nasti TH; Chang DY; Hashimoto M; Malik S; McManus DT; Lee J; McGuire DJ; Cardenas MA; Umana P
  • Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
    Oncologist Volume: 29 Page(s): 342 - 349
    04/04/2024 Authors: Gerber DE; Wang Y; Ramalingam SS; Bhalla S; Sun Z; Borghaei H; Brahmer JR; Schiller JH
  • Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy.
    Trends Cancer Volume: 10 Page(s): 332 - 346
    04/01/2024 Authors: Hashimoto M; Ramalingam SS; Ahmed R
  • DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    J Clin Invest Volume: 134
    03/07/2024 Authors: Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun S-Y
  • Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.
    Clin Pharmacol Ther Volume: 115 Page(s): 349 - 360
    02/01/2024 Authors: Johnson M; Serra Traynor C; Vishwanathan K; Overend P; Hartmaier R; Markovets A; Chmielecki J; Mugundu GM; Barrett JC; Tomkinson H
  • Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.
    Future Oncol Volume: 20 Page(s): 2503 - 2508
    01/01/2024 Authors: Ramalingam SS; Carlisle JW
  • Characterisation of clinical response and transcriptional profiling of proliferating CD8 T cells in the blood of cancer patients after PD-1 monotherapy or combination therapy.
    BMJ Oncol Volume: 3 Page(s): e000328
    01/01/2024 Authors: Obeng RC; Nasti TH; Martens K; Li P; Mariniello A; Chang DY; Eberhardt CS; McGuire D; Kissick H; Daugherty C
  • Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy inVitro Diagnostic.
    J Mol Diagn Volume: 26 Page(s): 73 - 84
    01/01/2024 Authors: Gray JE; Han J-Y; Telaranta-Keerie A; Huang X; Kohlmann A; Hodge R; Rukazenkov Y; Chmielecki J; Espenschied CR; Lefterova M
  • Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.
    Future Oncol Volume: 20 Page(s): 113 - 120
    01/01/2024 Authors: Dy GK; Govindan R; Velcheti V; Falchook GS; Italiano A; Wolf J; Sacher AG; Takahashi T; Ramalingam SS; Dooms C
  • Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
    Lung Cancer Volume: 187 Page(s): 107414
    01/01/2024 Authors: Kato T; Casarini I; Cobo M; Faivre-Finn C; Hegi-Johnson F; Lu S; zgrolu M; Ramalingam SS
  • A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer.
    Future Oncol Volume: 20 Page(s): 1047 - 1055
    01/01/2024 Authors: Riely GJ; Smit EF; Ahn M-J; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E
  • Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.
    Cancer Volume: 129 Page(s): 3713 - 3723
    12/01/2023 Authors: McCall NS; Janopaul-Naylor JR; McGinnis HS; Kesarwala AH; Tian S; Stokes WA; Shelton JW; Steuer CE; Carlisle JW; Leal TA
  • Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
    N Engl J Med Volume: 389 Page(s): 2063 - 2075
    11/30/2023 Authors: Ahn M-J; Cho BC; Felip E; Korantzis I; Ohashi K; Majem M; Juan-Vidal O; Handzhiev S; Izumi H; Lee J-S
  • BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.
    NPJ Vaccines Volume: 8 Page(s): 179
    11/21/2023 Authors: Valanparambil RM; Lai L; Johns MA; Davis-Gardner M; Linderman SL; McPherson TO; Chang A; Akhtar A; Gamarra ELB; Matia H
  • Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer.
    Cancer Cell Volume: 41 Page(s): 1838 - 1840
    11/13/2023 Authors: Rodilla AM; Valanparambil RM; Mack PC; Hsu C-Y; Cagan J; Tavolacci SC; Carreo JM; Brody R; Moore A; King JC
  • Characteristics and anatomic location of PD-1+TCF1+ stem-like CD8 T cells in chronic viral infection and cancer.
    Proc Natl Acad Sci U S A Volume: 120 Page(s): e2221985120
    10/10/2023 Authors: Im SJ; Obeng RC; Nasti TH; McManus D; Kamphorst AO; Gunisetty S; Prokhnevska N; Carlisle JW; Yu K; Sica GL
  • Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
    Clin Cancer Res Volume: 29 Page(s): 3340 - 3351
    09/01/2023 Authors: Gray JE; Ahn M-J; Oxnard GR; Shepherd FA; Imamura F; Cheng Y; Okamoto I; Cho BC; Lin M-C; Wu Y-L
  • Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
    J Thorac Oncol Volume: 18 Page(s): 1055 - 1069
    08/01/2023 Authors: Reck M; Ciuleanu T-E; Lee J-S; Schenker M; Zurawski B; Kim S-W; Mahave M; Alexandru A; Peters S; Pluzanski A
  • Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK-or ROS1-Rearranged NSCLC: A Brief Report.
    JTO Clin Res Rep Volume: 4 Page(s): 100546
    08/01/2023 Authors: Thummalapalli R; Choudhury NJ; Ehrich F; Beardslee T; Brazel D; Zhang SS; Merchant S; Chen MF; Heller G; Ramalingam SS
  • Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.
    J Clin Oncol Volume: 41 Page(s): 3700 - 3711
    07/20/2023 Authors: Riely GJ; Smit EF; Ahn M-J; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E
  • Cancer Turns 75!
    Cancer Volume: 129 Page(s): 1959 - 1961
    07/01/2023 Authors: Ramalingam SS
  • Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.
    J Clin Oncol Volume: 41 Page(s): 3311 - 3317
    06/20/2023 Authors: Dy GK; Govindan R; Velcheti V; Falchook GS; Italiano A; Wolf J; Sacher AG; Takahashi T; Ramalingam SS; Dooms C
  • Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer.
    bioRxiv
    06/14/2023 Authors: Koo J; Seong C-S; Parker RE; Dwivedi B; Arthur RA; Dinasarapu AR; Johnston HR; Claussen H; Tucker-Burden C; Ramalingam SS
  • Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
    Nat Commun Volume: 14 Page(s): 3179
    06/01/2023 Authors: Chmielecki J; Gray JE; Cheng Y; Ohe Y; Imamura F; Cho BC; Lin M-C; Majem M; Shah R; Rukazenkov Y
  • Author Correction: The landscape of viral associations in human cancers.
    Nat Genet Volume: 55 Page(s): 1077
    06/01/2023 Authors: Zapatka M; Borozan I; Brewer DS; Iskar M; Grundhoff A; Alawi M; Desai N; Sltmann H; Moch H; PCAWG Pathogens
  • Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing.
    Nat Genet Volume: 55 Page(s): 1076
    06/01/2023 Authors: Corts-Ciriano I; Lee JJ-K; Xi R; Jain D; Jung YL; Yang L; Gordenin D; Klimczak LJ; Zhang C-Z; Pellman DS
  • Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers.
    Nat Genet Volume: 55 Page(s): 1078
    06/01/2023 Authors: Yuan Y; Ju YS; Kim Y; Li J; Wang Y; Yoon CJ; Yang Y; Martincorena I; Creighton CJ; Weinstein JN
  • Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer.
    Nat Genet Volume: 55 Page(s): 1079
    06/01/2023 Authors: Akdemir KC; Le VT; Chandran S; Li Y; Verhaak RG; Beroukhim R; Campbell PJ; Chin L; Dixon JR; Futreal PA
  • Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition.
    Nat Genet Volume: 55 Page(s): 1080
    06/01/2023 Authors: Rodriguez-Martin B; Alvarez EG; Baez-Ortega A; Zamora J; Supek F; Demeulemeester J; Santamarina M; Ju YS; Temes J; Garcia-Souto D
  • CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
    J Thorac Oncol Volume: 18 Page(s): 650 - 656
    05/01/2023 Authors: Kim D-W; Kim S-W; Camidge DR; Shu CA; Marrone KA; Le X; Blakely CM; Park K; Chang G-C; Patel SP
  • The Association of Improved Overall Survival with NSAIDs in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Clin Lung Cancer Volume: 24 Page(s): 287 - 294
    05/01/2023 Authors: Sebastian NT; Stokes WA; Behera M; Jiang R; Gutman DA; Huang Z; Burns A; Sukhatme V; Lowe MC; Ramalingam SS
  • Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
    Lancet Volume: 401 Page(s): 733 - 746
    03/04/2023 Authors: de Langen AJ; Johnson ML; Mazieres J; Dingemans A-MC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F
  • Engagement and outcomes of cancer patients referred to a tobacco cessation program at a National Cancer Institute-designated cancer center.
    Cancer Med Volume: 12 Page(s): 7339 - 7347
    03/01/2023 Authors: Westergaard SA; Rupji M; Franklin LE; Behera M; Ramalingam SS; Higgins KA
  • Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.
    Target Oncol Volume: 18 Page(s): 311
    03/01/2023 Authors: Popat S; Ahn M-J; Ekman S; Leighl NB; Ramalingam SS; Reungwetwattana T; Siva S; Tsuboi M; Wu Y-L; Yang JC-H
  • Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.
    Nat Commun Volume: 14 Page(s): 1071
    02/27/2023 Authors: Chmielecki J; Mok T; Wu Y-L; Han J-Y; Ahn M-J; Ramalingam SS; John T; Okamoto I; Yang JC-H; Shepherd FA
  • Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
    Nat Commun Volume: 14 Page(s): 1070
    02/27/2023 Authors: Chmielecki J; Gray JE; Cheng Y; Ohe Y; Imamura F; Cho BC; Lin M-C; Majem M; Shah R; Rukazenkov Y
  • Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
    J Clin Oncol Volume: 41 Page(s): 1200 - 1212
    02/20/2023 Authors: Brahmer JR; Lee J-S; Ciuleanu T-E; Bernabe Caro R; Nishio M; Urban L; Audigier-Valette C; Lupinacci L; Sangha R; Pluzanski A
  • Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
    Ann Oncol Volume: 34 Page(s): 173 - 185
    02/01/2023 Authors: Borghaei H; Ciuleanu T-E; Lee J-S; Pluzanski A; Caro RB; Gutierrez M; Ohe Y; Nishio M; Goldman J; Ready N
  • Author Correction: Pan-cancer analysis of whole genomes.
    Nature Volume: 614 Page(s): E39
    02/01/2023 Authors: ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium
  • Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis.
    bioRxiv
    01/27/2023 Authors: Seong C-S; Huang C; Boese AC; Hou Y; Koo J; Mouw JK; Rupji M; Joseph G; Johnston HR; Claussen H
  • mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection.
    J Clin Invest Volume: 133
    01/17/2023 Authors: Ando S; Perkins CM; Sajiki Y; Chastain C; Valanparambil RM; Wieland A; Hudson WH; Hashimoto M; Ramalingam SS; Freeman GJ
  • Impact of concomitant fibrates on immunotherapy outcomes for advanced non-small cell lung cancer.
    Cancer Med Volume: 12 Page(s): 358 - 367
    01/01/2023 Authors: Stokes WA; Behera M; Jiang R; Gutman DA; Huang Z; Burns A; Sebastian NT; Sukhatme V; Lowe MC; Ramalingam SS
  • Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
    J Thorac Oncol Volume: 18 Page(s): 79 - 92
    01/01/2023 Authors: Paz-Ares LG; Ciuleanu T-E; Pluzanski A; Lee J-S; Gainor JF; Otterson GA; Audigier-Valette C; Ready N; Schenker M; Linardou H
  • Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer.
    Expert Rev Anticancer Ther Volume: 23 Page(s): 95 - 106
    01/01/2023 Authors: Yang JC-H; Zhou C; Jnne PA; Ramalingam SS; Kim TM; Riely GJ; Spira AI; Piotrowska Z; Mekhail T; Garcia Campelo MR
  • Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.
    Target Oncol Volume: 18 Page(s): 9 - 24
    01/01/2023 Authors: Popat S; Ahn M-J; Ekman S; Leighl NB; Ramalingam SS; Reungwetwattana T; Siva S; Tsuboi M; Wu Y-L; Yang JC-H
  • Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort.
    J Clin Med Volume: 12
    12/23/2022 Authors: Garcia Campelo MR; Zhou C; Ramalingam SS; Lin HM; Kim TM; Riely GJ; Mekhail T; Nguyen D; Goodman E; Mehta M
  • EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer.
    Cell Rep Volume: 41 Page(s): 111827
    12/13/2022 Authors: Kang J; Chun J; Hwang JS; Pan C; Li J; Boese AC; Young I; Malin CM; Kang Y; Gibbons DL
  • Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes.
    Nat Commun Volume: 13 Page(s): 7566
    12/08/2022 Authors: Reyna MA; Haan D; Paczkowska M; Verbeke LPC; Vazquez M; Kahraman A; Pulido-Tamayo S; Barenboim J; Wadi L; Dhingra P
  • Author Correction: Integrative pathway enrichment analysis of multivariate omics data.
    Nat Commun Volume: 13 Page(s): 7570
    12/08/2022 Authors: Paczkowska M; Barenboim J; Sintupisut N; Fox NS; Zhu H; Abd-Rabbo D; Mee MW; Boutros PC; PCAWG Drivers and Functional Interpretation Working Group; Reimand J
  • Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower.
    Nat Commun Volume: 13 Page(s): 7571
    12/08/2022 Authors: Shuai S; PCAWG Drivers and Functional Interpretation Working Group; Gallinger S; Stein LD; PCAWG Consortium
  • Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer.
    Nat Commun Volume: 13 Page(s): 7574
    12/08/2022 Authors: Sieverling L; Hong C; Koser SD; Ginsbach P; Kleinheinz K; Hutter B; Braun DM; Corts-Ciriano I; Xi R; Kabbe R
  • Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns.
    Nat Commun Volume: 13 Page(s): 7573
    12/08/2022 Authors: Jiao W; Atwal G; Polak P; Karlic R; Cuppen E; PCAWG Tumor Subtypes and Clinical Translation Working Group; Danyi A; de Ridder J; van Herpen C; Lolkema MP
  • Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig.
    Nat Commun Volume: 13 Page(s): 7567
    12/08/2022 Authors: Rubanova Y; Shi R; Harrigan CF; Li R; Wintersinger J; Sahin N; Deshwar AG; PCAWG Evolution and Heterogeneity Working Group; Morris QD; PCAWG Consortium
  • Author Correction: Inferring structural variant cancer cell fraction.
    Nat Commun Volume: 13 Page(s): 7568
    12/08/2022 Authors: Cmero M; Yuan K; Ong CS; Schrder J; PCAWG Evolution and Heterogeneity Working Group; Corcoran NM; Papenfuss T; Hovens CM; Markowetz F; Macintyre G
  • Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours.
    Nat Commun Volume: 13 Page(s): 7569
    12/08/2022 Authors: Bhandari V; Li CH; Bristow RG; Boutros PC; PCAWG Consortium
  • Author Correction: High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations.
    Nat Commun Volume: 13 Page(s): 7572
    12/08/2022 Authors: Zhang Y; Chen F; Fonseca NA; He Y; Fujita M; Nakagawa H; Zhang Z; Brazma A; PCAWG Transcriptome Working Group; PCAWG Structural Variation Working Group
  • Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
    J Clin Oncol Volume: 40 Page(s): 3808 - 3816
    11/20/2022 Authors: Valanparambil RM; Carlisle J; Linderman SL; Akthar A; Millett RL; Lai L; Chang A; McCook-Veal AA; Switchenko J; Nasti TH
  • Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1.
    Cancer Gene Ther Volume: 29 Page(s): 1801 - 1802
    11/01/2022 Authors: Deng Y; Ma G; Vallega KA; Wang D; Wang M; Wang C; Wang S; Ramalingam SS; Sun S-Y
  • A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
    Clin Lung Cancer Volume: 23 Page(s): e400 - e404
    11/01/2022 Authors: Osta BE; Carlisle J; Steuer C; Pakkala S; Leal T; Dhodapkar M; Liu Y; Chen Z; Owonikoko T; Ramalingam S
  • A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181.
    Clin Lung Cancer Volume: 23 Page(s): 547 - 560
    11/01/2022 Authors: Varlotto JM; Sun Z; Ky B; Upshaw J; Fitzgerald TJ; Diehn M; Lovly C; Belani C; Oettel K; Masters G
  • Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1.
    Cancer Gene Ther Volume: 29 Page(s): 1558 - 1569
    11/01/2022 Authors: Deng Y; Ma G; Vallega KA; Wang D; Wang M; Wang C; Wang S; Ramalingam SS; Sun S-Y
  • PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program.
    Nature Volume: 610 Page(s): 173 - 181
    10/01/2022 Authors: Hashimoto M; Araki K; Cardenas MA; Li P; Jadhav RR; Kissick HT; Hudson WH; McGuire DJ; Obeng RC; Wieland A
  • Multiplexed protein profiling reveals spatial subcellular signaling networks.
    iScience Volume: 25 Page(s): 104980
    09/16/2022 Authors: Cai S; Hu T; Venkatesan M; Allam M; Schneider F; Ramalingam SS; Sun S-Y; Coskun AF
  • Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era.
    Radiother Oncol Volume: 174 Page(s): 133 - 140
    09/01/2022 Authors: McCall NS; McGinnis HS; Janopaul-Naylor JR; Kesarwala AH; Tian S; Stokes WA; Shelton JW; Steuer CE; Carlisle JW; Leal T
  • Spatially variant immune infiltration scoring in human cancer tissues.
    NPJ Precis Oncol Volume: 6 Page(s): 60
    09/01/2022 Authors: Allam M; Hu T; Lee J; Aldrich J; Badve SS; Gkmen-Polar Y; Bhave M; Ramalingam SS; Schneider F; Coskun AF
  • Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).
    J Immunother Cancer Volume: 10
    09/01/2022 Authors: Atkins MB; Abu-Sbeih H; Ascierto PA; Bishop MR; Chen DS; Dhodapkar M; Emens LA; Ernstoff MS; Ferris RL; Greten TF
  • MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
    J Clin Invest Volume: 132
    08/01/2022 Authors: Yan D; Huelse JM; Kireev D; Tan Z; Chen L; Goyal S; Wang X; Frye SV; Behera M; Schneider F
  • Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes.
    J Clin Oncol Volume: 40 Page(s): 2285 - 2287
    07/20/2022 Authors: Leal TA; Dahlberg SE; Ramalingam SS
  • Neoadjuvant therapy gains FDA approval in non-small cell lung cancer.
    Cell Rep Med Volume: 3 Page(s): 100691
    07/19/2022 Authors: Leal TA; Ramalingam SS
  • High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
    JTO Clin Res Rep Volume: 3 Page(s): 100328
    06/01/2022 Authors: Piper-Vallillo AJ; Rotow JK; Aredo JV; Shaverdashvili K; Luo J; Carlisle JW; Husain H; Muzikansky A; Heist RS; Rangachari D
  • Systematic discovery of mutation-directed neo-protein-protein interactions in cancer.
    Cell Volume: 185 Page(s): 1974 - 1985.e12
    05/26/2022 Authors: Mo X; Niu Q; Ivanov AA; Tsang YH; Tang C; Shu C; Li Q; Qian K; Wahafu A; Doyle SP
  • Distinct phenotypic states and spatial distribution of CD8+ Tcell clonotypes in human brain metastases.
    Cell Rep Med Volume: 3 Page(s): 100620
    05/17/2022 Authors: Sudmeier LJ; Hoang KB; Nduom EK; Wieland A; Neill SG; Schniederjan MJ; Ramalingam SS; Olson JJ; Ahmed R; Hudson WH
  • ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
    Ann Oncol Volume: 33 Page(s): 466 - 487
    05/01/2022 Authors: Passaro A; Leighl N; Blackhall F; Popat S; Kerr K; Ahn MJ; Arcila ME; Arrieta O; Planchard D; de Marinis F
  • Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).
    JAMA Oncol Volume: 8 Page(s): 717 - 728
    05/01/2022 Authors: Kehl KL; Zahrieh D; Yang P; Hillman SL; Tan AD; Sands JM; Oxnard GR; Gillaspie EA; Wigle D; Malik S
  • CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
    Clin Lung Cancer Volume: 23 Page(s): e264 - e268
    05/01/2022 Authors: De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
  • Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both.
    Oncogene Volume: 41 Page(s): 1691 - 1700
    03/01/2022 Authors: Ma G; Deng Y; Qian L; Vallega KA; Zhang G; Deng X; Owonikoko TK; Ramalingam SS; Fang DD; Zhai Y
  • Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC.
    JTO Clin Res Rep Volume: 3 Page(s): 100274
    03/01/2022 Authors: Varlotto JM; Wang Y; Sun Z; Wakelee HA; Ramalingam S; Schiller J
  • Encorafenib plus binimetinib in patients with BRAFV600-mutant non-smallcell lung cancer: phase II PHAROS study design.
    Future Oncol Volume: 18 Page(s): 781 - 791
    03/01/2022 Authors: Riely GJ; Ahn M-J; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD
  • Surgical Outcomes for Early Stage Non-small Cell Lung Cancer at Facilities With Stereotactic Body Radiation Therapy Programs.
    Chest Volume: 161 Page(s): 833 - 844
    03/01/2022 Authors: Syed YA; Stokes W; Rupji M; Liu Y; Khullar O; Sebastian N; Higgins K; Bradley JD; Curran WJ; Ramalingam S
  • First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
    J Thorac Oncol Volume: 17 Page(s): 289 - 308
    02/01/2022 Authors: Paz-Ares LG; Ramalingam SS; Ciuleanu T-E; Lee J-S; Urban L; Caro RB; Park K; Sakai H; Ohe Y; Nishio M
  • Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
    BMJ Open Volume: 12 Page(s): e057663
    01/25/2022 Authors: Kok PS; Forde PM; Hughes B; Sun Z; Brown C; Ramalingam S; Cook A; Lesterhuis WJ; Yip S; O'Byrne K
  • JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
    Cancer Volume: 128 Page(s): 65 - 74
    01/01/2022 Authors: Ramalingam SS; Thara E; Awad MM; Dowlati A; Haque B; Stinchcombe TE; Dy GK; Spigel DR; Lu S; Iyer Singh N
  • The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.
    Pharmacol Res Volume: 175 Page(s): 105998
    01/01/2022 Authors: Chen Z; Vallega KA; Chen H; Zhou J; Ramalingam SS; Sun S-Y
  • Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer.
    Front Immunol Volume: 13 Page(s): 897991
    01/01/2022 Authors: Hong DS; Gopal AK; Shoushtari AN; Patel SP; He AR; Doi T; Ramalingam SS; Patnaik A; Sandhu S; Chen Y
  • The National Cancer Act of 1971: A seminal milestone in the fight against cancer.
    Cancer Volume: 127 Page(s): 4532 - 4533
    12/15/2021 Authors: Ramalingam SS; Khuri FR
  • Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.
    Oncogene Volume: 40 Page(s): 6653 - 6665
    12/01/2021 Authors: Chen Z; Yu D; Owonikoko TK; Ramalingam SS; Sun S-Y
  • Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
    JAMA Oncol Volume: 7 Page(s): e214761
    12/01/2021 Authors: Zhou C; Ramalingam SS; Kim TM; Kim S-W; Yang JC-H; Riely GJ; Mekhail T; Nguyen D; Garcia Campelo MR; Felip E
  • Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
    J Clin Oncol Volume: 39 Page(s): 3633 - 3644
    11/10/2021 Authors: Ramalingam SS; Novello S; Guclu SZ; Bentsion D; Zvirbule Z; Szilasi M; Bernabe R; Syrigos K; Byers LA; Clingan P
  • Advances in Immunotherapy and Implications for Current Practice in Non-Small-Cell Lung Cancer.
    JCO Oncol Pract Volume: 17 Page(s): 662 - 668
    11/01/2021 Authors: Steuer CE; Ramalingam SS
  • Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
    Nat Med Volume: 27 Page(s): 1910 - 1920
    11/01/2021 Authors: Forde PM; Anagnostou V; Sun Z; Dahlberg SE; Kindler HL; Niknafs N; Purcell T; Santana-Davila R; Dudek AZ; Borghaei H
  • Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
    Cancer Lett Volume: 519 Page(s): 141 - 149
    10/28/2021 Authors: Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun S-Y
  • Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
    Mol Cancer Res Volume: 19 Page(s): 1622 - 1634
    10/01/2021 Authors: Qian G; Guo J; Vallega KA; Hu C; Chen Z; Deng Y; Wang Q; Fan S; Ramalingam SS; Owonikoko TK
  • Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
    Cancer Res Volume: 81 Page(s): 4822 - 4834
    09/15/2021 Authors: Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD-Y; Wang Q; He Y; Owonikoko TK
  • Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
    JAMA Oncol Volume: 7 Page(s): 1368 - 1377
    09/01/2021 Authors: Gettinger SN; Redman MW; Bazhenova L; Hirsch FR; Mack PC; Schwartz LH; Bradley JD; Stinchcombe TE; Leighl NB; Ramalingam SS
  • Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
    J Immunother Cancer Volume: 9
    08/01/2021 Authors: Leighl NB; Redman MW; Rizvi N; Hirsch FR; Mack PC; Schwartz LH; Wade JL; Irvin WJ; Reddy SC; Crawford J
  • Cancer matters: Now more than ever!
    Cancer Volume: 127 Page(s): 2174 - 2176
    07/01/2021 Authors: Ramalingam SS
  • Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.
    Clin Lung Cancer Volume: 22 Page(s): 371 - 375
    07/01/2021 Authors: Lu S; Casarini I; Kato T; Cobo M; zgrolu M; Hodge R; van der Gronde T; Saggese M; Ramalingam SS
  • Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
    N Engl J Med Volume: 384 Page(s): 2371 - 2381
    06/24/2021 Authors: Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F
  • Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).
    Immunotherapy Volume: 13 Page(s): 727 - 734
    06/01/2021 Authors: Sands JM; Mandrekar SJ; Kozono D; Oxnard GR; Hillman SL; Wigle DA; Govindan R; Carlisle J; Gray J; Salama JK
  • A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
    Oncologist Volume: 26 Page(s): 523 - 532
    06/01/2021 Authors: Varlotto JM; Sun Z; Ky B; Upshaw J; Katz SI; Fitzgerald TJ; Wakelee H; Diehn M; Mankoff DA; Lovely C
  • Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.
    J Thorac Oncol Volume: 16 Page(s): 960 - 967
    06/01/2021 Authors: Steuer CE; Jegede OA; Dahlberg SE; Wakelee HA; Keller SM; Tester WJ; Gandara DR; Graziano SL; Adjei AA; Butts CA
  • Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504).
    JTO Clin Res Rep Volume: 2 Page(s): 100166
    05/01/2021 Authors: Khan SA; Sun Z; Dahlberg S; Malhotra J; Keresztes R; Ikpeazu C; Ma P; Ramalingam SS; Pillai R
  • A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
    Clin Lung Cancer Volume: 22 Page(s): 170 - 177
    05/01/2021 Authors: Waqar SN; Redman MW; Arnold SM; Hirsch FR; Mack PC; Schwartz LH; Gandara DR; Stinchcombe TE; Leighl NB; Ramalingam SS
  • Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.
    Clin Lung Cancer Volume: 22 Page(s): 187 - 194.e1
    05/01/2021 Authors: Owonikoko TK; Redman MW; Byers LA; Hirsch FR; Mack PC; Schwartz LH; Bradley JD; Stinchcombe TE; Leighl NB; Al Baghdadi T
  • An expanded universe of cancer targets.
    Cell Volume: 184 Page(s): 1142 - 1155
    03/04/2021 Authors: Hahn WC; Bader JS; Braun TP; Califano A; Clemons PA; Druker BJ; Ewald AJ; Fu H; Jagu S; Kemp CJ
  • YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
    J Thorac Oncol Volume: 16 Page(s): 464 - 476
    03/01/2021 Authors: Owonikoko TK; Dwivedi B; Chen Z; Zhang C; Barwick B; Ernani V; Zhang G; Gilbert-Ross M; Carlisle J; Khuri FR
  • Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
    Target Oncol Volume: 16 Page(s): 165 - 176
    03/01/2021 Authors: Cheng Y; He Y; Li W; Zhang H-L; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X
  • Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
    Clin Cancer Res Volume: 27 Page(s): 1019 - 1028
    02/15/2021 Authors: Hellmann MD; Jnne PA; Opyrchal M; Hafez N; Raez LE; Gabrilovich DI; Wang F; Trepel JB; Lee M-J; Yuno A
  • Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Oncotarget Volume: 12 Page(s): 251 - 252
    02/02/2021 Authors: Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414).
    JTO Clin Res Rep Volume: 2 Page(s): 100104
    02/01/2021 Authors: Pillai RN; Ramalingam SS; Thayu M; Lorenzini P; Alvarez Arias DA; Moy C; Hutnick N; Knoblauch R; Feng H; Kane C
  • Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor.
    PLoS One Volume: 16 Page(s): e0254125
    01/01/2021 Authors: Huang L; Bommireddy R; Munoz LE; Guin RN; Wei C; Ruggieri A; Menon AP; Li X; Shanmugam M; Owonikoko TK
  • Discovery of Small Molecule Bak Activator for Lung Cancer Therapy.
    Theranostics Volume: 11 Page(s): 8500 - 8516
    01/01/2021 Authors: Park D; Anisuzzaman ASM; Magis AT; Chen G; Xie M; Zhang G; Behera M; Sica GL; Ramalingam SS; Owonikoko TK
  • Co-Occurrence Conundrum: Brain Metastases from Lung Adenocarcinoma, Radiation Necrosis, and Gliosarcoma.
    Case Rep Oncol Volume: 14 Page(s): 487 - 492
    01/01/2021 Authors: Qian DC; Weinberg BD; Neill SG; Goodman AL; Olson JJ; Voloschin AD; Ramalingam SS; Shu H-KG
  • Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.
    Theranostics Volume: 11 Page(s): 3964 - 3980
    01/01/2021 Authors: Zhang S; Chen Z; Shi P; Fan S; He Y; Wang Q; Li Y; Ramalingam SS; Owonikoko TK; Sun S-Y
  • Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.
    J Clin Oncol Volume: 38 Page(s): 4208 - 4218
    12/10/2020 Authors: Burns TF; Borghaei H; Ramalingam SS; Mok TS; Peters S
  • Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.
    Cancer Volume: 126 Page(s): 5040 - 5049
    12/01/2020 Authors: Nazha B; Goyal S; Chen Z; Engelhart A; Carlisle JW; Beardslee TJ; Gill H; Odikadze L; Liu Y; Mishra MK
  • Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib.
    Lung Cancer Volume: 150 Page(s): 26 - 35
    12/01/2020 Authors: Gu J; Qian L; Zhang G; Mahajan NP; Owonikoko TK; Ramalingam SS; Sun S-Y
  • Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
    Lancet Oncol Volume: 21 Page(s): 1589 - 1601
    12/01/2020 Authors: Redman MW; Papadimitrakopoulou VA; Minichiello K; Hirsch FR; Mack PC; Schwartz LH; Vokes E; Ramalingam S; Leighl N; Bradley J
  • Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
    J Immunother Cancer Volume: 8
    12/01/2020 Authors: Pakkala S; Higgins K; Chen Z; Sica G; Steuer C; Zhang C; Zhang G; Wang S; Hossain MS; Nazha B
  • Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.
    Nat Commun Volume: 11 Page(s): 6232
    11/30/2020 Authors: Bailey MH; Meyerson WU; Dursi LJ; Wang L-B; Dong G; Liang W-W; Weerasinghe A; Li S; Li Y; Kelso S
  • Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck.
    Clin Cancer Res Volume: 26 Page(s): 5860 - 5868
    11/15/2020 Authors: Shin DM; Nannapaneni S; Patel MR; Shi Q; Liu Y; Chen Z; Chen AY; El-Deiry MW; Beitler JJ; Steuer CE
  • Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell LungCancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
    Clin Lung Cancer Volume: 21 Page(s): 520 - 526
    11/01/2020 Authors: Patel JD; Lee J-W; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ
  • Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
    Ann Oncol Volume: 31 Page(s): 1536 - 1544
    11/01/2020 Authors: Papadimitrakopoulou VA; Mok TS; Han J-Y; Ahn M-J; Delmonte A; Ramalingam SS; Kim SW; Shepherd FA; Laskin J; He Y
  • Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury.
    J Thorac Oncol Volume: 15 Page(s): 1727 - 1737
    11/01/2020 Authors: Rice SJ; Hyland V; Behera M; Ramalingam SS; Bunn P; Belani CP
  • EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
    Transl Lung Cancer Res Volume: 9 Page(s): 1720 - 1723
    10/01/2020 Authors: Steuer CE; Ramalingam SS
  • Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial.
    Cancer Med Volume: 9 Page(s): 7511 - 7523
    10/01/2020 Authors: Steffen McLouth LE; Zhao F; Owonikoko TK; Feliciano JL; Mohindra NA; Dahlberg SE; Wade JL; Srkalovic G; Lash BW; Leach JW
  • Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
    Br J Cancer Volume: 123 Page(s): 1228 - 1234
    10/01/2020 Authors: Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA
  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
    N Engl J Med Volume: 383 Page(s): 1207 - 1217
    09/24/2020 Authors: Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS
  • Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.
    Nat Commun Volume: 11 Page(s): 4748
    09/21/2020 Authors: Bailey MH; Meyerson WU; Dursi LJ; Wang L-B; Dong G; Liang W-W; Weerasinghe A; Li S; Li Y; Kelso S
  • RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC.
    JTO Clin Res Rep Volume: 1 Page(s): 100050
    09/01/2020 Authors: Osta BE; Ramalingam SS
  • The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer.
    J Thorac Oncol Volume: 15 Page(s): 1434 - 1448
    09/01/2020 Authors: Smeltzer MP; Wynes MW; Lantuejoul S; Soo R; Ramalingam SS; Varella-Garcia M; Meadows Taylor M; Richeimer K; Wood K; Howell KE
  • Sex differences in oncogenic mutational processes.
    Nat Commun Volume: 11 Page(s): 4330
    08/28/2020 Authors: Li CH; Prokopec SD; Sun RX; Yousif F; Schmitz N; PCAWG Tumour Subtypes and Clinical Translation; Boutros PC; PCAWG Consortium
  • MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.
    Cancer Volume: 126 Page(s): 3788 - 3799
    08/15/2020 Authors: Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun S-Y
  • Double immune checkpoint blockade in advanced NSCLC.
    Crit Rev Oncol Hematol Volume: 152 Page(s): 102980
    08/01/2020 Authors: Mariniello A; Novello S; Scagliotti GV; Ramalingam SS
  • Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q.
    Cancer Volume: 126 Page(s): 3140 - 3150
    07/01/2020 Authors: Pedro B; Rupji M; Dwivedi B; Kowalski J; Konen JM; Owonikoko TK; Ramalingam SS; Vertino PM; Marcus AI
  • Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic.
    J Thorac Oncol Volume: 15 Page(s): 1119 - 1136
    07/01/2020 Authors: Dingemans A-MC; Soo RA; Jazieh AR; Rice SJ; Kim YT; Teo LLS; Warren GW; Xiao S-Y; Smit EF; Aerts JG
  • A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
    Clin Cancer Res Volume: 26 Page(s): 2497 - 2505
    06/01/2020 Authors: Owonikoko TK; Harvey RD; Carthon B; Chen Z; Lewis C; Collins H; Zhang C; Lawson DH; Alese OB; Bilen MA
  • Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis.
    Oncologist Volume: 25 Page(s): e964 - e975
    06/01/2020 Authors: Behera M; Steuer CE; Liu Y; Fernandez F; Fu C; Higgins KA; Gillespie TW; Pakkala S; Pillai RN; Force S
  • Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
    Mol Cancer Volume: 19 Page(s): 93
    05/20/2020 Authors: Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
  • Osimertinib in EGFR-Mutated Advanced NSCLC. Reply.
    N Engl J Med Volume: 382 Page(s): 1864 - 1865
    05/07/2020 Authors: Ramalingam SS; Soria J-C
  • Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.
    Mol Oncol Volume: 14 Page(s): 882 - 895
    04/01/2020 Authors: Zang H; Qian G; Arbiser J; Owonikoko TK; Ramalingam SS; Fan S; Sun S-Y
  • TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
    Ann Oncol Volume: 31 Page(s): 507 - 516
    04/01/2020 Authors: Oxnard GR; Yang JC-H; Yu H; Kim S-W; Saka H; Horn L; Goto K; Ohe Y; Mann H; Thress KS
  • ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Cancer Volume: 126 Page(s): 1339 - 1350
    03/15/2020 Authors: Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun S-Y
  • Reply to N. Hanna et al and L. Xie et al.
    J Clin Oncol Volume: 38 Page(s): 771 - 772
    03/01/2020 Authors: Ramalingam SS; Dahlberg SE
  • Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
    Oncologist Volume: 25 Page(s): e528 - e535
    03/01/2020 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H
  • Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med Volume: 382 Page(s): 875
    02/27/2020 Authors: Hellmann MD; Ramalingam SS
  • Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).
    J Clin Oncol Volume: 38 Page(s): 613 - 622
    02/20/2020 Authors: Pillai RN; Fennell DA; Kovcin V; Ciuleanu T-E; Ramlau R; Kowalski D; Schenker M; Yalcin I; Teofilovici F; Vukovic VM
  • Pathway and network analysis of more than 2500 whole cancer genomes.
    Nat Commun Volume: 11 Page(s): 729
    02/05/2020 Authors: Reyna MA; Haan D; Paczkowska M; Verbeke LPC; Vazquez M; Kahraman A; Pulido-Tamayo S; Barenboim J; Wadi L; Dhingra P
  • High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations.
    Nat Commun Volume: 11 Page(s): 736
    02/05/2020 Authors: Zhang Y; Chen F; Fonseca NA; He Y; Fujita M; Nakagawa H; Zhang Z; Brazma A; PCAWG Transcriptome Working Group; PCAWG Structural Variation Working Group
  • Integrative pathway enrichment analysis of multivariate omics data.
    Nat Commun Volume: 11 Page(s): 735
    02/05/2020 Authors: Paczkowska M; Barenboim J; Sintupisut N; Fox NS; Zhu H; Abd-Rabbo D; Mee MW; Boutros PC; PCAWG Drivers and Functional Interpretation Working Group; Reimand J
  • Combined burden and functional impact tests for cancer driver discovery using DriverPower.
    Nat Commun Volume: 11 Page(s): 734
    02/05/2020 Authors: Shuai S; PCAWG Drivers and Functional Interpretation Working Group; Gallinger S; Stein LD; PCAWG Consortium
  • Divergent mutational processes distinguish hypoxic and normoxic tumours.
    Nat Commun Volume: 11 Page(s): 737
    02/05/2020 Authors: Bhandari V; Li CH; Bristow RG; Boutros PC; PCAWG Consortium
  • A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns.
    Nat Commun Volume: 11 Page(s): 728
    02/05/2020 Authors: Jiao W; Atwal G; Polak P; Karlic R; Cuppen E; PCAWG Tumor Subtypes and Clinical Translation Working Group; Danyi A; de Ridder J; van Herpen C; Lolkema MP
  • Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig.
    Nat Commun Volume: 11 Page(s): 731
    02/05/2020 Authors: Rubanova Y; Shi R; Harrigan CF; Li R; Wintersinger J; Sahin N; Deshwar AG; PCAWG Evolution and Heterogeneity Working Group; Morris QD; PCAWG Consortium
  • Genomic footprints of activated telomere maintenance mechanisms in cancer.
    Nat Commun Volume: 11 Page(s): 733
    02/05/2020 Authors: Sieverling L; Hong C; Koser SD; Ginsbach P; Kleinheinz K; Hutter B; Braun DM; Corts-Ciriano I; Xi R; Kabbe R
  • Inferring structural variant cancer cell fraction.
    Nat Commun Volume: 11 Page(s): 730
    02/05/2020 Authors: Cmero M; Yuan K; Ong CS; Schrder J; PCAWG Evolution and Heterogeneity Working Group; Corcoran NM; Papenfuss T; Hovens CM; Markowetz F; Macintyre G
  • Pan-cancer analysis of whole genomes.
    Nature Volume: 578 Page(s): 82 - 93
    02/01/2020 Authors: ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium
  • Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.
    Cancer Volume: 126 Page(s): 575 - 582
    02/01/2020 Authors: Martini DJ; Kline MR; Liu Y; Shabto JM; Williams MA; Khan AI; Lewis C; Collins H; Akce M; Kissick HT
  • Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Cancer Volume: 126 Page(s): 373 - 380
    01/15/2020 Authors: Papadimitrakopoulou VA; Han J-Y; Ahn M-J; Ramalingam SS; Delmonte A; Hsia T-C; Laskin J; Kim S-W; He Y; Tsai C-M
  • Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
    N Engl J Med Volume: 382 Page(s): 41 - 50
    01/02/2020 Authors: Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B
  • Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer.
    Clin Transl Sci Volume: 13 Page(s): 41 - 46
    01/01/2020 Authors: Vishwanathan K; Cantarini M; So K; Masson E; Fetterolf J; Ramalingam SS; Harvey RD
  • Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA.
    J Thorac Oncol Volume: 15 Page(s): 138 - 143
    01/01/2020 Authors: Brown H; Vansteenkiste J; Nakagawa K; Cobo M; John T; Barker C; Kohlmann A; Todd A; Saggese M; Chmielecki J
  • Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
    Cancer Volume: 126 Page(s): 2024 - 2033
    01/01/2020 Authors: Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun S-Y
  • The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET.
    Am J Cancer Res Volume: 10 Page(s): 3316 - 3327
    01/01/2020 Authors: Yu D; Li Y; Sun KD; Gu J; Chen Z; Owonikoko TK; Ramalingam SS; Sun S-Y
  • Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
    Lung Cancer Volume: 139 Page(s): 60 - 67
    01/01/2020 Authors: Gerber DE; Camidge DR; Morgensztern D; Cetnar J; Kelly RJ; Ramalingam SS; Spigel DR; Jeong W; Scaglioni PP; Zhang S
  • Mcl-1 Interacts with Akt to Promote Lung Cancer Progression.
    Cancer Res Volume: 79 Page(s): 6126 - 6138
    12/15/2019 Authors: Chen G; Park D; Magis AT; Behera M; Ramalingam SS; Owonikoko TK; Sica GL; Ye K; Zhang C; Chen Z
  • Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
    Oncologist
    12/05/2019 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H
  • Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
    Cancer Chemother Pharmacol Volume: 84 Page(s): 1289 - 1301
    12/01/2019 Authors: Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R
  • Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
    Invest New Drugs Volume: 37 Page(s): 1198 - 1206
    12/01/2019 Authors: Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL
  • Improving outcomes for brain metastases in EGFR mutated NSCLC.
    Transl Lung Cancer Res Volume: 8 Page(s): S355 - S359
    12/01/2019 Authors: Carlisle JW; Ramalingam SS
  • Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227-part 2 final analysis
    Volume: 30 Page(s): 67 - 68
    12/01/2019 Authors: Paz-Ares L; Ciuleanu TE; Yu X; Salman P; Pluzanski A; Nagrial A; Havel L; Kowalyszyn R; Audigier-Valette C; Wu Y-L
  • Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med Volume: 381 Page(s): 2020 - 2031
    11/21/2019 Authors: Hellmann MD; Paz-Ares L; Bernabe Caro R; Zurawski B; Kim S-W; Carcereny Costa E; Park K; Alexandru A; Lupinacci L; de la Mora Jimenez E
  • Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res Volume: 25 Page(s): 6644 - 6652
    11/15/2019 Authors: Gray JE; Okamoto I; Sriuranpong V; Vansteenkiste J; Imamura F; Lee JS; Pang Y-K; Cobo M; Kasahara K; Cheng Y
  • Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: APropensity Score-Matched Analysis of the National Cancer Database.
    Clin Lung Cancer Volume: 20 Page(s): 484 - 493.e6
    11/01/2019 Authors: Tian S; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP
  • Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
    Volume: 30
    11/01/2019 Authors: Wu Y-L; Mok TSK; Han J-Y; Ahn M-J; Delmonte A; Ramalingam SS; Kim S-W; Shepherd FA; Laskin J; He Y
  • Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
    Volume: 30
    11/01/2019 Authors: Cho BC; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Lee KH; Planchard D; Vansteenkiste JF; Gray JE
  • Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response
    Volume: 14 Page(s): S1152 - S1153
    11/01/2019 Authors: Brahmer J; Horn L; Hossein B; Ramalingam S; Pluzanski A; Burgio MA; Garassino MC; Chow LQM; Gettinger S; Crino L
  • Results from the IASLC Global Survey on Molecular Testing in Lung Cancer
    Volume: 14 Page(s): S1153 - S1154
    11/01/2019 Authors: Garcia MV; Smeltzer M; Wynes M; Lantuejoul S; Soo RA; Dalurzo L; Felip E; Howell K; Kerr K; Kim E
  • The Presence of Secondary Follicles in Early Stage Lung Adenocarcinoma Reflects Disease Burden
    Volume: 14 Page(s): S1146 - S1146
    11/01/2019 Authors: Obeng R; Behera M; Owonikoko T; Pillai R; Ahmed R; Ramalingam S; Sica G
  • Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer
    Volume: 14 Page(s): S1127 - S1127
    11/01/2019 Authors: Smeltzer M; Wynes M; Lantuejoul S; Soo RA; Dalurzo L; Felip E; Hollenbeck G; Howell K; Kerr K; Kim E
  • Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
    Lancet Oncol Volume: 20 Page(s): 1395 - 1408
    10/01/2019 Authors: Antonia SJ; Borghaei H; Ramalingam SS; Horn L; De Castro Carpeo J; Pluzanski A; Burgio MA; Garassino M; Chow LQM; Gettinger S
  • Integration of Durvalumab into the Treatment of Stage III Non-Small Cell Lung Cancer: Real-World Considerations
    Volume: 14 Page(s): S588 - S589
    10/01/2019 Authors: Gorgens S; Schreibmann E; Behera M; Steuer C; Pillai R; Owonikoko T; Shelton J; Ramalingam S; Curran W; Higgins K
  • E1505: Adjuvant Chemotherapy plus /- Bevacizumab for Early Stage NSCLC: Updated Chemotherapy Subset Analysis
    Volume: 14 Page(s): S271 - S271
    10/01/2019 Authors: Wakelee H; Dahlberg S; Keller S; Tester W; Aisner S; Rothman J; Patel J; Delaune R; Mcdermott S; Shafqat A
  • The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer
    Volume: 14 Page(s): S335 - S336
    10/01/2019 Authors: Smeltzer M; Wynes M; Taylor M; Richeimer K; Wood K; Howell K; Dalurzo M; Felip E; Kerr K; Kim E
  • A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer
    Volume: 14 Page(s): S214 - S214
    10/01/2019 Authors: Bazhenova L; Redman M; Gettinger S; Hirsch FR; Mack P; Schwartz L; Gandara D; Bradley J; Stinchcombe T; Leighl N
  • The Disparity of Lung Cancer Prevention, Diagnosis and Treatment Around the World ... What Is the Role of IASLC
    Volume: 14 Page(s): S9 - S10
    10/01/2019 Authors: Ramalingam S
  • High-Grade Chemotherapy-Induced Peripheral Neuropathy (CIPN): An Analysis of ECOG-ACRIN Lung Cancer Clinical Trials
    Volume: 14 Page(s): S224 - S224
    10/01/2019 Authors: Rashdan S; Dahlberg S; Gerber D; Sandler A; Schiller J; Johnson D; Ramalingam S
  • Five-Year Overall Survival for Patients With Advanced NonSmall-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
    J Clin Oncol Volume: 37 Page(s): 2518 - 2527
    10/01/2019 Authors: Garon EB; Hellmann MD; Rizvi NA; Carcereny E; Leighl NB; Ahn M-J; Eder JP; Balmanoukian AS; Aggarwal C; Horn L
  • Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.
    J Clin Oncol Volume: 37 Page(s): 2360 - 2367
    09/10/2019 Authors: Ramalingam SS; Dahlberg SE; Belani CP; Saltzman JN; Pennell NA; Nambudiri GS; McCann JC; Winegarden JD; Kassem MA; Mohamed MK
  • Radiomic Analysis of Radiation Induced Fibrosis Following Stereotactic Body Radiation Therapy
    Volume: 105 Page(s): E505 - E506
    09/01/2019 Authors: Escott C; Madden NA; Schreibmann E; Tian S; Cassidy RJ; Sutter AI; Whitaker D; Switchenko J; Pfister NT; Xu KM
  • Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
    BMC Cancer Volume: 19 Page(s): 857
    08/29/2019 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL
  • The Immune Landscape of Cancer.
    Immunity Volume: 51 Page(s): 411 - 412
    08/20/2019 Authors: Thorsson V; Gibbs DL; Brown SD; Wolf D; Bortone DS; Ou Yang T-H; Porta-Pardo E; Gao GF; Plaisier CL; Eddy JA
  • Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced -TrCP degradation.
    Oncogene Volume: 38 Page(s): 6270 - 6282
    08/01/2019 Authors: Deng L; Qian G; Zhang S; Zheng H; Fan S; Lesinski GB; Owonikoko TK; Ramalingam SS; Sun S-Y
  • Acetylation regulates ribonucleotide reductase activity and cancer cell growth.
    Nat Commun Volume: 10 Page(s): 3213
    07/19/2019 Authors: Chen G; Luo Y; Warncke K; Sun Y; Yu DS; Fu H; Behera M; Ramalingam SS; Doetsch PW; Duong DM
  • Clinical prognostic model for older patients with advanced non-small cell lung cancer.
    J Geriatr Oncol Volume: 10 Page(s): 555 - 559
    07/01/2019 Authors: Ganti AK; Wang X; Stinchcombe TE; Wang Y; Bradley J; Cohen HJ; Kelly K; Paulus R; Ramalingam SS; Vokes EE
  • A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer.
    Cancer Volume: 125 Page(s): 2148 - 2153
    07/01/2019 Authors: Gill HS; Ramalingam SS
  • DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells.
    DNA Repair (Amst) Volume: 79 Page(s): 1 - 9
    07/01/2019 Authors: Teneng I; Picchi MA; Leng S; Dagucon CP; Ramalingam S; Tellez CS; Belinsky SA
  • Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response
    Volume: 79
    07/01/2019 Authors: Brahmer J; Borghaei H; Ramalingam SS; Horn L; Holgado E; Pluzanski A; Burgio MA; Garassino M; Chow LQ; Gettinger S
  • Identification of gene signatures associated with response in a Phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy
    Volume: 79
    07/01/2019 Authors: Ordentlich P; Wang L; Tamang D; Sullivan AH; Church SE; Rozelle D; Meyers ML; Ramalingam SS; Hellmann MD
  • Immunotherapy with TMV vaccine inhibits metastatic tumor growth in an immune checkpoint resistant murine lung cancer model
    Volume: 79
    07/01/2019 Authors: Huang HL; Bommireddy R; Munoz LE; Menon AP; Ramalingam S; Selvaraj P
  • Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
    Volume: 79
    07/01/2019 Authors: Ramalingam SS; Saka H; Ahn M-J; Yu H; Horn L; Hida T; Cantarini M; Verheijen R; Wessen J; Oxnard G
  • A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).
    Volume: 37
    05/20/2019 Authors: Bazhenova L; Redman MW; Gettinger SN; Hirsch FR; Mack PC; Schwartz LH; Gandara DR; Bradley JD; Stinchcombe T; Leighl NB
  • Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).
    Volume: 37
    05/20/2019 Authors: Waqar SN; Redman MW; Arnold SM; Hirsch FR; Mack PC; Schwartz LH; Gandara DR; Stinchcombe T; Leighl NB; Ramalingam SS
  • Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience.
    Volume: 37
    05/20/2019 Authors: Nazha B; Chen Z; Goyal S; Engelhart A; Carlisle JW; Beardslee T; Gill H; Odikadze L; Liu Y; Mishra MK
  • A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).
    Volume: 37
    05/20/2019 Authors: Owonikoko TK; Higgins KA; Chen Z; Zhang C; Pillai RN; Steuer CE; Saba NF; Pakkala S; Shin DM; Zhang G
  • Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
    J Thorac Oncol Volume: 14 Page(s): 876 - 889
    05/01/2019 Authors: El Osta B; Behera M; Kim S; Berry LD; Sica G; Pillai RN; Owonikoko TK; Kris MG; Johnson BE; Kwiatkowski DJ
  • Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
    Volume: 41 Page(s): 1490 - 1498
    05/01/2019 Authors: Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R
  • The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations.
    Transl Oncol Volume: 12 Page(s): 705 - 713
    05/01/2019 Authors: Shi P; Zhang S; Zhu L; Qian G; Ren H; Ramalingam SS; Chen M; Sun S-Y
  • Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.
    J Pharmacol Exp Ther Volume: 369 Page(s): 291 - 299
    05/01/2019 Authors: Grande E; Harvey RD; You B; Batlle JF; Galbraith H; Sarantopoulos J; Ramalingam SS; Mann H; So K; Johnson M
  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
    J Clin Oncol Volume: 37 Page(s): 992 - 1000
    04/20/2019 Authors: Ready N; Hellmann MD; Awad MM; Otterson GA; Gutierrez M; Gainor JF; Borghaei H; Jolivet J; Horn L; Mates M
  • Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
    Mol Cancer Volume: 18 Page(s): 85
    04/10/2019 Authors: Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
  • Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res Volume: 25 Page(s): 2058 - 2063
    04/01/2019 Authors: Planchard D; Boyer MJ; Lee J-S; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A
  • Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts.
    Volume: 30 Suppl 2 Page(s): ii48
    04/01/2019 Authors: Yang JC-H; Ramalingam SS; Lee CK; Kurata T; Kim D-W; John T; Nogami N; Ohe Y; Rukazenkov Y; Murphy M
  • Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.
    Am J Clin Oncol Volume: 42 Page(s): 331 - 336
    04/01/2019 Authors: Saba NF; Force S; Staley C; Fernandez F; Willingham F; Pickens A; Cardona K; Chen Z; Goff L; Cardin D
  • Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
    Lancet Respir Med Volume: 7 Page(s): 347 - 357
    04/01/2019 Authors: Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn M-J; Eder JP; Balmanoukian AS; Aggarwal C; Horn L
  • Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.
    Cancer Volume: 125 Page(s): 892 - 901
    03/15/2019 Authors: Ahn M-J; Tsai C-M; Shepherd FA; Bazhenova L; Sequist LV; Hida T; Yang JCH; Ramalingam SS; Mitsudomi T; Jnne PA
  • Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer.
    Future Oncol Volume: 15 Page(s): 805 - 816
    03/01/2019 Authors: Carlisle JW; Ramalingam SS
  • Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
    Ann Oncol Volume: 30 Page(s): 161 - 165
    02/01/2019 Authors: Peters S; Dafni U; Boyer M; De Ruysscher D; Faivre-Finn C; Felip E; Garrido P; Girard N; Guckenberger M; Haanen J
  • Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol Volume: 14 Page(s): 298 - 303
    02/01/2019 Authors: Schild SE; Fan W; Stinchcombe TE; Vokes EE; Ramalingam SS; Bradley JD; Kelly K; Pang HH; Wang X
  • A banner year for immunotherapy and targeted therapy.
    Nat Rev Clin Oncol Volume: 16 Page(s): 79 - 80
    02/01/2019 Authors: Carlisle JW; Ramalingam SS
  • Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.
    J Clin Oncol Volume: 37 Page(s): 222 - 229
    01/20/2019 Authors: Owonikoko TK; Dahlberg SE; Sica GL; Wagner LI; Wade JL; Srkalovic G; Lash BW; Leach JW; Leal TB; Aggarwal C
  • Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.
    J Thorac Oncol Volume: 14 Page(s): 99 - 106
    01/01/2019 Authors: Cho BC; Chewaskulyong B; Lee KH; Dechaphunkul A; Sriuranpong V; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C
  • The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
    Cancer Volume: 125 Page(s): 127 - 134
    01/01/2019 Authors: Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL
  • Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
    Jpn J Clin Oncol Volume: 49 Page(s): 29 - 36
    01/01/2019 Authors: Ohe Y; Imamura F; Nogami N; Okamoto I; Kurata T; Kato T; Sugawara S; Ramalingam SS; Uchida H; Hodge R
  • Repurposing Food and Drug Administration-Approved Drugs to Promote Antitumor Immunity.
    Cancer J Volume: 25 Page(s): 88 - 99
    01/01/2019 Authors: Sukhatme VV; Ramalingam SS; Ahmed R; Sukhatme VP
  • Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).
    Lancet Respir Med Volume: 6 Page(s): 915 - 924
    12/01/2018 Authors: Altorki NK; Wang X; Wigle D; Gu L; Darling G; Ashrafi AS; Landrenau R; Miller D; Liberman M; Jones DR
  • Pilot Study of Potential Activation of c-MYC by Aurora Kinase A in Everolimus-Resistant Localized Esophageal Cancer Treated with XELOX followed by Carboplatin/Radiation
    Volume: 102 Page(s): E27 - E27
    11/01/2018 Authors: Saba NF; Force S; Staley CA; Fernandez F; Willingham FF; Pickens A; Cardona K; Chen Z; Goff L; Cardin D
  • Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blocker use During Stereotactic Body Radiation Therapy Associated with Decreased Pneumonitis: A Multi-center Analysis
    Volume: 102 Page(s): E680 - E681
    11/01/2018 Authors: Escott C; Cassidy RJ; Tian S; Switchenko J; Pfister NT; Xu KM; Patel PR; Eaton BR; Force S; Ramalingam S
  • Report of Neurotoxicity after Concurrent Whole Brain Radiation Therapy and Checkpoint Blockade Immunotherapy for Patients with Brain Metastases
    Volume: 102 Page(s): E340 - E340
    11/01/2018 Authors: Press RH; Buchwald ZS; Steuer C; Pillai R; Owonikoko TK; Ramalingam S; Curran WJ; Higgins KA
  • Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.
    Cell Rep Volume: 25 Page(s): 1304 - 1317.e5
    10/30/2018 Authors: Wang Y; Xu X; Maglic D; Dill MT; Mojumdar K; Ng PK-S; Jeong KJ; Tsang YH; Moreno D; Bhavana VH
  • A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- Superfamily.
    Cell Syst Volume: 7 Page(s): 422 - 437.e7
    10/24/2018 Authors: Korkut A; Zaidi S; Kanchi RS; Rao S; Gough NR; Schultz A; Li X; Lorenzi PL; Berger AC; Robertson G
  • Debate 1: Chemotherapy Will Become a Thing of the past in the Management of Advanced NSCLC - For
    Volume: 13 Page(s): S246 - S247
    10/01/2018 Authors: Ramalingam S
  • Evolving Immunotherapy Practice Patterns in Advanced NSCLC: Analysis of an Online Treatment Decision Tool
    Volume: 13 Page(s): S421 - S421
    10/01/2018 Authors: Gandara D; Quill T; Edelman M; Ramalingam S; Wakelee H; Fea H; Obholz K
  • Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report from ALCHEMIST (Alliance A151216)
    Volume: 13 Page(s): S646 - S647
    10/01/2018 Authors: Oxnard G; Mandrekar S; Hillman S; Tan A; Govindan R; Wigle D; Malik S; Watt C; Gerber D; Chaft J
  • PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial
    Volume: 13 Page(s): S408 - S408
    10/01/2018 Authors: Brown H; Vansteenkiste J; Nakagawa K; Cobo Dols M; John T; Barker C; Kohlmann A; Todd A; Saggese M; Chmielecki J
  • Osimertinib Maintenance After Definitive Chemoradiation in Patients with Unresectable EGFRm-Positive Stage III NSCLC (LAURA)
    Volume: 13 Page(s): S497 - S497
    10/01/2018 Authors: Shun L; Nash T; Saggese M; Mann H; Ramalingam S
  • Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO).
    Volume: 29 Suppl 8 Page(s): viii42
    10/01/2018 Authors: Bilen MA; Martini DJ; Shabto JM; Liu Y; Khan AI; Williams MA; Lewis C; Collins HH; Kissick H; Carthon BC
  • Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study.
    Volume: 29 Suppl 8 Page(s): viii741
    10/01/2018 Authors: Papadimitrakopoulou VA; Wu Y-L; Han J-Y; Ahn M-J; Ramalingam SS; John T; Okamoto I; Yang JC-H; Bulusu KC; Laus G
  • SLFN11 Expression and Efficacy of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study
    Volume: 13 Page(s): S972 - S972
    10/01/2018 Authors: Owonikoko T; Dahlberg S; Sica G; Poirier J; Byers L; Rudin C; Wistuba I; Ramalingam S
  • CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC.
    Volume: 29 Suppl 8 Page(s): viii544 - viii545
    10/01/2018 Authors: Gettinger S; Beck T; Yang X; Telivala B; Morgensztern D; Velcheti V; Ramalingam SS; Schalper K; Dajee M; Ranck A
  • Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study.
    Volume: 29 Suppl 8 Page(s): viii740
    10/01/2018 Authors: Ramalingam SS; Cheng Y; Zhou C; Ohe Y; Imamura F; Cho BC; Lin M-C; Majem M; Shah R; Rukazenkov Y
  • Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC
    Volume: 13 Page(s): S507 - S508
    10/01/2018 Authors: Zhou C; Cheng Y; He Y; Li W; Zhang H; Zhou Q; Wang B; Liu C; Ramalingam S; Walding A
  • E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC
    Volume: 13 Page(s): S370 - S370
    10/01/2018 Authors: Patel J; Lee J; Wagner H; Carbone D; Shanker A; Horn L; Johnson M; Gerben D; Liu JJ; Das M
  • Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).
    Ann Oncol Volume: 29 Suppl 8 Page(s): viii433
    10/01/2018 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins HH; Akce M; Kissick H; Carthon BC; Shaib WL
  • Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Volume: 29 Suppl 8 Page(s): viii519
    10/01/2018 Authors: Plummer R; Cook N; Arkenau T; Melear J; Redfern C; Spira AI; Chung K; Haddad T; Ramalingam SS; Wesolowski R
  • Radiation Therapy Is Associated With an Increased Incidence of Cardiac Events in Patients with Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys Volume: 102 Page(s): 383 - 390
    10/01/2018 Authors: Ferris MJ; Jiang R; Behera M; Ramalingam SS; Curran WJ; Higgins KA
  • CheckMate 227: Nivolumab plus Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden
    Volume: 13 Page(s): S152 - S153
    09/01/2018 Authors: Mathias C; Reck M; Hellmann M; Ramalingam S; Brahmer J; O'Byrne K; Bhagavatheeswaran P; Nathan F; Borghaei H; Paz-Ares L
  • Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
    Cancer Volume: 124 Page(s): 3586 - 3595
    09/01/2018 Authors: Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS
  • Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers.
    Lung Cancer Volume: 123 Page(s): 99 - 106
    09/01/2018 Authors: Tessema M; Rossi MR; Picchi MA; Yingling CM; Lin Y; Ramalingam SS; Belinsky SA
  • Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy.
    Clin Lung Cancer Volume: 19 Page(s): 377 - 386
    09/01/2018 Authors: Shukla ND; Salahudeen AA; Taylor GA; Ramalingam SS; Vokes EE; Goss GD; Decker RH; Kelly K; Scagliotti GV; Mok TS
  • CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol Page(s): JCO2018783118
    08/28/2018 Authors: Reungwetwattana T; Nakagawa K; Cho BC; Cobo M; Cho EK; Bertolini A; Bohnet S; Zhou C; Lee KH; Nogami N
  • Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.
    Cancer Cell Volume: 34 Page(s): 211 - 224.e6
    08/13/2018 Authors: Kahles A; Lehmann K-V; Toussaint NC; Hser M; Stark SG; Sachsenberg T; Stegle O; Kohlbacher O; Sander C; Cancer Genome Atlas Research Network
  • Personalized therapy for lung cancer: striking a moving target.
    JCI Insight Volume: 3
    08/09/2018 Authors: Pakkala S; Ramalingam SS
  • Comprehensive Characterization of Cancer Driver Genes and Mutations.
    Cell Volume: 174 Page(s): 1034 - 1035
    08/09/2018 Authors: Bailey MH; Tokheim C; Porta-Pardo E; Sengupta S; Bertrand D; Weerasinghe A; Colaprico A; Wendl MC; Kim J; Reardon B
  • Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
    Ann Oncol Volume: 29 Page(s): 1701 - 1709
    08/01/2018 Authors: Bonomi PD; Gandara D; Hirsch FR; Kerr KM; Obasaju C; Paz-Ares L; Bellomo C; Bradley JD; Bunn PA; Culligan M
  • Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for StageIIINSCLC.
    J Thorac Oncol Volume: 13 Page(s): 1171 - 1182
    08/01/2018 Authors: Schild SE; Pang HH; Fan W; Stinchcombe TE; Vokes EE; Ramalingam SS; Bradley JD; Kelly K; Wang X
  • Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.
    Clin Lung Cancer Volume: 19 Page(s): 331 - 339
    07/01/2018 Authors: Hirsch FR; Kerr KM; Bunn PA; Kim ES; Obasaju C; Prol M; Bonomi P; Bradley JD; Gandara D; Jett JR
  • Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO)
    Volume: 78
    07/01/2018 Authors: Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai R
  • Targeting Mcl-1 enhances DNA replication stress sensitivity for cancer therapy
    Volume: 78
    07/01/2018 Authors: Chen G; Magis A; Xu K; Park D; Yu D; Owonikoko T; Sica G; Satola S; Ramalingam S; Curran W
  • The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
    Cell Rep Volume: 23 Page(s): 3698
    06/19/2018 Authors: Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R
  • Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
    N Engl J Med Volume: 378 Page(s): 2093 - 2104
    05/31/2018 Authors: Hellmann MD; Ciuleanu T-E; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P
  • Safety and efficacy of combining pembrolizmumab and dose escalation/fraction de-escalation SRS for melanoma and NSCLC brain metastasis: Preliminary results from arm a of a prospective pilot trial.
    Volume: 36
    05/20/2018 Authors: Khan MK; Nasti T; Masoumy L; Kamphorst AO; Yushak MI; Owonikoko TK; Kudchadkar RR; Ramalingam SS; Lawson DH; Ahmed R
  • Overexpression of the base excision repair NTHL1 glycosylase causes genomic instability and early cellular hallmarks of cancer.
    Nucleic Acids Res Volume: 46 Page(s): 4515 - 4532
    05/18/2018 Authors: Limpose KL; Trego KS; Li Z; Leung SW; Sarker AH; Shah JA; Ramalingam SS; Werner EM; Dynan WS; Cooper PK
  • Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
    Clin Lung Cancer Volume: 19 Page(s): 270 - 279.e3
    05/01/2018 Authors: Ramalingam SS; Prol M; Reck M; Kowalyszyn RD; Gautschi O; Kimmich M; Cho EK; Czyzewicz G; Grigorescu A; Karaseva N
  • Efficacy of immunotherapy approaches in metastatic and non-metastatic lung cancer models
    Volume: 200
    05/01/2018 Authors: Bommireddy R; Menon AP; Munoz LE; Huang L; Kim J; Kumar J; Lakshmanan R; Ramalingam SS; Selvaraj P
  • The Immune Landscape of Cancer.
    Immunity Volume: 48 Page(s): 812 - 830.e14
    04/17/2018 Authors: Thorsson V; Gibbs DL; Brown SD; Wolf D; Bortone DS; Ou Yang T-H; Porta-Pardo E; Gao GF; Plaisier CL; Eddy JA
  • Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.
    Cancer Cell Volume: 33 Page(s): 721 - 735.e8
    04/09/2018 Authors: Liu Y; Sethi NS; Hinoue T; Schneider BG; Cherniack AD; Sanchez-Vega F; Seoane JA; Farshidfar F; Bowlby R; Islam M
  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy.
    Cancer Cell Volume: 33 Page(s): 676 - 689.e3
    04/09/2018 Authors: Taylor AM; Shih J; Ha G; Gao GF; Zhang X; Berger AC; Schumacher SE; Wang C; Hu H; Liu J
  • lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.
    Cancer Cell Volume: 33 Page(s): 706 - 720.e9
    04/09/2018 Authors: Wang Z; Yang B; Zhang M; Guo W; Wu Z; Wang Y; Jia L; Li S; Cancer Genome Atlas Research Network; Xie W
  • A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
    Cancer Cell Volume: 33 Page(s): 690 - 705.e9
    04/09/2018 Authors: Berger AC; Korkut A; Kanchi RS; Hegde AM; Lenoir W; Liu W; Liu Y; Fan H; Shen H; Ravikumar V
  • Oncogenic Signaling Pathways in The Cancer Genome Atlas.
    Cell Volume: 173 Page(s): 321 - 337.e10
    04/05/2018 Authors: Sanchez-Vega F; Mina M; Armenia J; Chatila WK; Luna A; La KC; Dimitriadoy S; Liu DL; Kantheti HS; Saghafinia S
  • An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
    Cell Volume: 173 Page(s): 400 - 416.e11
    04/05/2018 Authors: Liu J; Lichtenberg T; Hoadley KA; Poisson LM; Lazar AJ; Cherniack AD; Kovatich AJ; Benz CC; Levine DA; Lee AV
  • Comprehensive Characterization of Cancer Driver Genes and Mutations.
    Cell Volume: 173 Page(s): 371 - 385.e18
    04/05/2018 Authors: Bailey MH; Tokheim C; Porta-Pardo E; Sengupta S; Bertrand D; Weerasinghe A; Colaprico A; Wendl MC; Kim J; Reardon B
  • Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.
    Cell Volume: 173 Page(s): 338 - 354.e15
    04/05/2018 Authors: Malta TM; Sokolov A; Gentles AJ; Burzykowski T; Poisson L; Weinstein JN; Kamiska B; Huelsken J; Omberg L; Gevaert O
  • A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.
    Cell Volume: 173 Page(s): 386 - 399.e12
    04/05/2018 Authors: Chen H; Li C; Peng X; Zhou Z; Weinstein JN; Cancer Genome Atlas Research Network; Liang H
  • Pathogenic Germline Variants in 10,389 Adult Cancers.
    Cell Volume: 173 Page(s): 355 - 370.e14
    04/05/2018 Authors: Huang K-L; Mashl RJ; Wu Y; Ritter DI; Wang J; Oh C; Paczkowska M; Reynolds S; Wyczalkowski MA; Oak N
  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
    Cell Volume: 173 Page(s): 291 - 304.e6
    04/05/2018 Authors: Hoadley KA; Yau C; Hinoue T; Wolf DM; Lazar AJ; Drill E; Shen R; Taylor AM; Cherniack AD; Thorsson V
  • Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.
    Cell Volume: 173 Page(s): 305 - 320.e10
    04/05/2018 Authors: Ding L; Bailey MH; Porta-Pardo E; Thorsson V; Colaprico A; Bertrand D; Gibbs DL; Weerasinghe A; Huang K-L; Tokheim C
  • Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.
    Cell Rep Volume: 23 Page(s): 282 - 296.e4
    04/03/2018 Authors: Seiler M; Peng S; Agrawal AA; Palacino J; Teng T; Zhu P; Smith PG; Cancer Genome Atlas Research Network; Buonamici S; Yu L
  • Systematic Analysis of Splice-Site-Creating Mutations in Cancer.
    Cell Rep Volume: 23 Page(s): 270 - 281.e3
    04/03/2018 Authors: Jayasinghe RG; Cao S; Gao Q; Wendl MC; Vo NS; Reynolds SM; Zhao Y; Climente-Gonzlez H; Chai S; Wang F
  • Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
    Cell Rep Volume: 23 Page(s): 239 - 254.e6
    04/03/2018 Authors: Knijnenburg TA; Wang L; Zimmermann MT; Chambwe N; Gao GF; Cherniack AD; Fan H; Shen H; Way GP; Greene CS
  • Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.
    Cell Rep Volume: 23 Page(s): 172 - 180.e3
    04/03/2018 Authors: Way GP; Sanchez-Vega F; La K; Armenia J; Chatila WK; Luna A; Sander C; Cherniack AD; Mina M; Ciriello G
  • The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
    Cell Rep Volume: 23 Page(s): 313 - 326.e5
    04/03/2018 Authors: Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R
  • Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.
    Cell Rep Volume: 23 Page(s): 213 - 226.e3
    04/03/2018 Authors: Ge Z; Leighton JS; Wang Y; Peng X; Chen Z; Chen H; Sun Y; Yao F; Li J; Zhang H
  • Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.
    Cell Rep Volume: 23 Page(s): 297 - 312.e12
    04/03/2018 Authors: Chiu H-S; Somvanshi S; Patel E; Chen T-W; Singh VP; Zorman B; Patil SL; Pan Y; Chatterjee SS; Cancer Genome Atlas Research Network
  • Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
    Cell Rep Volume: 23 Page(s): 227 - 238.e3
    04/03/2018 Authors: Gao Q; Liang W-W; Foltz SM; Mutharasu G; Jayasinghe RG; Cao S; Liao W-W; Reynolds SM; Wyczalkowski MA; Yao L
  • Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.
    Cell Rep Volume: 23 Page(s): 255 - 269.e4
    04/03/2018 Authors: Peng X; Chen Z; Farshidfar F; Xu X; Lorenzi PL; Wang Y; Cheng F; Tan L; Mojumdar K; Du D
  • Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
    Cell Rep Volume: 23 Page(s): 194 - 212.e6
    04/03/2018 Authors: Campbell JD; Yau C; Bowlby R; Liu Y; Brennan K; Fan H; Taylor AM; Wang C; Walter V; Akbani R
  • A pooled analysis of radiotherapy dose & targeting strategies for stage 3 non-small cell lung cancer
    Volume: 127 Page(s): S253 - S253
    04/01/2018 Authors: Schild S; Fan W; Stinchcombe T; Vokes E; Ramalingam S; Bradley J; Kelly K; Pang H; Wang X
  • Throwing More Cold Water on Heat Shock Protein 90 Inhibitors in NSCLC.
    J Thorac Oncol Volume: 13 Page(s): 473 - 474
    04/01/2018 Authors: Pillai RN; Ramalingam SS
  • Impact of a Non-small Cell Lung Cancer Educational Program for Interdisciplinary Teams.
    Chest Volume: 153 Page(s): 876 - 887
    04/01/2018 Authors: Murgu S; Rabito R; Lasko G; Jackson C; Mino-Kenudson M; Ettinger DS; Ramalingam SS; Edell ES; GAIN collaborators
  • Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med Volume: 378 Page(s): 1262 - 1263
    03/29/2018 Authors: Soria J-C; Ramalingam SS
  • Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.
    Cell Syst Volume: 6 Page(s): 271 - 281.e7
    03/28/2018 Authors: Ellrott K; Bailey MH; Saksena G; Covington KR; Kandoth C; Stewart C; Hess J; Ma S; Chiotti KE; McLellan M
  • Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
    Cell Syst Volume: 6 Page(s): 282 - 300.e2
    03/28/2018 Authors: Schaub FX; Dhankani V; Berger AC; Trivedi M; Richardson AB; Shaw R; Zhao W; Zhang X; Ventura A; Liu Y
  • Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol Volume: 36 Page(s): 841 - 849
    03/20/2018 Authors: Ramalingam SS; Yang JC-H; Lee CK; Kurata T; Kim D-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y
  • Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
    J Clin Oncol Volume: 36 Page(s): 911 - 919
    03/20/2018 Authors: Kalemkerian GP; Narula N; Kennedy EB; Biermann WA; Donington J; Leighl NB; Lew M; Pantelas J; Ramalingam SS; Reck M
  • The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
    Clin Cancer Res Volume: 24 Page(s): 1038 - 1047
    03/01/2018 Authors: Aisner DL; Sholl LM; Berry LD; Rossi MR; Chen H; Fujimoto J; Moreira AL; Ramalingam SS; Villaruz LC; Otterson GA
  • Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
    J Clin Oncol Volume: 36 Page(s): 631 - 632
    03/01/2018 Authors: Steuer CE; Ramalingam SS
  • Health care disparities among octogenarians and nonagenarians with stage III lung cancer.
    Cancer Volume: 124 Page(s): 775 - 784
    02/15/2018 Authors: Cassidy RJ; Zhang X; Switchenko JM; Patel PR; Shelton JW; Tian S; Nanda RH; Steuer CE; Pillai RN; Owonikoko TK
  • The Integrated Genomic Landscape of Thymic Epithelial Tumors.
    Cancer Cell Volume: 33 Page(s): 244 - 258.e10
    02/12/2018 Authors: Radovich M; Pickering CR; Felau I; Ha G; Zhang H; Jo H; Hoadley KA; Anur P; Zhang J; McLellan M
  • Immunotherapy in previously treated non-small cell lung cancer (NSCLC).
    J Thorac Dis Volume: 10 Page(s): S422 - S432
    02/01/2018 Authors: Leal TA; Ramalingam SS
  • Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.
    J Thorac Oncol Volume: 13 Page(s): 165 - 183
    02/01/2018 Authors: Socinski MA; Obasaju C; Gandara D; Hirsch FR; Bonomi P; Bunn PA; Kim ES; Langer CJ; Natale RB; Novello S
  • CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions.
    Annu Rev Med Volume: 69 Page(s): 301 - 318
    01/29/2018 Authors: Hashimoto M; Kamphorst AO; Im SJ; Kissick HT; Pillai RN; Ramalingam SS; Araki K; Ahmed R
  • Immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Cancer Volume: 124 Page(s): 248 - 261
    01/15/2018 Authors: Assi HI; Kamphorst AO; Moukalled NM; Ramalingam SS
  • Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
    Cancer Volume: 124 Page(s): 271 - 277
    01/15/2018 Authors: Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
  • Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med Volume: 378 Page(s): 113 - 125
    01/11/2018 Authors: Soria J-C; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T
  • Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy.
    J Clin Invest Volume: 128 Page(s): 500 - 516
    01/02/2018 Authors: Chen G; Magis AT; Xu K; Park D; Yu DS; Owonikoko TK; Sica GL; Satola SW; Ramalingam SS; Curran WJ
  • Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials.
    Oncology Volume: 95 Page(s): 138 - 146
    01/01/2018 Authors: Owonikoko TK; Busari AK; Kim S; Chen Z; Akintayo A; Lewis C; Carthon BC; Alese OB; El-Rayes BF; Ramalingam SS
  • CheckMate 227: Nivolumab (Nivo) plus Ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line treatment for advanced non-small cell lung cancer (NSCLC) with high Tumor Mutational Burden (TMB)
    Volume: 41 Page(s): 268 - 269
    01/01/2018 Authors: Reck M; Hellmann MD; Paz-Ares Rodriguez L; Ramalingam SS; Brahmer J; O'Byrne KJ; Bhagavatheeswaran P; Nathan F; Borghaei H
  • Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
    Ann Oncol Volume: 29 Page(s): i20 - i27
    01/01/2018 Authors: Remon J; Steuer CE; Ramalingam SS; Felip E
  • Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
    Lancet Oncol Volume: 18 Page(s): 1610 - 1623
    12/01/2017 Authors: Wakelee HA; Dahlberg SE; Keller SM; Tester WJ; Gandara DR; Graziano SL; Adjei AA; Leighl NB; Aisner SC; Rothman JM
  • Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).
    Ann Oncol Volume: 28 Page(s): 3037 - 3043
    12/01/2017 Authors: Argiris A; Lee JW; Stevenson J; Sulecki MG; Hugec V; Choong NW; Saltzman JN; Song W; Hansen RM; Evans TL
  • ENCORE-601: Phase 1b/2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Volume: 5
    11/07/2017 Authors: Gandhi L; Johnson ML; Opyrchal M; Ramalingam S; Janne P; Chachoua A; Ordentlich P; Brouwer S; Sankoh S; Schmidt E
  • Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.
    Cell Volume: 171 Page(s): 950 - 965.e28
    11/02/2017 Authors: Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca; Cancer Genome Atlas Research Network
  • Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer.
    Clin Lung Cancer Volume: 18 Page(s): 640 - 650.e2
    11/01/2017 Authors: Ganti AK; Hirsch FR; Wynes MW; Ravelo A; Ramalingam SS; Ionescu-Ittu R; Pivneva I; Borghaei H
  • Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis.
    Clin Lung Cancer Volume: 18 Page(s): 706 - 718
    11/01/2017 Authors: Ahmed HZ; Liu Y; O'Connell K; Ahmed MZ; Cassidy RJ; Gillespie TW; Patel P; Pillai RN; Behera M; Steuer CE
  • Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
    Clin Cancer Res Volume: 23 Page(s): 6567 - 6579
    11/01/2017 Authors: Shi P; Oh Y-T; Deng L; Zhang G; Qian G; Zhang S; Ren H; Wu G; Legendre B; Anderson E
  • Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence.
    Cancer Prev Res (Phila) Volume: 10 Page(s): 635 - 640
    11/01/2017 Authors: Belinsky SA; Leng S; Wu G; Thomas CL; Picchi MA; Lee SJ; Aisner S; Ramalingam S; Khuri FR; Karp DD
  • Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
    J Thorac Oncol Volume: 12 Page(s): 1687 - 1695
    11/01/2017 Authors: Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG
  • Change in Practice Patterns from an Online NSCLC Treatment Decision Support Tool
    Volume: 12 Page(s): S1830 - S1831
    11/01/2017 Authors: Gandara DR; Herbst R; Mok T; Ramalingam S; Obholz K; Quill T; Chow H; Scagliotti G
  • LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor
    Volume: 12 Page(s): S2275 - S2275
    11/01/2017 Authors: Kris M; Aisner D; Sholl L; Berry L; Rossi M; Chen H; Fujimoto J; Moreira A; Ramalingam S; Villaruz L
  • Radiation Therapy is Associated with an Increased Incidence of Cardiac Events in Small Cell Lung Cancer Patients
    Volume: 12 Page(s): S1745 - S1745
    11/01/2017 Authors: Ferris M; Jiang R; Ward K; Ramalingam S; Behera M; Higgins K
  • A Phase 1b/2 Study of Atezolizumab With or Without Daratumumab in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Volume: 12 Page(s): S2288 - S2288
    11/01/2017 Authors: Pillai R; Ramalingam S; Paz-Ares L; Thayu M; Watson P; Reck M
  • Utilization of PET Scan in Advanced Stage Non-Small Cell Lung Cancer in the United States
    Volume: 12 Page(s): S2325 - S2326
    11/01/2017 Authors: Behera M; Jiang R; Higgins K; Pillai R; Owonikoko T; Belani C; Khuri F; Ward K; Curran W; Ramalingam S
  • Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable, Stage III Non-Small Cell Lung Cancer: A Phase I Study
    Volume: 12 Page(s): S2013 - S2014
    11/01/2017 Authors: Higgins K; Pillai R; Chen Z; Zhang C; Patel P; Pakkala S; Shelton J; Force S; Fernandez F; Steuer C
  • Exploratory Analysis for Predictors of Benefit of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study
    Volume: 12 Page(s): S1766 - S1767
    11/01/2017 Authors: Owonikoko T; Dahlberg S; Poirier J; Sica G; Rudin C; Ramalingam S
  • Clinical Prognostic Model for Older Patients with Advanced Non-Small Cell Lung Cancer
    Volume: 12 Page(s): S1878 - S1879
    11/01/2017 Authors: Ganti AK; Wang X; Stinchcombe T; Wang Y; Kelly K; Paulus R; Bradley J; Ramalingam S; Cohen H; Vokes E
  • HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
    Cancer Volume: 123 Page(s): 4099 - 4105
    11/01/2017 Authors: Pillai RN; Behera M; Berry LD; Rossi MR; Kris MG; Johnson BE; Bunn PA; Ramalingam SS; Khuri FR
  • KRAS Mutant Non-small Cell Lung Cancer is Associated With Increased Risk of Salvage Whole Brain Radiation after Stereotactic Radiosurgery for Brain Metastases
    Volume: 99 Page(s): E100 - E101
    10/01/2017 Authors: Press RH; Zhang X; Cassidy RJ; Ferris MJ; Zhong J; Steuer C; Pillai R; Owonikoko TK; Ramalingam S; Patel PR
  • Next Generation Sequencing and Clinical Outcomes of Lung Adenocarcinomas Treated With Stereotactic Body Radiation Therapy
    Volume: 99 Page(s): S241 - S241
    10/01/2017 Authors: Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer C; Pillai R
  • Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.
    J Thorac Oncol Volume: 12 Page(s): 1489 - 1495
    10/01/2017 Authors: Garcia S; Bisen A; Yan J; Xie X-J; Ramalingam S; Schiller JH; Johnson DH; Gerber DE
  • Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937.
    J Thorac Oncol Volume: 12 Page(s): 1561 - 1570
    10/01/2017 Authors: Gore EM; Hu C; Sun AY; Grimm DF; Ramalingam SS; Dunlap NE; Higgins KA; Werner-Wasik M; Allen AM; Iyengar P
  • Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
    Cancer Volume: 123 Page(s): 3681 - 3690
    10/01/2017 Authors: Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN
  • Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
    Cancer Volume: 123 Page(s): 3476 - 3485
    09/15/2017 Authors: Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K
  • Gene methylation biomarkers in sputum as a classifier for lung cancer risk.
    Oncotarget Volume: 8 Page(s): 63978 - 63985
    09/08/2017 Authors: Leng S; Wu G; Klinge DM; Thomas CL; Casas E; Picchi MA; Stidley CA; Lee SJ; Aisner S; Siegfried JM
  • First signal-finding study of soluble HLA-G and -E (sHLA-G/E) as potential prognostic markers of clinical outcome in advanced, refractory squamous-cell NSCLC (SCC) treated with nivolumab (NIVO): checkMate 063
    Volume: 40 Page(s): 218 - +
    09/01/2017 Authors: Eberhardt WEE; Rebmann V; Rizvi N; Antonia SJ; Planchard D; Cappuzzo F; Mazieres J; Zalcman G; Lena H; Wolf J
  • Stereotactic Body Radiotherapy for Early-stage Non-small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center Analysis.
    Clin Lung Cancer Volume: 18 Page(s): 551 - 558.e6
    09/01/2017 Authors: Cassidy RJ; Patel PR; Zhang X; Press RH; Switchenko JM; Pillai RN; Owonikoko TK; Ramalingam SS; Fernandez FG; Force SD
  • Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
    Cancer Cell Volume: 32 Page(s): 185 - 203.e13
    08/14/2017 Authors: Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu; Cancer Genome Atlas Research Network
  • Assays for PD-L1 Expression: Do All Roads Lead to Rome?
    JAMA Oncol Volume: 3 Page(s): 1058 - 1059
    08/01/2017 Authors: Sica GL; Ramalingam SS
  • Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
    JAMA Oncol Volume: 3 Page(s): 1120 - 1129
    08/01/2017 Authors: Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ
  • Gene methylation biomarkers in sputum as a classifier for lung cancer risk.
    Oncotarget
    07/15/2017 Authors: Leng S; Wu G; Klinge DM; Thomas CL; Casas E; Picchi MA; Stidley CA; Lee SJ; Aisner S; Siegfried JM
  • Plasma ctDNA Analysis for Detection of the EGFRT790M Mutation in Patients with Advanced Non-SmallCell Lung Cancer.
    J Thorac Oncol Volume: 12 Page(s): 1061 - 1070
    07/01/2017 Authors: Jenkins S; Yang JC-H; Ramalingam SS; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jnne PA; Mitsudomi T
  • Smoking History Predicts Sensitivity to PARP InhibitorVeliparib in Patients with Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol Volume: 12 Page(s): 1098 - 1108
    07/01/2017 Authors: Reck M; Blais N; Juhasz E; Gorbunova V; Jones CM; Urban L; Orlov S; Barlesi F; Kio E; Keilholz U
  • Modulation of Bax and mTOR for cancer therapeutics
    Volume: 77
    07/01/2017 Authors: Li R; Ding C; Zhang J; Xie M; Park D; Ding Y; Chen G; Zhang G; Gilbert-Ross M; Zhou W
  • Modulation of Bax and mTOR for Cancer Therapeutics.
    Cancer Res Volume: 77 Page(s): 3001 - 3012
    06/01/2017 Authors: Li R; Ding C; Zhang J; Xie M; Park D; Ding Y; Chen G; Zhang G; Gilbert-Ross M; Zhou W
  • EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform.
    Volume: 35
    05/20/2017 Authors: Chaft JE; Dahlberg SE; Gerber DE; Oxnard GR; Malik SM; Simone CB; Edelman MJ; Heymach J; Rudin CM; Ramalingam SS
  • Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).
    Volume: 35
    05/20/2017 Authors: Saba NF; Force SD; Staley CA; Fernandez FG; Willingham FF; Allan P; Cardona K; Chen Z; Cardin DB; Lambright E
  • Early proliferation of PD-1+CD8 T cells in peripheral blood as predictive of response to PD-1 inhibition for patients with advanced NSCLC
    Volume: 35
    05/20/2017 Authors: Pillai RN; Kamphorst A; Yang S; Owonikoko TK; Sica G; Nasti T; Akondy R; Wieland A; Wu H; Patel N
  • Presence of genetic aberrations in patients with brain metastases from non-small cell lung cancer (NSCLC) and clinical outcomes
    Volume: 35
    05/20/2017 Authors: Press RH; Zhang X; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Ramalingam SS; Patel PR
  • Optimal thoracic radiation dose in limited stage small cell lung cancer.
    Volume: 35
    05/20/2017 Authors: Behera M; Zhang X; Jiang R; Pillai RN; Patel PR; Pakkala S; Steuer CE; Saba NF; Owonikoko TK; Belani C
  • Impact of prior radiation on survival in metastatic lung cancer ECOG-ACRIN trials.
    Volume: 35
    05/20/2017 Authors: Khan SA; Puligandla M; Dahlberg SE; Masters GA; Langer CJ; Brahmer JR; Hanna NH; Bonomi P; Gerber DE; Johnson DH
  • Risk factors associated with brain metastases in ECOG-ACRIN E1505, a phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (>/=4 cm) - IIIA non-small cell lung cancer (NSCLC).
    Volume: 35
    05/20/2017 Authors: Varlotto JM; Dahlberg SE; Wakelee HA; Ramalingam SS; Schiller JH
  • Survival outcomes in extensive stage small cell lung cancer patients treated with thoracic radiation.
    Volume: 35
    05/20/2017 Authors: Higgins KA; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP
  • Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
    Proc Natl Acad Sci U S A Volume: 114 Page(s): 4993 - 4998
    05/09/2017 Authors: Kamphorst AO; Pillai RN; Yang S; Nasti TH; Akondy RS; Wieland A; Sica GL; Yu K; Koenig L; Patel NT
  • Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer in Patients 80 Years and Older: A Multi-Center Analysis.
    Int J Radiat Oncol Biol Phys Volume: 98 Page(s): 229 - 230
    05/01/2017 Authors: Cassidy RJ; Patel PR; Zhang X; Press RH; Switchenko J; Pillai R; Owonikoko TK; Ramalingam S; Fernandez F; Force S
  • Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.
    Volume: 18 Page(s): 286 - 292
    05/01/2017 Authors: Steuer CE; Behera M; Liu Y; Fu C; Gillespie TW; Saba NF; Shin DM; Pillai RN; Pakkala S; Owonikoko TK
  • Discussing molecular testing in oncology care: Comparing patient and physician information preferences.
    Cancer Volume: 123 Page(s): 1610 - 1616
    05/01/2017 Authors: Pinheiro APM; Pocock RH; Switchenko JM; Dixon MD; Shaib WL; Ramalingam SS; Pentz RD
  • Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
    J Clin Oncol Volume: 35 Page(s): 1288 - 1296
    04/20/2017 Authors: Yang JC-H; Ahn M-J; Kim D-W; Ramalingam SS; Sequist LV; Su W-C; Kim S-W; Kim J-H; Planchard D; Felip E
  • Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.
    Clin Cancer Res Volume: 23 Page(s): 1937 - 1944
    04/15/2017 Authors: Ramalingam SS; Blais N; Mazieres J; Reck M; Jones CM; Juhasz E; Urban L; Orlov S; Barlesi F; Kio E
  • Using Metaphors to Explain Molecular Testing to Cancer Patients.
    Oncologist Volume: 22 Page(s): 445 - 449
    04/01/2017 Authors: Pinheiro APM; Pocock RH; Dixon MD; Shaib WL; Ramalingam SS; Pentz RD
  • CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in hemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC)
    Volume: 28
    04/01/2017 Authors: Paz-Ares L; Brahmer J; Hellmann MD; Reck M; O'Byrne K; Borghaei H; Geese WJ; Lu H; Nathan FE; Ramalingam S
  • Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.
    Volume: 355 Page(s): 1423 - 1427
    03/31/2017 Authors: Kamphorst AO; Wieland A; Nasti T; Yang S; Zhang R; Barber DL; Konieczny BT; Daugherty CZ; Koenig L; Yu K
  • Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma.
    JCI Insight Volume: 2 Page(s): e90487
    03/09/2017 Authors: Gilbert-Ross M; Konen J; Koo J; Shupe J; Robinson BS; Wiles WG; Huang C; Martin WD; Behera M; Smith GH
  • Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    N Engl J Med Volume: 376 Page(s): 629 - 640
    02/16/2017 Authors: Mok TS; Wu Y-L; Ahn M-J; Garassino MC; Kim HR; Ramalingam SS; Shepherd FA; He Y; Akamatsu H; Theelen WSME
  • Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
    Hematol Oncol Clin North Am Volume: 31 Page(s): 83 - 99
    02/01/2017 Authors: Pakkala S; Ramalingam SS
  • Integrated genomic characterization of oesophageal carcinoma.
    Nature Volume: 541 Page(s): 169 - 175
    01/12/2017 Authors: Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency; Brigham and Womens Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University; Greater Poland Cancer Centre
  • Smoking Behavior in Patients with Early Stage Non-Small Cell Lung Cancer: A Report from ECOG-ACRIN 1505 Trial
    Volume: 12 Page(s): S256 - S256
    01/01/2017 Authors: Ramalingam S; Dahlberg S; Wakelee H; Keller S; Tester W; Gandara DR; Graziano S; Adjei A; Butts C; Schiller J
  • Impact of Chemotherapy for Small Cell Lung Cancer in the Third Line and beyond, a SEER-MEDICARE Analysis
    Volume: 12 Page(s): S703 - S704
    01/01/2017 Authors: Kim S; Ragin C; Chen Z; Behera M; Pillai R; Steuer C; Belani C; Khuri F; Ramalingam S; Owonikoko T
  • Evaluation of Toxicity Profile of PD-1 versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
    Volume: 12 Page(s): S253 - S254
    01/01/2017 Authors: Pillai R; Behera M; Owonikoko T; Kamphorst A; Pakkala S; Belani C; Khuri F; Ahmed R; Ramalingam S
  • Trends, Patterns of Treatment and Outcomes in Non-Small Cell Lung Cancer (NSCLC) as a Second Primary: A National Cancer Data Base (NCDB) Analysis
    Volume: 12 Page(s): S470 - S470
    01/01/2017 Authors: Behera M; Gillespie T; Liu Y; Jia Y; Higgins K; Steuer C; Saba N; Shin D; Pakkala S; Pillai R
  • American Society of Clinical Oncology Policy Brief: FDA's Regulation of Electronic Nicotine Delivery Systems and Tobacco Products.
    J Oncol Pract Volume: 13 Page(s): 58 - 60
    01/01/2017 Authors: Merrill JK; Alberg AJ; Goffin JR; Ramalingam SS; Simmons VN; Warren GW
  • Guideline Concordant Care is Associated with Better Survival for Patients with Stage III Non-Small Cell Lung Cancer
    Volume: 12 Page(s): S855 - S856
    01/01/2017 Authors: Ahmed H; Liu Y; O'Conne K; Gillespie T; Ahmed M; Pate P; Pillai R; Behera M; Steuer C; Owonikoko T
  • National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys Volume: 97 Page(s): 128 - 137
    01/01/2017 Authors: Higgins KA; O'Connell K; Liu Y; Gillespie TW; McDonald MW; Pillai RN; Patel KR; Patel PR; Robinson CG; Simone CB
  • Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe.
    Clin Lung Cancer Volume: 18 Page(s): 5 - 12
    01/01/2017 Authors: Salahudeen AA; Patel MI; Baas P; Curran WJ; Bradley JD; Gandara DR; Goss GD; Mok TS; Ramalingam SS; Vokes EE
  • Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Lung Patients: A Pooled Analysis of US Cooperative Group Trials
    Volume: 12 Page(s): S922 - S923
    01/01/2017 Authors: Wang X; Cao X; Stinchcombe T; Bradley J; Adjei A; Gandara DR; Ramalingam S; Pang H; Vokes E; Crawford J
  • Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.
    Cancer Immunol Immunother Volume: 66 Page(s): 45 - 50
    01/01/2017 Authors: Owonikoko TK; Kumar M; Yang S; Kamphorst AO; Pillai RN; Akondy R; Nautiyal V; Chatwal MS; Book WM; Sahu A
  • The American Perspective
    Volume: 12 Page(s): S109 - S110
    01/01/2017 Authors: Ramalingam S
  • EGFR-Mutated NSCLC: Clinical Practice Assessment and Gap Analysis
    Volume: 12 Page(s): S1218 - S1219
    01/01/2017 Authors: Herrmann T; Hamarstrom E; Ramalingam S
  • Randomized Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3)
    Volume: 12 Page(s): S5 - S6
    01/01/2017 Authors: Papadimitrakopoulou V; Wu YL; Ahn M-J; Ramalingam S; Garassino M; Kim HR; Shepherd F; Akamatsu H; Theelen W; Lee CK
  • Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor.
    Oncology Volume: 93 Page(s): 336 - 342
    01/01/2017 Authors: Evans M; Liu Y; Chen C; Steuer C; Cassidy R; Landry J; Higgins K; Beitler JJ; Willingham F; Owonikoko TK
  • Identification of On-Target Mechanisms of Resistance to EGFR Inhibitors Using ctDNA Next-Generation Sequencing
    Volume: 12 Page(s): S1255 - S1256
    01/01/2017 Authors: Lin J; Fairclough S; Nagy R; Gadgeel S; Gubens M; Halmos B; Ramalingam S; Lanman R; Shaw A
  • Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
    Lancet Oncol Volume: 17 Page(s): 1661 - 1671
    12/01/2016 Authors: Neal JW; Dahlberg SE; Wakelee HA; Aisner SC; Bowden M; Huang Y; Carbone DP; Gerstner GJ; Lerner RE; Rubin JL
  • Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment.
    J Thorac Oncol Volume: 11 Page(s): 2066 - 2081
    12/01/2016 Authors: Langer CJ; Obasaju C; Bunn P; Bonomi P; Gandara D; Hirsch FR; Kim ES; Natale RB; Novello S; Paz-Ares L
  • Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.
    J Clin Oncol Volume: 34 Page(s): 3992 - 3999
    11/20/2016 Authors: Pang HH; Wang X; Stinchcombe TE; Wong ML; Cheng P; Ganti AK; Sargent DJ; Zhang Y; Hu C; Mandrekar SJ
  • Thoracic Oncology Clinical Trial Eligibility Criteria: Ongoing Increase in Recent Years
    Volume: 11 Page(s): S270 - S271
    11/01/2016 Authors: Gerber DE; Garcia S; Yan J; Xie X-J; Ramalingam S; Schiller J; Johnson D
  • PS01.02: Thoracic Oncology Clinical Trial Eligibility Criteria: Ongoing Increase inRecent Years: Topic: Medical Oncology.
    J Thorac Oncol Volume: 11 Page(s): S270 - S271
    11/01/2016 Authors: Gerber DE; Garcia S; Yan J; Xie X-J; Ramalingam S; Schiller J; Johnson D
  • Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation.
    Cancer Volume: 122 Page(s): 3207 - 3214
    10/15/2016 Authors: Nooka AK; Behera M; Lonial S; Dixon MD; Ramalingam SS; Pentz RD
  • Lung Stereotactic Body Radiation Therapy (SBRT) Versus Pneumonectomy in Patients With Non-Small Cell Lung Cancer (NSCLC) Ages 70 or Older.
    Int J Radiat Oncol Biol Phys Volume: 96 Page(s): E468
    10/01/2016 Authors: Higgins KA; Jia Y; Liu Y; Force S; Fernandez F; Ramalingam S; Behera M; Owonikoko TK; Pillai RN; Simone CB
  • Better Overall Survival with Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis.
    Int J Radiat Oncol Biol Phys Volume: 96 Page(s): E438 - E439
    10/01/2016 Authors: Higgins KA; O'Connell K; Liu Y; Patel PR; Pillai RN; Owonikoko TK; Simone CB; Robinson CG; McDonald MW; Gillespie TW
  • P2.36: Nivolumab (nivo) in Patients (pts) WithAdvanced (adv) NSCLC and CentralNervous System (CNS) Metastases (mets): Track: Immunotherapy.
    J Thorac Oncol Volume: 11 Page(s): S238 - S239
    10/01/2016 Authors: Goldman JW; Crino L; Vokes EE; Holgado E; Reckamp K; Pluzanski A; Spigel D; Kohlhaeufl M; Garassino M; Chow LQ
  • P2.39: Long-Term OS for Patients WithAdvanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy.
    J Thorac Oncol Volume: 11 Page(s): S241 - S242
    10/01/2016 Authors: Ramalingam S; Hui R; Gandhi L; Carcereny E; Felip E; Ahn M-J; Eder JP; Balmanoukian AS; Leighl N; Aggarwal C
  • Metastatic Lung Cancer: Emerging Therapeutic Strategies.
    Semin Respir Crit Care Med Volume: 37 Page(s): 736 - 749
    10/01/2016 Authors: Saif Ur Rehman S; Ramalingam SS
  • Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Cancer Lett Volume: 380 Page(s): 494 - 504
    10/01/2016 Authors: Shi P; Oh Y-T; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK
  • Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab
    Volume: 11 Page(s): S241 - S242
    10/01/2016 Authors: Ramalingam S; Hui R; Gandhi L; Carcereny E; Felip E; Ahn M-J; Eder JP; Balmanoukian AS; Leighl N; Aggarwal C
  • Lung Stereotactic Body Radiation Therapy (SBRT) Versus Pneumonectomy in Patients With Non-Small Cell Lung Cancer (NSCLC) Ages 70 or Older
    Volume: 96 Page(s): E468 - E468
    10/01/2016 Authors: Higgins KA; Jia Y; Liu Y; Force S; Fernandez F; Ramalingam S; Behera M; Owonikoko TK; Pillai RN; Simone CB
  • Better Overall Survival with Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis
    Volume: 96 Page(s): E438 - E439
    10/01/2016 Authors: Higgins KA; O'Connell K; Liu Y; Patel PR; Pillai RN; Owonikoko TK; Simone CB; Robinson CG; McDonald MW; Gillespie TW
  • Better Overall Survival with Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis
    Volume: 96 Page(s): E438 - E439
    10/01/2016 Authors: Higgins KA; O'Connell K; Liu Y; Patel PR; Pillai RN; Owonikoko TK; Simone CB; Robinson CG; McDonald MW; Gillespie TW
  • Lung Stereotactic Body Radiation Therapy (SBRT) Versus Pneumonectomy in Patients With Non-Small Cell Lung Cancer (NSCLC) Ages 70 or Older
    Volume: 96 Page(s): E468 - E468
    10/01/2016 Authors: Higgins KA; Jia Y; Liu Y; Force S; Fernandez F; Ramalingam S; Behera M; Owonikoko TK; Pillai RN; Simone CB
  • Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.
    Am J Clin Oncol Volume: 39 Page(s): 441 - 447
    10/01/2016 Authors: Langer CJ; Socinski MA; Patel JD; Sandler AB; Schiller JH; Leon L; Hazard SJ; Ramalingam SS
  • Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma.
    Volume: 17 Page(s): e57 - e64
    09/01/2016 Authors: Behera M; Owonikoko TK; Gal AA; Steuer CE; Kim S; Pillai RN; Khuri FR; Ramalingam SS; Sica GL
  • Clinicopathologic Features of Advanced Squamous NSCLC.
    J Thorac Oncol Volume: 11 Page(s): 1411 - 1422
    09/01/2016 Authors: Socinski MA; Obasaju C; Gandara D; Hirsch FR; Bonomi P; Bunn P; Kim ES; Langer CJ; Natale RB; Novello S
  • Evaluating Intensity-Modulated Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer: Results From the National CancerData Base.
    Clin Lung Cancer Volume: 17 Page(s): 398 - 405
    09/01/2016 Authors: Jegadeesh N; Liu Y; Gillespie T; Fernandez F; Ramalingam S; Mikell J; Lipscomb J; Curran WJ; Higgins KA
  • Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
    Cancer Volume: 122 Page(s): 2371 - 2378
    08/01/2016 Authors: Belani CP; Dahlberg SE; Rudin CM; Fleisher M; Chen HX; Takebe N; Velasco MR; Tester WJ; Sturtz K; Hann CL
  • Mcl-1 dictates DNA double-strand break repair pathway choice
    Volume: 76
    07/01/2016 Authors: Chen G; Xu K; Xie M; Owonikoko TK; Ramalingam SS; Doetsch PW; Deng X
  • c-Met hyperactivation is an universal resistance mechanism to both first and third generation EGFR inhibitors
    Volume: 76
    07/01/2016 Authors: Shi P; Oh Y-T; Zhang G; Yao W; Yue P; Kanteti R; Riehm J; Salgia R; Owonikoko T; Ramalingam SS
  • International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes.
    J Thorac Oncol Volume: 11 Page(s): 1153 - 1169
    07/01/2016 Authors: de Marinis F; Bria E; Ciardiello F; Crin L; Douillard JY; Griesinger F; Lambrechts D; Perol M; Ramalingam SS; Smit EF
  • EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
    Cancer Discov Volume: 6 Page(s): 601 - 611
    06/01/2016 Authors: Konduri K; Gallant J-N; Chae YK; Giles FJ; Gitlitz BJ; Gowen K; Ichihara E; Owonikoko TK; Peddareddigari V; Ramalingam SS
  • Preliminary results of ENCORE 601, a phase 1 b/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Volume: 34
    05/20/2016 Authors: Johnson ML; Adjei AA; Ramalingam SS; Janne PA; Dominguez G; Gabrilovich D; Deleon L; Hasapidis JL; Diede SJ; Ordentlich P
  • Case series of EGFR C797S mutations in non-small cell lung cancer identified with cell-free circulating tumor DNA next generation sequencing.
    Volume: 34
    05/20/2016 Authors: Fairclough SR; Zill OA; Chudova DA; Lee CE; Lanman RB; Banks KC; Nagy RJ; Mortimer S; Eltoukhy H; Talasaz A
  • Access to biomarker testing in patients with advanced non-small cell lung cancer.
    Volume: 34
    05/20/2016 Authors: Borghaei H; Hirsch FR; Wynes M; Ravelo A; Ramalingam SS; Ionescu-Ittu R; Pivneva I; Ganti AK
  • PPHM 1501-An open-label, randomized, phase II trial of durvalumab ( MEDI4736) with or without bavituximab in patients with previously treated metastatic non-small cell lung cancer ( NSCLC): Safety report on first 18 patients.
    Volume: 34
    05/20/2016 Authors: Natale RB; Spigel DR; Sanborn RE; Chiappori A; Ramalingam SS; Dragnev KH; Shan J; Stepp L; McCleod M; Waterhouse DM
  • E3508: Randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (Cx) in patients (pts) with advanced non-squamous, non-small cell lung cancer (NSCLC).
    Volume: 34
    05/20/2016 Authors: Argiris A; Lee J-W; Stevenson J; Sulecki MG; Hugec V; Choong NW; Saltzman JN; Song W; Hansen RM; Evans TL
  • Access to specialist care and treatment in patients with advanced non-small cell lung cancer.
    Volume: 34
    05/20/2016 Authors: Ganti AK; Borghaei H; Hirsch FR; Wynes M; Ravelo A; Ionescu-Ittu R; Pivneva I; Ramalingam SS
  • Role of anti-EGFR monoclonal antibody in EGFR FISH positive NSCLC patients: A meta-analysis of phase III randomized controlled trials.
    Volume: 34
    05/20/2016 Authors: Patel N; Behera M; Pillai RN; Owonikoko TK; Pakkala S; Belani CP; Khuri FR; Ramalingam SS
  • Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).
    Volume: 34
    05/20/2016 Authors: Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
  • National Cancer Data Base analysis of proton versus photon radiotherapy in non-small cell lung cancer(NSCLC).
    Volume: 34
    05/20/2016 Authors: Behera M; OConnell KA; Liu Y; Gillespie TW; Pillai RN; Patel P; Simone CB; Robinson CG; Owonikoko TK; Belani CP
  • Non-small cell lung cancer (NSCLC) as a second primary: Analysis of the National Cancer Data Base (NCDB).
    Volume: 34
    05/20/2016 Authors: Behera M; Gillespie TW; Liu Y; Jia Y; Higgins KA; Steuer CE; Saba NF; Shin DM; Pakkala S; Pillai RN
  • Effect of definitive concurrent therapy with or without surgery on resectable esophageal cancer survival: An analysis of the National Cancer Data Base
    Volume: 34
    05/20/2016 Authors: Naik K; Liu Y; Goodman M; Gillespie TW; El-Rayes BF; Pickens A; Force S; Steuer CE; Owonikoko TK; Ramalingam SS
  • Comparative features and overall survival in adenosquamous carcinoma, a rare tumor of the esophagus.
    Volume: 34
    05/20/2016 Authors: Evans M; Liu Y; Chen C; Gillespie TW; Steuer CE; Owonikoko TK; Ramalingam SS; Beitler JJ; El-Rayes BF; Fernandez F
  • Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
    J Transl Med Volume: 14 Page(s): 111
    05/03/2016 Authors: Owonikoko TK; Zhang G; Kim HS; Stinson RM; Bechara R; Zhang C; Chen Z; Saba NF; Pakkala S; Pillai R
  • Scientific Advances in Lung Cancer 2015.
    J Thorac Oncol Volume: 11 Page(s): 613 - 638
    05/01/2016 Authors: Tsao AS; Scagliotti GV; Bunn PA; Carbone DP; Warren GW; Bai C; de Koning HJ; Yousaf-Khan AU; McWilliams A; Tsao MS
  • Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
    Volume: 11 Page(s): S152 - S152
    04/01/2016 Authors: Ramalingam S; Yang JC-H; Lee CK; Kurata T; Kim D-W; John T; Nogami N; Ohe Y; Janne PA
  • Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results
    Volume: 11 Page(s): S152 - S153
    04/01/2016 Authors: Yang J; Ramalingam SS; Janne PA; Cantarini M; Mitsudomi T
  • Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
    Oncologist Volume: 21 Page(s): 402 - 403
    04/01/2016 Authors: Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L
  • An early treatment window to target FAK-dependent collective invasion in Lkb1-mutant lung adenocarcinoma
    Volume: 76
    04/01/2016 Authors: Gilbert-Ross M; Konen J; Shupe J; Koo J; Sica GL; Ramalingam SS; Fu H; Khuri FR; Zhou W; Marcus AI
  • 134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC).
    J Thorac Oncol Volume: 11 Page(s): S153 - S154
    04/01/2016 Authors: Jenkins S; Yang J; Ramalingam S; Yu K; Patel S; Weston S; Lawrance R; Cantarini M; Jnne P; Mitsudomi T
  • 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial.
    J Thorac Oncol Volume: 11 Page(s): S115
    04/01/2016 Authors: Ahn M-J; Yang J; Yu H; Saka H; Ramalingam S; Goto K; Kim S-W; Yang L; Walding A; Oxnard GR
  • LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts.
    J Thorac Oncol Volume: 11 Page(s): S152
    04/01/2016 Authors: Ramalingam S; Yang JC-H; Lee CK; Kurata T; Kim D-W; John T; Nogami N; Ohe Y; Jnne PA
  • LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results.
    J Thorac Oncol Volume: 11 Page(s): S152 - S153
    04/01/2016 Authors: Yang J; Ramalingam SS; Jnne PA; Cantarini M; Mitsudomi T
  • 137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses.
    J Thorac Oncol Volume: 11 Page(s): S115 - S116
    04/01/2016 Authors: Lena H; Rizvi NA; Wolf J; Cappuzzo F; Zalcman G; Baas P; Mazieres J; Farsaci B; Blackwood-Chirchir MA; Ramalingam S
  • Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
    Cancer Volume: 122 Page(s): 766 - 772
    03/01/2016 Authors: Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA
  • Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives.
    Curr Opin Oncol Volume: 28 Page(s): 150 - 158
    03/01/2016 Authors: Pakkala S; Ramalingam SS
  • Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
    J Mol Diagn Volume: 18 Page(s): 299 - 315
    03/01/2016 Authors: Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS
  • Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
    Ann Oncol Volume: 27 Page(s): 423 - 429
    03/01/2016 Authors: Ramalingam SS; O'Byrne K; Boyer M; Mok T; Jnne PA; Zhang H; Liang J; Taylor I; Sbar EI; Paz-Ares L
  • Lung cancer: Disparities and implications for immunotherapy
    Volume: 25
    03/01/2016 Authors: Ramalingam SS
  • Small-Cell Lung Cancer: New Directions for Systemic Therapy.
    J Oncol Pract Volume: 12 Page(s): 119 - 120
    02/01/2016 Authors: Ramalingam SS
  • Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.
    Cancer Volume: 122 Page(s): 50 - 60
    01/01/2016 Authors: Behera M; Ragin C; Kim S; Pillai RN; Chen Z; Steuer CE; Saba NF; Belani CP; Khuri FR; Ramalingam SS
  • NRG Oncology/RTOG 0937: Randomized Phase 2 Study Comparing Prophylactic Cranial Irradiation (PCI) Alone to PCI and Consolidative Extracranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
    Volume: 94 Page(s): 5 - 5
    01/01/2016 Authors: Gore EM; Hu C; Sun A; Grimm D; Ramalingam S; Dunlap NE; Higgins KA; Werner-Wasik M; Allen AM; Iyengar P
  • ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Clin Cancer Res Volume: 21 Page(s): 5439 - 5444
    12/15/2015 Authors: Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jnne PA
  • Analysis of liver-directed therapies in U.S. cancer patients.
    Curr Oncol Volume: 22 Page(s): e457 - e461
    12/01/2015 Authors: Alese OB; Kim S; Chen Z; Ramalingam SS; Owonikoko TK; El-Rayes BF
  • Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.
    Volume: 1 Page(s): 1293 - 1300
    12/01/2015 Authors: Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Ramalingam SS; Khuri FR; Flowers CR
  • Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis.
    Cancer Volume: 121 Page(s): 4222 - 4230
    12/01/2015 Authors: Nanda RH; Liu Y; Gillespie TW; Mikell JL; Ramalingam SS; Fernandez FG; Curran WJ; Lipscomb J; Higgins KA
  • Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.
    J Clin Oncol Volume: 33 Page(s): 4106 - 4111
    12/01/2015 Authors: Rudin CM; Ismaila N; Hann CL; Malhotra N; Movsas B; Norris K; Pietanza MC; Ramalingam SS; Turrisi AT; Giaccone G
  • Targeting EGFR in lung cancer: Lessons learned and future perspectives.
    Mol Aspects Med Volume: 45 Page(s): 67 - 73
    11/01/2015 Authors: Steuer CE; Ramalingam SS
  • Survival After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung Cancer: An Analysis from the National Cancer Data Base.
    J Thorac Oncol Volume: 10 Page(s): 1625 - 1633
    11/01/2015 Authors: Khullar OV; Liu Y; Gillespie T; Higgins KA; Ramalingam S; Lipscomb J; Fernandez FG
  • Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.
    Lung Cancer Volume: 90 Page(s): 296 - 301
    11/01/2015 Authors: McKeegan EM; Ansell PJ; Davis G; Chan S; Chandran RK; Gawel SH; Dowell BL; Bhathena A; Chakravartty A; McKee MD
  • Development Of A Patient-Reported Outcome (Pro) Assessment Of Core Non-Small Cell Lung Cancer (Nsclc) Symptoms.
    Value Health Volume: 18 Page(s): A471
    11/01/2015 Authors: DeBusk K; Johnson N; Evans C; Sandler A; Ramalingam SS; Campbell A
  • LONGER-TERM FOLLOW-UP OF A PHASE 2 STUDY (CHECKMATE 063) OF NIVOLUMAB IN PATIENTS WITH ADVANCED REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)
    Asia-Pacific Journal of Clinical Oncology Volume: 11 Page(s): 124 - 124
    11/01/2015 Authors: Horn L; Rizvi N; Mazieres J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Lena H; Minenza E; Mennecier B
  • Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors.
    Semin Oncol Volume: 42 Page(s): 713 - 723
    10/01/2015 Authors: Miles G; Rae J; Ramalingam SS; Pfeifer J
  • Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer.
    J Thorac Oncol Volume: 10 Page(s): 1421 - 1429
    10/01/2015 Authors: Chow H; Edelman MJ; Giaccone G; Ramalingam SS; Quill TA; Bowser AD; Mortimer J; Guerra W; Beckett LA; West HL
  • Veliparib with carboplatin and paclitaxel: factors predictive of favorable outcomes in NSCLC
    Volume: 51 Page(s): S630 - S630
    09/01/2015 Authors: Reck M; Ramalingam S; Blais N; Mazieres J; Jones M; Juhasz E; Urban L; Orlov S; Barlesi F; Kio E
  • Characterization of advanced NSCLC patients with prolonged benefit after veliparib plus carboplatin/paclitaxel: Phase 2 results
    Volume: 51 Page(s): S629 - S630
    09/01/2015 Authors: Juhasz E; Ramalingam S; Blais N; Mazieres J; Reck M; Jones M; Urban L; Orlov S; Barlesi F; Kio E
  • Early detection of lung cancer in China: The immediate imperative.
    Cancer Volume: 121 Suppl 17 Page(s): 3055 - 3057
    09/01/2015 Authors: Veeraraghavan S; Ramalingam SS; Khuri FR
  • Lung cancer in China: The new frontier?
    Cancer Volume: 121 Suppl 17 Page(s): 3058 - 3060
    09/01/2015 Authors: Ramalingam SS; Khuri FR
  • AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies
    Volume: 51 Page(s): S625 - S626
    09/01/2015 Authors: Ahn MJ; Tsai CM; Yang JCH; Shepherd FA; Satouchi M; Kim DW; Bazhenova L; Hirashima T; Rukazenkov Y; Cantarini M
  • Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)
    Volume: 51 Page(s): S631 - S631
    09/01/2015 Authors: Gettinger SN; Horn L; Ramalingam SS; Spigel DR; Paz-Ares L; Paik P; Reck M; Reckamp K; Mazieres J; Stinchcombe T
  • Access to Cancer Directed Therapies and Cancer Specialists in Patients with Metastatic Lung Cancer
    Volume: 10 Page(s): S231 - S232
    09/01/2015 Authors: Ganti AK; Hirsch FR; Wynes M; Ravelo A; Ramalingam SS; Ionescu-Ittu R; Pivneva I; Lin P; Borghaei H
  • Real-World Patterns of Access to Cancer Specialist Care Among Patients With Lung Cancer in the United States: A Claims Database Analysis
    Volume: 10 Page(s): S272 - S273
    09/01/2015 Authors: Ganti AK; Borghaei H; Hirsch FR; Wynes M; Ravelo A; Ionescu-Ittu R; Pivneva I; Lin P; Ramalingam SS
  • Squamous Cell Carcinoma of Lung in the United States: Analysis of the National Cancer Database (NCDB)
    JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S367 - S367
    09/01/2015 Authors: Behera M; Owonikoko TK; Liu Y; Gillespie TW; Yuan M; Pillai RN; Steuer C; Higgins KA; Pakkala S; Belani CP
  • A Systematic Review of Carboplatin-Paclitaxel versus Cisplatin-Etoposide Concurrent with Thoracic Radiation for Stage III NSCLC Patients
    JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S212 - S212
    09/01/2015 Authors: Steuer C; Behera M; Higgins KA; Saba N; Shin D; Pakkala S; Pillai R; Owonikoko TK; Curran WJ; Belani CP
  • Stereotactic Body Radiation vs. Observation for Early-Stage NSCLC in Elderly Patients
    JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S326 - S326
    09/01/2015 Authors: Nanda RH; Gillespie TW; Mikell JL; Liu Y; Libscomb J; Ramalingam SS; Fernandez F; Curran WJ; Higgins KA
  • Survival Impact of Adjuvant Radiation and Chemotherapy in Patients with Typical and Atypical Pulmonary Carcinoids
    JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S507 - S507
    09/01/2015 Authors: Hannan LM; Switchenko J; Liu Y; Behera M; Higgins KA; Fernandez F; Pillai RN; Khuri F; Ramalingam SS; Gillespie TW
  • Androgen Deprivation Therapy for Prostate Cancer Associated with Improved Survival in Non Small Cell Lung Cancer: A SEER-MEDICARE Analysis
    JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S545 - S545
    09/01/2015 Authors: Kumar M; Ragin C; Zhang C; Chen Z; Han EJ; Ernani V; Behera M; Steuer C; Saba N; Shin D
  • Comparison of the Efficacy of Dacomitinib v Erlotinib for NSCLC Pts with Del 19/L858R
    Volume: 10 Page(s): S278 - S278
    09/01/2015 Authors: Ramalingam SS; O'Byrne KJ; Mok T; Boyer M; Jaenne PA; Goldberg Z; Mather CB; Taylor I; Zhang H; Paz-Ares L
  • AZD9291 in Treatment-Naive EGFRm Advanced NSCLC: AURA First-Line Cohort
    Volume: 10 Page(s): S319 - S320
    09/01/2015 Authors: Ramalingam SS; Yang JC-H; Lee C; Kurata T; Kim D-W; John T; Nogami N; Ohe Y; Rukazenkov Y; Frewer P
  • AZD9291 in Pre-Treated T790M Positive Advanced NSCLC: AURA Study Phase II Extension Cohort
    Volume: 10 Page(s): S319 - S319
    09/01/2015 Authors: Yang JC-H; Ahn M-J; Ramalingam SS; Sequist LV; Novello S; Su W-C; Hirashima T; Kim D-W; Lawrance R; Cantarini M
  • Patterns of Disease Progression for Stage IV NSCLC While on PD-1 Directed Therapy as Compared to Standard Chemotherapy
    JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S644 - S644
    09/01/2015 Authors: Chatwal MS; Ernani V; Owonikoko TK; Ramalingam SS; Pillai RN
  • Relationship between EGFR Mutation Status and Response to Specific Chemotherapeutic Agents in Patients with Stage IV Non-Small Cell Lung Cancer
    JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S525 - S525
    09/01/2015 Authors: Ernani V; Chatwal MS; Kumar M; Zhang C; Chen Z; Owonikoko TK; Ramalingam SS
  • Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results of E1505
    Volume: 10 Page(s): S66 - S66
    09/01/2015 Authors: Wakelee HA; Dahlberg SE; Keller SM; Tester WJ; Gandara DR; Graziano SL; Adjei A; Leighl N; Aisner SC; Rothman JM
  • Longer-Term Follow-Up of a Phase 2 Study (CheckMate 063) of Nivolumab in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
    Volume: 10 Page(s): S175 - S176
    09/01/2015 Authors: Horn L; Rizvi NA; Mazieres J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Lena H; Minenza E; Mennecier B
  • Smoking Predicts Sensitivity to PARP Inhibitor, Veliparib, in Advanced NSCLC Patients
    Volume: 10 Page(s): S373 - S373
    09/01/2015 Authors: Blais N; Ramalingam SS; Mazieres J; Reck M; Jones CM; Juhasz E; Urban L; Orlov S; Barlesi F; Kio E
  • Development of a Patient-Reported Outcome (pro) Assessment of Core Non-Small Cell Lung Cancer (NSCLC) Symptoms
    Volume: 10 Page(s): S660 - S660
    09/01/2015 Authors: Debusk K; Johnson N; Evans C; Jubb A; Sandler A; Ramalingam SS; Campbell AK
  • Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results of E1505
    Volume: 10 Page(s): S796 - S796
    09/01/2015 Authors: Wakelee HA; Dahlberg SE; Keller SM; Tester WJ; Gandara DR; Graziano SL; Adjei A; Leighl N; Aisner SC; Rothman JM
  • Anti-Angiogenic Therapy: Current and Future Agents
    Volume: 10 Page(s): S94 - S94
    09/01/2015 Authors: Ramalingam SS
  • Phase II Study of Defactinib, VS-6063, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
    Volume: 10 Page(s): S372 - S372
    09/01/2015 Authors: Gerber DE; Camidge DR; Morgensztern D; Cetnar J; Kelly R; Ramalingam SS; Spigel DR; Jeong W; Scaglioni P; Li M
  • Oncogenic Drivers including RET and ROS1 plus PTEN Loss and MET by IHC in Patients with Lung Adenocarcinomas: Lung Cancer Mutation Consortium 2.0
    Volume: 10 Page(s): S295 - S295
    09/01/2015 Authors: Johnson BE; Kris MG; Wistuba II; Berry L; Socinski MA; Ramalingam SS; Glisson B; Otterson G; Schiller J; Cetnar J
  • A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512
    Volume: 10 Page(s): S373 - S373
    09/01/2015 Authors: Neal JW; Dahlberg SE; Wakelee HA; Aisner SC; Bowden M; Carbone DP; Ramalingam SS
  • A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors
    Volume: 75
    08/01/2015 Authors: Owonikoko TK; Harvey RD; Lewis C; Chen Z; Kauh JS; Renfroe M; Deovic R; Sica GL; Carthon BC; Harris WB
  • Biomarker evaluation for PD-1 targeted therapies in non-small cell lung cancer (NSCLC) patients
    Volume: 75
    08/01/2015 Authors: Kamphorst AO; Pillai RN; Yang S; Akondy R; Koenig L; Yu K; McCausland M; Sica G; Khuri FR; Owonikoko TK
  • Development of Bcl2 BH4 antagonist for cancer therapy
    Volume: 75
    08/01/2015 Authors: Han B; Park D; Li R; Xie M; Owonikoko T; Sica G; Ding C; Zhou J; Magis A; Ramalingam S
  • Nonclinical Factors Associated with 30-Day Mortality after Lung Cancer Resection: An Analysis of 215,000 Patients Using the National Cancer Data Base.
    J Am Coll Surg Volume: 221 Page(s): 550 - 563
    08/01/2015 Authors: Melvan JN; Sancheti MS; Gillespie T; Nickleach DC; Liu Y; Higgins K; Ramalingam S; Lipscomb J; Fernandez FG
  • Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
    J Thorac Oncol Volume: 10 Page(s): 1142 - 1147
    08/01/2015 Authors: Behera M; Pillai RN; Owonikoko TK; Kim S; Steuer C; Chen Z; Saba NF; Belani CP; Khuri FR; Ramalingam SS
  • A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
    Ann Oncol Volume: 26 Page(s): 1741 - 1748
    08/01/2015 Authors: Ramalingam S; Goss G; Rosell R; Schmid-Bindert G; Zaric B; Andric Z; Bondarenko I; Komov D; Ceric T; Khuri F
  • Time to divest from tobacco-funded research.
    Cancer Volume: 121 Page(s): 2294 - 2295
    07/15/2015 Authors: Khuri FR; Ramalingam SS
  • Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
    J Thorac Oncol Volume: 10 Page(s): 1099 - 1106
    07/01/2015 Authors: Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR
  • Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508).
    Volume: 121 Page(s): 2253 - 2261
    07/01/2015 Authors: Hanna NH; Dahlberg SE; Kolesar JM; Aggarwal C; Hirsch FR; Ramalingam SS; Schiller JH
  • A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).
    Lung Cancer Volume: 89 Page(s): 66 - 70
    07/01/2015 Authors: Owonikoko TK; Dahlberg SE; Khan SA; Gerber DE; Dowell J; Moss RA; Belani CP; Hann CL; Aggarwal C; Ramalingam SS
  • Genomic Classification of Cutaneous Melanoma.
    Cell Volume: 161 Page(s): 1681 - 1696
    06/18/2015 Authors: Cancer Genome Atlas Network
  • Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
    Cancer Cell Volume: 27 Page(s): 852 - 863
    06/08/2015 Authors: Han B; Park D; Li R; Xie M; Owonikoko TK; Zhang G; Sica GL; Ding C; Zhou J; Magis AT
  • Racial disparities in squamous cell carcinoma of the oral tongue among women: a SEER data analysis.
    Oral Oncol Volume: 51 Page(s): 586 - 592
    06/01/2015 Authors: Joseph LJ; Goodman M; Higgins K; Pilai R; Ramalingam SS; Magliocca K; Patel MR; El-Deiry M; Wadsworth JT; Owonikoko TK
  • Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States.
    World J Oncol Volume: 6 Page(s): 349 - 354
    06/01/2015 Authors: Alese OB; Kim S; Chen Z; Shaib W; Staley CA; Ramalingam SS; Owonikoko TK; El-Rayes BF
  • ROLE FOR ADENYLYL CYCLASE 1 IN ETHANOL-MEDIATED LOCOMOTOR SENSITIZATION AND STRIATAL NMDA GLUTAMATE RECEPTOR REGULATION
    Volume: 39 Page(s): 187A - 187A
    06/01/2015 Authors: Bosse KE; Susick LL; Ramalingam S; Conti AC
  • Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).
    Volume: 33
    05/20/2015 Authors: Neal JW; Dahlberg SE; Wakelee HA; Aisner SC; Bowden M; Carbone DP; Ramalingam SS
  • A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naive patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation.
    Volume: 33
    05/20/2015 Authors: Ramalingam SS; Rukazenkov Y; Thomas K; Soria J-C
  • ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer.
    Volume: 33
    05/20/2015 Authors: Gerber DE; Oxnard GR; Mandrekar SJ; Dahlberg SE; Malik SM; Mooney MM; Abrams JS; Janne PA; Li T; Ramalingam SS
  • Smoking status to predict sensitivity to PARP inhibitor, veliparib, in patients with advanced NSCLC.
    Volume: 33
    05/20/2015 Authors: Ramalingam SS; Blais N; Mazieres J; Reck M; Jones CM; Juhasz E; Urban L; Orlov S; Barlesi F; Kio EA
  • Veliparib (ABT-888) or placebo combined with carboplatin and paclitaxel in patients with previously untreated advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC): A randomized phase 3 trial.
    Volume: 33
    05/20/2015 Authors: McKee MD; Bondarenko I; Guclu SZ; Gorbunova V; Urban L; Clingan P; Lesniewski-Kmak K; Mazieres J; Ramalingam SS; Pedersen M
  • Does time to progression (TTP) influence post-progression survival (ppOS)?: Analyses from the PointBreak, ECOG 4599, and ARIES studies of bevacizumab in non-small cell lung cancer (NSCLC).
    Volume: 33
    05/20/2015 Authors: Langer CJ; Wozniak AJ; Socinski MA; Leon L; Liu S; Hazard S; Ramalingam SS
  • Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0).
    Volume: 33
    05/20/2015 Authors: Kris MG; Johnson BE; Kwiatkowski DJ; Wistuba II; Berry LD; Haura EB; Socinski MA; Ramalingam SS; Glisson BS; Waqar SN
  • Investigating the correlation between disease burden and symptoms in patients with advanced stage lung cancer.
    Volume: 33
    05/20/2015 Authors: Geiger C; Chen Z; Zhang C; Behera M; Steuer CE; Pillai RN; Ramalingam SS
  • AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.
    Volume: 33
    05/20/2015 Authors: Ramalingam SS; Yang JC-H; Lee CK; Kurata T; Kim D-W; John T; Nogami N; Ohe Y; Rukazenkov Y; Frewer P
  • Aneuploidy of anaplastic lymphoma kinase (ALK) gene and association with non squamous lung cancer patient characteristics and outcomes.
    Volume: 33
    05/20/2015 Authors: Owonikoko TK; Nelson M; Park SY; Kim S; Steuer CE; Behera M; Chen Z; Han E; Kumar M; Ernani V
  • PD-L1, PD-1, and CTLA-4 as prognostic biomarkers in resected non-small cell lung cancer.
    Volume: 33
    05/20/2015 Authors: Owonikoko TK; Kowalski J; Kim S; Dwivedi B; Chen Z; Behera M; Mayfield W; Hermann RC; Chen L; Khuri FR
  • Pemetrexed versus taxane-containing platinum doublet therapy for advanced non-squamous non-small cell lung cancer (NSCLC): A systematic analysis.
    Volume: 33
    05/20/2015 Authors: Behera M; Pillai RN; Owonikoko TK; Pakkala S; Steuer CE; Saba NF; Shin DM; Belani CP; Khuri FR; Ramalingam SS
  • Trimodality therapy in the treatment of stage IIIA non-small cell lung cancer (NSCLC): Analysis of the National Cancer Database.
    Volume: 33
    05/20/2015 Authors: Behera M; Steuer CE; Fernandez F; Liu Y; Fu C; Gillespie TW; Higgins KA; Saba NF; Pillai RN; Force S
  • Comparative genomics of pulmonary and extrapulmonary small cell carcinoma.
    Volume: 33
    05/20/2015 Authors: Sica G; Hanley K; Newman S; Mosunjac M; Martinez A; Han E; Zhang G; Ramalingam SS; Khuri FR; Rossi MR
  • Innovative Clinical Trials: The LUNG-MAP Study.
    Clin Pharmacol Ther Volume: 97 Page(s): 488 - 491
    05/01/2015 Authors: Steuer CE; Papadimitrakopoulou V; Herbst RS; Redman MW; Hirsch FR; Mack PC; Ramalingam SS; Gandara DR
  • AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
    N Engl J Med Volume: 372 Page(s): 1689 - 1699
    04/30/2015 Authors: Jnne PA; Yang JC-H; Kim D-W; Planchard D; Ohe Y; Ramalingam SS; Ahn M-J; Kim S-W; Su W-C; Horn L
  • GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Oncotarget Volume: 6 Page(s): 8974 - 8987
    04/20/2015 Authors: Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
    Clin Cancer Res Volume: 21 Page(s): 1859 - 1868
    04/15/2015 Authors: Owonikoko TK; Ramalingam SS; Miller DL; Force SD; Sica GL; Mendel J; Chen Z; Rogatko A; Tighiouart M; Harvey RD
  • The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer.
    Cancer Volume: 121 Page(s): E1 - E6
    04/15/2015 Authors: Steuer CE; Khuri FR; Ramalingam SS
  • Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis.
    Lung Cancer Volume: 88 Page(s): 80 - 84
    04/01/2015 Authors: Steuer CE; Behera M; Kim S; Patel N; Chen Z; Pillai R; Saba NF; Shin DM; Owonikoko TK; Khuri FR
  • Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.
    Clin Cancer Res Volume: 21 Page(s): 1514 - 1524
    04/01/2015 Authors: Herbst RS; Gandara DR; Hirsch FR; Redman MW; LeBlanc M; Mack PC; Schwartz LH; Vokes E; Ramalingam SS; Bradley JD
  • PHASE 2 STUDY OF NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]) IN PATIENTS (PTS) WITH ADVANCED, REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)
    Volume: 26
    04/01/2015 Authors: Zalcman G; Rizvi NA; Lena H; Wolf J; Mazieres J; Antonia SJ; Minenza E; Planchard D; Lestini BJ; Ramalingam SS
  • A PHASE I STUDY OF AZD9291 IN PATIENTS WITH EGFR-TKI-RESISTANT ADVANCED NSCLC - UPDATED PROGRESSION FREE SURVIVAL AND DURATION OF RESPONSE DATA
    Volume: 26
    04/01/2015 Authors: Jaenne PA; Ahn M-J; Kim D-W; Kim S-W; Planchard D; Ramalingam SS; Frewer P; Cantarini M; Ghiorghiu S; Yang JC-H
  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
    Lancet Oncol Volume: 16 Page(s): 257 - 265
    03/01/2015 Authors: Rizvi NA; Mazires J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B
  • Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base.
    J Thorac Oncol Volume: 10 Page(s): 462 - 471
    03/01/2015 Authors: Mikell JL; Gillespie TW; Hall WA; Nickleach DC; Liu Y; Lipscomb J; Ramalingam SS; Rajpara RS; Force SD; Fernandez FG
  • Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis.
    J Thorac Oncol Volume: 10 Page(s): 479 - 485
    03/01/2015 Authors: Steuer CE; Behera M; Kim S; Chen Z; Saba NF; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS
  • Minimize toxicity or preserve efficacy? A delicate trade-off in the management of older patients with lung cancer.
    J Clin Oncol Volume: 33 Page(s): 534 - 536
    02/20/2015 Authors: Owonikoko TK; Ramalingam SS
  • Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.
    J Clin Oncol Volume: 33 Page(s): 433 - 441
    02/10/2015 Authors: Ramalingam SS; Shtivelband M; Soo RA; Barrios CH; Makhson A; Segalla JGM; Pittman KB; Kolman P; Pereira JR; Srkalovic G
  • POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF VORINOSTAT IN PATIENTS WITH ADVANCED SOLID TUMORS WITH VARYING DEGREES OF HEPATIC FUNCTION.
    Volume: 97 Page(s): S67 - S68
    02/01/2015 Authors: Yang H; Ramalingam S; Kummar S; Harvey R; Ivy P; Beumer J
  • Socioeconomic risk factors for long-term mortality after pulmonary resection for lung cancer: an analysis of more than 90,000 patients from the National Cancer Data Base.
    J Am Coll Surg Volume: 220 Page(s): 156 - 168.e4
    02/01/2015 Authors: Khullar OV; Gillespie T; Nickleach DC; Liu Y; Higgins K; Ramalingam S; Lipscomb J; Fernandez FG
  • Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
    J Thorac Oncol Volume: 10 Page(s): S1 - 63
    01/01/2015 Authors: Morgensztern D; Campo MJ; Dahlberg SE; Doebele RC; Garon E; Gerber DE; Goldberg SB; Hammerman PS; Heist RS; Hensing T
  • Lung
    Page(s): 205 - 220
    01/01/2015 Authors: Ramalingam SS; Fernandez F; Higgins KA; Auffermann WF; Khuri FR
  • Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells.
    Oncoscience Volume: 2 Page(s): 765 - 776
    01/01/2015 Authors: Webber PJ; Park C; Qui M; Ramalingam SS; Khuri FR; Fu H; Du Y
  • Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
    Cancer Volume: 120 Page(s): 3940 - 3951
    12/15/2014 Authors: Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J
  • Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Cancer Med Volume: 3 Page(s): 1579 - 1594
    12/01/2014 Authors: Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM
  • Necitumumab: a new therapeutic option for squamous cell lung cancer?
    Transl Lung Cancer Res Volume: 3 Page(s): 382 - 383
    12/01/2014 Authors: Pillai RN; Ramalingam SS
  • Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
    Lung Cancer Volume: 86 Page(s): 350 - 357
    12/01/2014 Authors: Langer C; Ravelo A; Hazard SJ; Guerin A; Ionescu-Ittu R; Latremouille-Viau D; Wu EQ; Ramalingam S
  • A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) With Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer
    Volume: 90 Page(s): S4 - S5
    11/15/2014 Authors: Ramalingam S; Blais N; Mazieres J; Reck M; Jones CM; Juhasz E; Urban L; Orlov S; Barlesi F; Kio E
  • Investigating the Molecular Profile of Lung Adenocarcinoma: A Single-Institution Analysis
    Volume: 90 Page(s): S50 - S51
    11/15/2014 Authors: Steuer C; Behera M; Rossi M; Fisher K; Sica G; Gal A; Pakkala S; Pillai R; Owonikoko T; Khuri F
  • Clinical and Pathologic Characterization of Folate Receptor Alpha, Mesothelin, and Endosialin Expression in Mesotheliomas
    Volume: 90 Page(s): S29 - S29
    11/15/2014 Authors: Owonikoko TK; Busari A; Chen Z; Kim S; Alexis D; Somers EB; O'Shannessy DJ; Ramalingam S; Khuri F; Sica GL
  • Evaluation of Hospitalization Trends in Lung Cancer Patients With Hyponatremia
    Volume: 90 Page(s): S62 - S62
    11/15/2014 Authors: Kazi HA; Behera M; Steuer C; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS
  • Higher Dose of Palliative Thoracic Radiation Is Associated With Improved Survival for Patients With Stage IV Non-Small Cell Lung Cancer
    Volume: 90 Page(s): S48 - S48
    11/15/2014 Authors: Rajpara RS; Gillespie TW; Nickleach DC; Liu Y; Lipscomb J; Fernandez FG; Mikell JL; Ramalingam SS; Owonikoko TK; Pillai RN
  • A Comparison of Palliative Inpatient Management Strategies for Cancer-Related Superior Vena Cava Obstruction
    Volume: 90 Page(s): S68 - S69
    11/15/2014 Authors: Hall WA; Steuer CE; Nickleach DC; Behera M; Owonikoko TK; Higgins KA; Khuri FR; Curran WJ; Ramalingam SS
  • Postoperative Radiation Therapy (PORT) Is Associated With Better Survival in Non-Small Cell Lung Cancer With Involved N2 Lymph Nodes
    Volume: 90 Page(s): S18 - S18
    11/15/2014 Authors: Mikell JL; Gillespie TW; Hall WA; Nickleach DC; Liu Y; Lipscomb J; Ramalingam SS; Rajpara RS; Force SD; Fernandez FG
  • Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.
    J Clin Oncol Volume: 32 Page(s): 3673 - 3679
    11/10/2014 Authors: Leighl NB; Rekhtman N; Biermann WA; Huang J; Mino-Kenudson M; Ramalingam SS; West H; Whitlock S; Somerfield MR
  • Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
    Lancet Oncol Volume: 15 Page(s): 1369 - 1378
    11/01/2014 Authors: Ramalingam SS; Jnne PA; Mok T; O'Byrne K; Boyer MJ; Von Pawel J; Pluzanski A; Shtivelband M; Docampo LI; Bennouna J
  • Ethnic, gender, and age disparities and outcome of phase I clinical trials of biologically targeted anticancer agents
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION Volume: 23
    11/01/2014 Authors: Owonikoko TK; Lewis C; Busari AK; Kim S; Chen Z; Lawson DH; Carthon BC; El-Rayes BF; Khuri FR; Kauh J
  • Integrated genomic characterization of papillary thyroid carcinoma.
    Cell Volume: 159 Page(s): 676 - 690
    10/23/2014 Authors: Cancer Genome Atlas Research Network
  • Development of small molecule Bax agonists for lung cancer treatment
    Volume: 74
    10/01/2014 Authors: Xin M; Li R; Park D; Owonikoko TK; Sica GL; Corsino PE; Ding JZC; Magis AT; Ramalingam SS; Curran WJ
  • Preserved histological and molecular phenotypes following serial in vivo propagation of patient-derived xenografts of small cell lung cancer
    Volume: 74
    10/01/2014 Authors: Owonikoko TK; Zhang G; Sica GL; Kim HS; Ogee-Nwankwo OC; Ramalingam SS; Rossi MR; Khuri FR
  • Evaluating markers of cisplatin sensitivity and survival in small cell lung cancer
    Volume: 74
    10/01/2014 Authors: Owonikoko TK; Zhang G; Sica GL; Chen Z; Switchenko JM; Kim S; Gal AA; Ramalingam SS; Deng X; Rossi MR
  • Evaluation of genomic profiling in the GALAXY-1 (NCT01348126), a randomized Phase 2b study of ganetespib in combination with docetaxel versus docetaxel alone as second line therapy in patients with advanced NSCLC
    Volume: 74
    10/01/2014 Authors: Fennell D; Antonov A; Martins ML; Popat S; Ramalingam SS; Spicer J; Vukovic VM; El-Hariry I; Reichert V; Rosell R
  • Risk factors for long-term mortality after pulmonary resection for lung cancer: an analysis of over 90,000 patients from the National Cancer Data Base
    Volume: 219 Page(s): E66 - E66
    10/01/2014 Authors: Khullar OV; Gillespie T; Nickleach D; Liu Y; Higgins K; Ramalingam S; Lipscomb J; Fernandez FG
  • Risk factors for 30-day mortality after pulmonary resection for lung cancer from The National Cancer Data Base: an analysis of over 200,000 patients
    Volume: 219 Page(s): E64 - E64
    10/01/2014 Authors: Sancheti MS; Gillespie T; Nickleach D; Liu Y; Higgins K; Ramalingam S; Lipscomb J; Fernandez FG
  • Small-molecule Bax agonists for cancer therapy.
    Nat Commun Volume: 5 Page(s): 4935
    09/17/2014 Authors: Xin M; Li R; Xie M; Park D; Owonikoko TK; Sica GL; Corsino PE; Zhou J; Ding C; White MA
  • Comprehensive molecular profiling of lung adenocarcinoma (vol 489, pg 519, 2012)
    NATURE Volume: 513 Page(s): 543 - 550
    09/11/2014 Authors: Collisson EA; Campbell JD; Brooks AN; Berger AH; Lee W; Chmielecki J; Beers DG; Cope L; Creighton CJ; Danilova L
  • Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review.
    Oral Oncol Volume: 50 Page(s): 888 - 894
    09/01/2014 Authors: Behera M; Owonikoko TK; Kim S; Chen Z; Higgins K; Ramalingam SS; Shin DM; Khuri FR; Beitler JJ; Saba NF
  • A Comparison of Palliative Inpatient Management Strategies for Cancer-Related Superior Vena Cava Obstruction
    Volume: 90 Page(s): S80 - S81
    09/01/2014 Authors: Hall WA; Steuer CE; Nickleach DC; Behera M; Owonikoko TK; Higgins KA; Khuri FR; Curran WJ; Ramalingam SS
  • EVALUATION OF HOSPITALIZATION TRENDS IN LUNG CANCER PATIENTS WITH HYPONATREMIA
    JOURNAL OF THORACIC ONCOLOGY Volume: 9 Page(s): S182 - S182
    09/01/2014 Authors: Kazi HA; Behera M; Steuer C; Owonikoko T; Pillai R; Ramalingam SS; Khuri FR
  • 449PDUPDATED SAFETY AND EFFICACY FROM A PHASE I STUDY OF AZD9291 IN PATIENTS (PTS) WITH EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER (NSCLC).
    Ann Oncol Volume: 25 Page(s): iv149
    09/01/2014 Authors: Yang JC; Kim D; Planchard D; Ohe Y; Ramalingam SS; Ahn M; Kim S; Su W; Horn L; Haggstrom D
  • 1243PDACOMITINIB (D) VERSUS ERLOTINIB (E) IN 2ND/3RD LINE NSCLC: OUTCOME FOR ASIAN PATIENTS FROM THE ARCHER 1009 GLOBAL PHASE 3 TRIAL.
    Ann Oncol Volume: 25 Page(s): iv435
    09/01/2014 Authors: Mok T; O'Byrne KJ; Ramalingam SS; Janne PA; Boyer M; Ahn JS; Zhang H; O'Connell J; Taylor I; Mather C
  • ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options.
    Cancer Volume: 120 Page(s): 2392 - 2402
    08/15/2014 Authors: Steuer CE; Ramalingam SS
  • Comprehensive molecular profiling of lung adenocarcinoma.
    Nature Volume: 511 Page(s): 543 - 550
    07/31/2014 Authors: Cancer Genome Atlas Research Network
  • Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis.
    Cell Death Differ Volume: 21 Page(s): 1160 - 1169
    07/01/2014 Authors: Wang B; Xie M; Li R; Owonikoko TK; Ramalingam SS; Khuri FR; Curran WJ; Wang Y; Deng X
  • Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).
    Cancer Chemother Pharmacol Volume: 74 Page(s): 177 - 183
    07/01/2014 Authors: Pillai RN; Aisner J; Dahlberg SE; Rogers JS; DiPaola RS; Aisner S; Ramalingam SS; Schiller JH
  • HPV-associated lung cancers: an international pooled analysis.
    Carcinogenesis Volume: 35 Page(s): 1267 - 1275
    06/01/2014 Authors: Ragin C; Obikoya-Malomo M; Kim S; Chen Z; Flores-Obando R; Gibbs D; Koriyama C; Aguayo F; Koshiol J; Caporaso NE
  • Second-generation ALK inhibitors: filling the non "MET" gap.
    Cancer Discov Volume: 4 Page(s): 634 - 636
    06/01/2014 Authors: Ramalingam SS; Khuri FR
  • Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib itt combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma.
    Volume: 32
    05/20/2014 Authors: Ramalingam SS; Zaric B; Ceric T; Cluleanu TE; Spicer JF; Bondarenko I; Komov D; Felip E; Caromany E; Von Pawel J
  • Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009).
    Volume: 32
    05/20/2014 Authors: Ramalingam SS; Janne PA; Mok T; O'Byrne K; Boyer MJ; Zhang H; Liang JQ; Doherty JP; Taylor I; Mather CA
  • Second primary lung cancers: Analysis of E5597 selenium chemoprevention study.
    Volume: 32
    05/20/2014 Authors: Pillai RN; Lee SJ; Karp DD; Aisner SC; Ruckdeschel JC; Ramalingam SS; Khuri FR
  • Predictors and outcomes of venous thromboembolism (VTE) in hospitalized lung cancer patients: A nationwide inpatient sample (NIS) database analysis
    Volume: 32
    05/20/2014 Authors: Steuer CE; Behera M; Kim S; Patel N; Chen Z; Pillai RN; Saba NF; Shin DM; Owonlkoko TK; Khuri FR
  • A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer
    Volume: 32
    05/20/2014 Authors: Herbst RS; Gurpide A; Surmont V; Kim D-W; Waqar SN; Herder J; Lee DH; Carcereny E; Reguart N; Wallmark JM
  • Predictive value of gene expression signatures in premalignant lesions of the head and neck for response to cheinoprevention with EGFR and COX-2 inhibitors.
    Volume: 32
    05/20/2014 Authors: Saba NF; Rossi MR; Dwivedi B; Switchenko JM; Magllocca KR; Ramalingam SS; Owonlkoko TK; Khuri FR; Chen ZG; Kowalski J
  • Management approaches and outcomes of lung cancer patients hospitalized for malignant pleural effusions.
    Volume: 32
    05/20/2014 Authors: Behera M; Steuer CE; Kim S; Pillai RN; Chen Z; Owonikoko TK; Belani CP; Khuri FR; Ramalingam SS
  • Clinical characteristics and outcomes of atypical carcinoid (AC) tumor of the lung: A Surveillance, Epidemiology, and End Results database analysis.
    Volume: 32
    05/20/2014 Authors: Steuer CE; Behera M; Kim S; Chen Z; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS
  • Trends in small cell lung cancer (SCLC) survival: Predictors and impact of systemic therapy
    Volume: 32
    05/20/2014 Authors: Behera M; Ragin C; Kim S; Chen Z; Steuer CE; Saba NF; Pillal RN; Belani CP; Ramalingam SS; Khuri FR
  • A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer
    Volume: 32
    05/20/2014 Authors: Gerber DE; Ramalingam SS; Morgensztern D; Kelly RJ; Burns TF; Lopez-Chavez A; Spigel DR; Wehbe AM; Sorensen R; Weaver DT
  • Racial disparities in the incidence and survival trends in women with squamous cell carcinoma of the oral tongue based on the Surveillance, Epidemiology, and End Results (SEER) analysis.
    Volume: 32
    05/20/2014 Authors: Joseph L; Goodman M; Higgins KA; Pilai R; Ramalingam SS; Owonikoko TK; Beitler JJ; Shin DM; Khuri FR; Saba NF
  • Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer.
    Cancer Volume: 120 Page(s): 1394 - 1400
    05/01/2014 Authors: Kang H; Gillespie TW; Goodman M; Brodie SA; Brandes M; Ribeiro M; Ramalingam SS; Shin DM; Khuri FR; Brandes JC
  • Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape.
    Asia Pac J Clin Oncol Volume: 10 Suppl 2 Page(s): 2 - 10
    04/01/2014 Authors: Boyer M; Tsao M-S; Jnne P; Ramalingam S; Pitman Lowenthal S; Alam M
  • Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer.
    Cancer Prev Res (Phila) Volume: 7 Page(s): 351 - 361
    03/01/2014 Authors: Brodie SA; Li G; El-Kommos A; Kang H; Ramalingam SS; Behera M; Gandhi K; Kowalski J; Sica GL; Khuri FR
  • Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.
    Head Neck Pathol Volume: 8 Page(s): 66 - 72
    03/01/2014 Authors: Saba NF; Magliocca KR; Kim S; Muller S; Chen Z; Owonikoko TK; Sarlis NJ; Eggers C; Phelan V; Grist WJ
  • Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
    Cancer Prev Res (Phila) Volume: 7 Page(s): 283 - 291
    03/01/2014 Authors: Saba NF; Hurwitz SJ; Kono SA; Yang CS; Zhao Y; Chen Z; Sica G; Mller S; Moreno-Williams R; Lewis M
  • Advances in the diagnosis and treatment of non-small cell lung cancer.
    Mol Cancer Ther Volume: 13 Page(s): 557 - 564
    03/01/2014 Authors: Pillai RN; Ramalingam SS
  • Heat shock protein 90 inhibitors in non-small-cell lung cancer.
    Curr Opin Oncol Volume: 26 Page(s): 159 - 164
    03/01/2014 Authors: Pillai RN; Ramalingam SS
  • SOX2 Expression in EGFR and KRAS Mutated Lung Adenocarcinomas
    Volume: 27 Page(s): 476A - 476A
    02/01/2014 Authors: Fatima N; Fisher K; Rossi MR; Zhang L; Owanikoko T; Ramalingam S; Khuri F; Gal A; Cohen C; Sica G
  • c-Met Immunohistochemistry in EGFR Mutant Adenocarcinoma: Comparison with Fluorescence In-Situ Hybridization
    Volume: 27 Page(s): 499A - 499A
    02/01/2014 Authors: Willis BC; Martin DR; Saxe D; Ramalingam SS; Khuri F; Fisher KE; Rossi MR; Cohen C; Sica G
  • c-Met Immunohistochemistry in EGFR Mutant Adenocarcinoma: Comparison with Fluorescence In-Situ Hybridization
    Volume: 94 Page(s): 499A - 499A
    02/01/2014 Authors: Willis BC; Mortin DR; Saxe D; Ramalingam SS; Khuri F; Fisher KE; Rossi MR; Cohen C; Sica G
  • Molecular Detection of Clinically Actionable Lung Cancer Mutations: Multiplexed Single Gene Assays Versus Next-Generation Sequencing Following Target-Enrichment
    Volume: 94 Page(s): 476A - 477A
    02/01/2014 Authors: Fisher KE; Wang J; Pillai RN; Owonikoko TK; Ramalingam SR; Khuri FR; Gal AA; Mann KP; Hill CE; Sica GL
  • Molecular Detection of Clinically Actionable Lung Cancer Mutations: Multiplexed Single Gene Assays Versus Next-Generation Sequencing Following Target-Enrichment
    Volume: 27 Page(s): 476A - 477A
    02/01/2014 Authors: Fisher KE; Wang J; Pillai RN; Owonikoko TK; Ramalingam SR; Khuri FR; Gal AA; Mann KP; Hill CE; Sica GL
  • SOX2 Expression in EGFR and KRAS Mutated Lung Adenocarcinomas
    Volume: 94 Page(s): 476A - 476A
    02/01/2014 Authors: Fatima N; Fisher K; Rossi MR; Zhang L; Owanikoko T; Ramalingam S; Khuri F; Gal A; Cohen C; Sica G
  • Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase.
    Cancer Res Volume: 74 Page(s): 212 - 223
    01/01/2014 Authors: Xie M; Yen Y; Owonikoko TK; Ramalingam SS; Khuri FR; Curran WJ; Doetsch PW; Deng X
  • E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
    Cancer Chemother Pharmacol Volume: 73 Page(s): 171 - 180
    01/01/2014 Authors: Owonikoko TK; Aisner J; Wang XV; Dahlberg SE; Rubin EH; Ramalingam SS; Gounder M; Rausch PG; Axelrod RS; Schiller JH
  • Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung cancer.
    Cancer Volume: 119 Page(s): 3753 - 3760
    11/01/2013 Authors: Eaton BR; Kim S; Marcus DM; Prabhu R; Chen Z; Ramalingam SS; Curran WJ; Higgins KA
  • A PHASE IB PREOPERATIVE PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF EVEROLIMUS IN OPERABLE NON SMALL CELL LUNG CANCER
    JOURNAL OF THORACIC ONCOLOGY Volume: 8 Page(s): S628 - S629
    11/01/2013 Authors: Owonikoko TK; Miller DL; Force S; Sica G; Saba NF; Kono SA; Behera M; Lewis C; Chen Z; Pickens A
  • PATIENT REPORT OF DACOMITINIB (PF-00299804)-ASSOCIATED SYMPTOM AND HRQOL BENEFIT IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    JOURNAL OF THORACIC ONCOLOGY Volume: 8 Page(s): S906 - S906
    11/01/2013 Authors: Doherty JP; Reckamp KL; Connell JO; Letrent S; Ramalingam SS; Boyer M; Jaenne PA; Park K; Kim D-W; Gadgeel S
  • Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
    Ann Oncol Volume: 24 Page(s): 2875 - 2880
    11/01/2013 Authors: Ramalingam S; Crawford J; Chang A; Manegold C; Perez-Soler R; Douillard J-Y; Thatcher N; Barlesi F; Owonikoko T; Wang Y
  • GALAXY-1: RANDOMIZED PHASE II STUDY OF DOCETAXEL WITH OR WITHOUT GANETESPIB IN ADVANCED LUNG ADENOCARCINOMA: RESULTS IN BIOMARKER SUB-GROUPS AND ALL ADENOCARCINOMA PATIENTS.
    JOURNAL OF THORACIC ONCOLOGY Volume: 8 Page(s): S139 - S139
    11/01/2013 Authors: Ramalingam SS; Shapiro G; Hirsh V; Zaric B; Ceric T; Poddubskaya E; Goldman J; Ciuleanu T; Khuri FR; Spicer J
  • EFFICACY AND SAFETY OF PACLITAXEL AND CARBOPLATIN WITH BEVACIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSES BASED ON AGE IN THE PHASE 3 POINTBREAK AND E4599 TRIALS
    JOURNAL OF THORACIC ONCOLOGY Volume: 8 Page(s): S291 - S292
    11/01/2013 Authors: Langer CJ; Socinski MA; Patel JD; Sandler AB; Schiller JH; Leon L; Hazard S; Ramalingam SS
  • OVERALL SURVIVAL AND HOSPITALIZATION RATES IN MEDICARE PATIENTS DIAGNOSED WITH ADVANCED NSCLC TREATED WITH BEVACIZUMAB- PACLITAXEL-CARBOPLATIN VS PACLITAXEL-CARBOPLATIN: A RETROSPECTIVE COHORT STUDY
    JOURNAL OF THORACIC ONCOLOGY Volume: 8 Page(s): S877 - S877
    11/01/2013 Authors: Langer CJ; Ravelo A; Hazard S; Guerin A; Latremouille-Viau D; Ionescu-Ittu R; Wu EQ; Ramalingam SS
  • Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
    Mol Cancer Ther Volume: 12 Page(s): 2200 - 2212
    10/01/2013 Authors: Li R; Hu Z; Sun S-Y; Chen ZG; Owonikoko TK; Sica GL; Ramalingam SS; Curran WJ; Khuri FR; Deng X
  • Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
    Cancer Res Volume: 73 Page(s): 5485 - 5496
    09/01/2013 Authors: Park D; Magis AT; Li R; Owonikoko TK; Sica GL; Sun S-Y; Ramalingam SS; Khuri FR; Curran WJ; Deng X
  • A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.
    Lung Cancer Volume: 81 Page(s): 416 - 421
    09/01/2013 Authors: Ramalingam SS; Kotsakis A; Tarhini AA; Heron DE; Smith R; Friedland D; Petro DP; Raez LE; Brahmer JR; Greenberger JS
  • Ganetespib in combination with docetaxel versus docetaxel alone in second line adenocarcinoma patients with KRAS mutations and elevated LDH levels
    Volume: 49 Page(s): S801 - S801
    09/01/2013 Authors: Fennell DA; Goss GD; Andric Z; Bondarenko I; Zaric B; Ceric T; Poddubskaya E; Teofilovici F; Guo W; Ramalingam S
  • Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.
    J Thorac Oncol Volume: 8 Page(s): 1121 - 1127
    09/01/2013 Authors: Dahlberg SE; Schiller JH; Bonomi PB; Sandler AB; Brahmer JR; Ramalingam SS; Johnson DH
  • Class I HDACs are mediators of smoke-carcinogen induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer
    CANCER RESEARCH Volume: 73
    07/01/2013 Authors: Brodie SA; Li G; El-Kommos A; Ramalingam SS; Behera M; Kowalski J; Gandhi K; Khuri FH; Vertino P; Brandes JC
  • A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
    Clin Cancer Res Volume: 19 Page(s): 3068 - 3077
    06/01/2013 Authors: Socinski MA; Goldman J; El-Hariry I; Koczywas M; Vukovic V; Horn L; Paschold E; Salgia R; West H; Sequist LV
  • A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1)
    Volume: 31
    05/20/2013 Authors: Ramalingam SS; Goss GD; Andric ZG; Bondarenko I; Zaric B; Ceric T; Poddubskaya EV; Ciuleanu T-E; Spicer JF; Felip E
  • Exploratory biomarker analyses from ECOG 4508: Three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients (pts)
    Volume: 31
    05/20/2013 Authors: Aggarwal C; Dahlberg SE; Hanna N; Kolesar J; Hirsch FR; Ramalingam SS; Schiller JH
  • Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trials
    Volume: 31
    05/20/2013 Authors: Langer CJ; Socinski MA; Patel JD; Sandler A; Schiller JH; Leon L; Uttamsingh S; Ramalingam SS
  • Adherence reporting in phase III trials of approved oral anticancer agents: A systematic review.
    Volume: 31
    05/20/2013 Authors: Harvey RD; McKibbin T; Behera M; Ramalingam SS
  • Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study.
    Volume: 31
    05/20/2013 Authors: Saba NF; Kono SA; Mendel JR; Hurwitz SJ; Owonikoko TK; Lewis CM; Harvey D; Rogerio JW; Chen Z; Wadsworth T
  • A retrospective cohort study of inpatient chemotherapy utilization in hospitalized advanced lung cancer patients in the United States.
    Volume: 31
    05/20/2013 Authors: Kang H; Kim S; Chen Z; El-Rayes BF; Brandes JC; Saba NF; Khuri FR; Ramalingam SS; Owonikoko TK
  • Bevacizumab in combination with taxane versus non-taxane-containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC): A systematic review.
    Volume: 31
    05/20/2013 Authors: Behera M; Pillai RN; Owonikoko TK; Kim S; Chen Z; Saba NF; Belani CP; Khuri FR; Ramalingam SS
  • Multiplatform assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in signet ring cell carcinoma of the gastrointestinal tract
    Volume: 31
    05/20/2013 Authors: Alese OB; El-Rayes BF; Sica G; Zhang G; Rossi MR; Adsay V; Alexis D; La Rosa FG; Varella-Garcia M; Chen Z
  • GALAXY-2 trial: A randomized phase III study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma.
    Volume: 31
    05/20/2013 Authors: Fennell DA; Goss GD; Socinski MA; Nakagawa K; Schiller JH; Bonomi P; Hirsh V; Kelly K; Spicer JF; Rosell R
  • Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
    J Biol Chem Volume: 288 Page(s): 13215 - 13224
    05/10/2013 Authors: Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR
  • Poly (ADP) ribose polymerase (PARP) enzyme inhibitor, CEP8983, potentiates bendamustine activity in small cell lung cancer (SCLC)
    Volume: 73
    04/15/2013 Authors: Owonikoko TK; Zhang G; Yue P; Ramalingam S; Khuri FR; Sun S-Y
  • Development of small molecule BcI-XL inhibitors for treatment of lung cancer
    Volume: 73
    04/15/2013 Authors: Park D; Magis AT; Li R; Owonikoko TKK; Sica GL; Sun S-Y; Ramalingam SS; Khuri FR; Curran WJ; Deng X
  • Window of opportunity preoperative interrogation of mTOR pathway in patients with resectable non-small cell lung cancer (NSCLC).
    Volume: 73
    04/15/2013 Authors: Owonikoko TK; Miller DL; Force S; Sica G; Kono S; Behera M; Mendel J; Chen Z; Pickens A; Fu RW
  • Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer.
    Cancer Volume: 119 Page(s): 1503 - 1511
    04/15/2013 Authors: Owonikoko TK; Hossain MS; Bhimani C; Chen Z; Kim S; Ramalingam SS; Sun S-Y; Shin DM; Waller EK; Khuri FR
  • Reply to M.C. Garassino et al.
    J Clin Oncol Volume: 31 Page(s): 1255
    03/20/2013 Authors: Ramalingam SS; O'Connell J; Liang JQ
  • CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
    Clin Cancer Res Volume: 19 Page(s): 1603 - 1611
    03/15/2013 Authors: Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG
  • A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
    Br J Cancer Volume: 108 Page(s): 762 - 765
    03/05/2013 Authors: Harvey RD; Owonikoko TK; Lewis CM; Akintayo A; Chen Z; Tighiouart M; Ramalingam SS; Fanucchi MP; Nadella P; Rogatko A
  • Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
    J Thorac Oncol Volume: 8 Page(s): 369 - 372
    03/01/2013 Authors: Ramalingam SS; Owonikoko TK; Behera M; Subramanian J; Saba NF; Kono SA; Gal AA; Sica G; Harvey RD; Chen Z
  • Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables.
    Clin Lung Cancer Volume: 14 Page(s): 128 - 138
    03/01/2013 Authors: Behera M; Heine JJ; Sica GL; Fowler EE; Tran H; Fu RW; Gal AA; Hermann R; Mayfield W; Khuri FR
  • Inhibition of insulin-like growth factor receptor: end of a targeted therapy?
    Transl Lung Cancer Res Volume: 2 Page(s): 14 - 22
    02/01/2013 Authors: Pillai RN; Ramalingam SS
  • Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.
    Oncologist Volume: 18 Page(s): 600 - 610
    01/01/2013 Authors: Owonikoko TK; Ragin C; Chen Z; Kim S; Behera M; Brandes JC; Saba NF; Pentz R; Ramalingam SS; Khuri FR
  • Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions.
    PLoS One Volume: 8 Page(s): e81162
    01/01/2013 Authors: Marullo R; Werner E; Degtyareva N; Moore B; Altavilla G; Ramalingam SS; Doetsch PW
  • The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.
    Cancer Lett Volume: 325 Page(s): 139 - 146
    12/28/2012 Authors: Ren H; Chen M; Yue P; Tao H; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • Two phase I trials exploring different dosing schedules of carboplatin (C), paclitaxel (P), and the poly-ADP-ribose polymerase (PARP) inhibitor, veliparib (ABT-888) (V) with activity in triple negative breast cancer (TNBC)
    CANCER RESEARCH Volume: 72
    12/15/2012 Authors: Puhalla SL; Appleman LJ; Beumer JH; Tawbi H; Stoller RG; Owonikoko TK; Ramalingam SS; Belani CP; Brufsky AM; Abraham J
  • c-Myc suppression of DNA double-strand break repair.
    Neoplasia Volume: 14 Page(s): 1190 - 1202
    12/01/2012 Authors: Li Z; Owonikoko TK; Sun S-Y; Ramalingam SS; Doetsch PW; Xiao Z-Q; Khuri FR; Curran WJ; Deng X
  • Hsp90 inhibitors.
    J Thorac Oncol Volume: 7 Page(s): S407 - S408
    12/01/2012 Authors: Pillai RN; Ramalingam SS
  • Hypogonadism related to crizotinib therapy: implications for patient care.
    Cancer Volume: 118 Page(s): E1 - E2
    11/01/2012 Authors: Ramalingam SS; Shaw AT
  • Clinical practice guidelines for cancer care: utilization and expectations of the practicing oncologist.
    J Oncol Pract Volume: 8 Page(s): 350 - 353
    11/01/2012 Authors: Dillmon M; Goldberg JM; Ramalingam SS; Mayer RJ; Loehrer P; Van Poznak C
  • THE GALAXY TRIAL (NCT01348126): A RANDOMIZED IIB/III STUDY OF GANETESPIB (STA-9090) IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE AS SECOND LINE THERAPY IN PATIENTS WITH STAGE MB OR IV NSCLC
    Volume: 7 Page(s): S446 - S446
    11/01/2012 Authors: Fennell D; Ramalingam S; Spicer J; Manegold C; Rosen R; Vukovic V; El-Hariry I; Teofilovici F; Guo W; Ivlulcahey S
  • ARCHER: DACOMITINIB (D; PF-00299804) VERSUS ERLOTINIB (E) FOR ADVANCED (ADV) NSCLC; A RANDOMIZED DOUBLE-BLIND PHASE III STUDY
    Volume: 23 Page(s): 22 - 23
    10/01/2012 Authors: Boyer M; Jaenne PA; Mok T; O'Byrne K; Paz-Ares L; Ramalingam SS; Liang J; Taylor I; Campbell A; O'Connell J
  • EVALUATION OF SYMPTOM IMPACT OF DACOMITINIB (PF-00299804) VERSUS ERLOTINIB IN PATIENTS WITH ADVANCED NSCLC AFTER CHEMOTHERAPY FAILURE
    Volume: 23 Page(s): 30 - 30
    10/01/2012 Authors: O'Connell J; Bottomley A; Ramalingam SS; Boyer MJ; Park K; Blackhall F; Mundayat R; Lee S-Y; Campbell A
  • Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
    J Clin Oncol Volume: 30 Page(s): 3337 - 3344
    09/20/2012 Authors: Ramalingam SS; Blackhall F; Krzakowski M; Barrios CH; Park K; Bover I; Seog Heo D; Rosell R; Talbot DC; Frank R
  • Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data.
    Cancer Volume: 118 Page(s): 4444 - 4451
    09/15/2012 Authors: Ellington CL; Goodman M; Kono SA; Grist W; Wadsworth T; Chen AY; Owonikoko T; Ramalingam S; Shin DM; Khuri FR
  • Lung cancer with translocation in the anaplastic lymphoma kinase gene: a disease within a disease.
    Cancer Volume: 118 Page(s): 4370 - 4371
    09/15/2012 Authors: Ramalingam SS; Khuri FR
  • MOLECULAR PROFILING AS AN OUTCOME PREDICTOR IN THE GALAXY TRIALTM (NCT01348126): A RANDOMIZED IIB/III STUDY OF GANETESPIB (STA-9090) IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN SUBJECTS WITH STAGE IIIB/IV NSCLC
    Volume: 23 Page(s): 529 - 529
    09/01/2012 Authors: Rosell R; Ramalingam SS; Fennell D; Manegold C; El Hariry I; Vukovic V; Teofilovici F; Reichert V; Goss G
  • The Role of Reactive Oxygen Species in Cisplatin Cytotoxicity
    Volume: 53 Page(s): S32 - S32
    09/01/2012 Authors: Marullo R; Degtyareva NP; Werner E; Ramalingam SS; Doetsch PW
  • Dacomitinib (D) Versus Erlotinib (E) in Patients (pt) with EGFR-mutated (mu) Advanced Non-small Cell Lung Cancer (NSCLC): Analyses from a Randomized, Phase 2 Trial
    JOURNAL OF THORACIC ONCOLOGY Volume: 7 Page(s): S203 - S203
    09/01/2012 Authors: Ramalingam S; Blackhall F; Rosell R; Mok T; Boyer M; Liang J; O'Connell J; Wang T; Taylor I
  • Parp Enzyme Inhibitor, Veliparib (ABT-888), Potentiates the Efficacy Of Chemotherapy And Radiation In Small Cell Lung Cancer (SCLC)
    Volume: 7 Page(s): S278 - S278
    09/01/2012 Authors: Owonikoko TK; Zhang G; Deng X; Li C; Beumer JH; Rossi MR; Ramalingam SS; Curran WJ; Sun S; Khuri FR
  • Tissue Expression of Activated Phosphorylated Forms of Bcl2 and Mcl1 as Prognostic Markers in Small Cell Lung Cancer
    JOURNAL OF THORACIC ONCOLOGY Volume: 7 Page(s): S219 - S219
    09/01/2012 Authors: Owonikoko TK; Chowdry RP; Chen Z; Goodman A; Kim S; Deng X; Gal A; Khuri FR; Ramalingam SS; Sica G
  • A Systematic Analysis Of High-dose Radiation In The Treatment Of Surgically Unresectable, Locally Advanced Non-small Cell Lung Cancer.
    JOURNAL OF THORACIC ONCOLOGY Volume: 7 Page(s): S212 - S213
    09/01/2012 Authors: Behera M; Beitler JJ; Bhimani C; Higgins K; Chen Z; Deng X; Curran WJ; Khuri FR; Ramalingam SS; Owonikoko TK
  • Development and Utilization of an Online Tool to Guide Choice of First-line and Maintenance Therapy (Tx) for Patients (Pts) With Advanced Non-Small-Cell Lung Cancer (NSCLC)
    JOURNAL OF THORACIC ONCOLOGY Volume: 7 Page(s): S271 - S271
    09/01/2012 Authors: Gandara DR; Edelman MJ; Giaccone G; Ramalingam SS; Guerra WM; Bowser AD; Mortimer J; West HL
  • Treatment of lung cancer.
    Radiol Clin North Am Volume: 50 Page(s): 961 - 974
    09/01/2012 Authors: Gadgeel SM; Ramalingam SS; Kalemkerian GP
  • Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis.
    Lung Cancer Volume: 77 Page(s): 331 - 338
    08/01/2012 Authors: Behera M; Owonikoko TK; Chen Z; Kono SA; Khuri FR; Belani CP; Ramalingam SS
  • Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.
    Cancer Chemother Pharmacol Volume: 70 Page(s): 201 - 205
    07/01/2012 Authors: Aregbe AO; Sherer EA; Egorin MJ; Scher HI; Solit DB; Ramanathan RK; Ramalingam S; Belani CP; Ivy PS; Bies RR
  • ARCHER: A RANDOMIZED DOUBLE-BLINDED PHASE III STUDY OF DACOMITINIB (PF-00299804) VERSUS ERLOTINIB FOR ADVANCED (ADV) NON-SMALL CELL LUNG CANCER (NSCLC)
    Volume: 7 Page(s): S67 - S67
    06/01/2012 Authors: Antic V; Boyer M; Janne P; Mok T; O'Byrne K; Paz-Ares L; Ramalingam SS; Liang J; Taylor I; Letrent S
  • EVALUATION OF SYMPTOM IMPACT OF DACOMITINIB (PF-00299804) VS ERLOTINIB IN PATIENTS WITH ADVANCED NSCLC AFTER CHEMOTHERAPY FAILURE: RESULTS FROM A PHASE 2 RANDOMIZED CLINICAL TRIAL
    Volume: 7 Page(s): S60 - S61
    06/01/2012 Authors: O'Connell J; Bottomley A; Ramalingam SS; Boyer M; Park K; Blackhall F; Mundayat R; Campbell A
  • Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
    Clin Cancer Res Volume: 18 Page(s): 3163 - 3169
    06/01/2012 Authors: Rudin CM; Hann CL; Garon EB; Ribeiro de Oliveira M; Bonomi PD; Camidge DR; Chu Q; Giaccone G; Khaira D; Ramalingam SS
  • The GALAXY Trial (NCT01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIIB or IV NSCLC
    Volume: 30
    05/20/2012 Authors: Goss GD; Manegold C; Rosell R; Fennell DA; Vukovic VM; El-Hariry I; Teofilovici F; Enke AS; Ramalingam SS
  • ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)-A randomized double-blind phase III study.
    Volume: 30
    05/20/2012 Authors: Boyer MJ; Janne PA; Mok T; O'Byrne KJ; Paz-Ares LG; Ramalingam SS; Liang JQ; Taylor I; Campbell A; O'Connell JP
  • A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
    Volume: 30
    05/20/2012 Authors: Owonikoko TK; Harvey RD; Kauh JS; Lewis CM; Hossain MS; Akintayo AO; Merriewether AR; Chen Z; Hawk NN; Saba NF
  • A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies
    Volume: 30
    05/20/2012 Authors: Kauh JS; Harvey RD; Owonikoko TK; El-Rayes BF; Shin DM; Murali S; Lewis CM; Karol MD; Teofilovici F; Du Y
  • Prognostic impact of circulating endothelial cell counts in patients with advanced non-small cell lung cancer
    Volume: 30
    05/20/2012 Authors: DeJoubner NJ; Kang H; Li Q; Harris WAC; Stewart R; Price A; Quyyumi A; Kono SA; Ramalingam SS; Owonikoko TK
  • Acetylated tubulin and risk of nodal metastases in squamous cell carcinoma of the head and neck (SCCHN)
    Volume: 30
    05/20/2012 Authors: Saba NF; Magliocca KR; Kim S; Muller S; Chen Z; Eggers C; Phelan VH; Kono SA; Owonikoko TK; Ramalingam SS
  • Expression pattern and biologic relevance of Bcl-2 and Mcl-1 in pulmonary neuroendocrine tumors.
    Volume: 30
    05/20/2012 Authors: Chowdry RP; Sica G; Chen Z; Goodman A; Kim S; Deng X; Curran WJ; Gal AA; Khuri FR; Ramalingam SS
  • Using CHFR expression to predict response and survival after first line treatment with carboplatin-paclitaxel in NSCLC.
    Volume: 30
    05/20/2012 Authors: Pillai RN; Brodie SA; Li G; Herman JG; Brock M; Owonikoko TK; Ramalingam SS; Khuri FR; Brandes JC
  • A systematic analysis of high-dose radiation in the treatment of surgically unresectable, locally advanced non-small cell lung cancer
    Volume: 30
    05/20/2012 Authors: Behera M; Beitler JJ; Bhimani C; Higgins K; Chen Z; Kim S; Deng X; Curran WJ; Khuri FR; Ramalingam SS
  • Paranasal sinus squamous cell carcinomas (PNSSCC) incidence and survival trends.
    Volume: 30
    05/20/2012 Authors: Ansa B; Goodman M; Ward K; Kono SA; Kunle T; Grist OW; Wadsworth T; El-Deiry M; Chen AY; Ramalingam SS
  • A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer.
    J Thorac Oncol Volume: 7 Page(s): 866 - 872
    05/01/2012 Authors: Owonikoko TK; Behera M; Chen Z; Bhimani C; Curran WJ; Khuri FR; Ramalingam SS
  • GSK3 plays a crucial role in determining cell response to mTOR inhibitors
    CANCER RESEARCH Volume: 72
    04/15/2012 Authors: Koo J; Yue P; Tao H; Ramalingam SS; Khuri FR; Sun S-Y
  • An endogenous mTOR inhibitor, PRAS40, is upregulated in lung cancer and contributes to tumor cell invasion and chemoresistance
    CANCER RESEARCH Volume: 72
    04/15/2012 Authors: Li Z; Du Y; Sica G; Ramalingam SS; Gal AA; Pan L; Tighiouart MM; Khuri FRFR; Fu H
  • The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.
    Curr Oncol Rep Volume: 14 Page(s): 105 - 110
    04/01/2012 Authors: Pillai RN; Ramalingam SS
  • A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
    Cancer Chemother Pharmacol Volume: 69 Page(s): 835 - 843
    03/01/2012 Authors: Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz H-J; Lim D; Shibata S; Chung V; Stoller RG
  • Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
    Cancer Biol Ther Volume: 13 Page(s): 272 - 280
    03/01/2012 Authors: Li Y; Fan S; Koo J; Yue P; Chen ZG; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
    J Thorac Oncol Volume: 7 Page(s): 574 - 578
    03/01/2012 Authors: Gitlitz BJ; Tsao-Wei DD; Groshen S; Davies A; Koczywas M; Belani CP; Argiris A; Ramalingam S; Vokes EE; Edelman M
  • An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.
    Cancer Chemother Pharmacol Volume: 69 Page(s): 605 - 612
    03/01/2012 Authors: O'Bryant CL; Haluska P; Rosen L; Ramanathan RK; Venugopal B; Leong S; Boinpally R; Franke A; Witt K; Evans J
  • Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases.
    J Biol Chem Volume: 287 Page(s): 6113 - 6127
    02/24/2012 Authors: Qi Q; He K; Yoo M-H; Chan C-B; Liu X; Zhang Z; Olson JJ; Xiao G; Wang L; Mao H
  • Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
    J Clin Pharmacol Volume: 52 Page(s): 180 - 194
    02/01/2012 Authors: Wu H; Ramanathan RK; Zamboni BA; Strychor S; Ramalingam S; Edwards RP; Friedland DM; Stoller RG; Belani CP; Maruca LJ
  • Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.
    Int J Nanomedicine Volume: 7 Page(s): 5555 - 5564
    01/01/2012 Authors: Wu H; Ramanathan RK; Zamboni BA; Strychor S; Ramalingam S; Edwards RP; Friedland DM; Stoller RG; Belani CP; Maruca LJ
  • Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy.
    Cancer Volume: 118 Page(s): 164 - 172
    01/01/2012 Authors: Pakkala S; Chen Z; Rimland D; Owonikoko TK; Gunthel C; Brandes JR; Saba NR; Shin DM; Curran WJ; Khuri FR
  • Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
    J Clin Oncol Volume: 29 Page(s): 4574 - 4580
    12/01/2011 Authors: Ramalingam SS; Spigel DR; Chen D; Steins MB; Engelman JA; Schneider C-P; Novello S; Eberhardt WEE; Crino L; Habben K
  • A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.
    Invest New Drugs Volume: 29 Page(s): 1426 - 1431
    12/01/2011 Authors: Heath EI; Lorusso P; Ramalingam SS; Awada A; Egorin MJ; Besse-Hamer T; Cardoso F; Valdivieso M; Has T; Alland L
  • Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data.
    Biomed Eng Online Volume: 10 Page(s): 97
    11/08/2011 Authors: Behera M; Fowler EE; Owonikoko TK; Land WH; Mayfield W; Chen Z; Khuri FR; Ramalingam SS; Heine JJ
  • Histone deacetylase inhibitors.
    J Thorac Oncol Volume: 6 Page(s): S1808 - S1809
    11/01/2011 Authors: Ramalingam SS
  • Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
    J Thorac Oncol Volume: 6 Page(s): 1741 - 1745
    10/01/2011 Authors: Ramalingam SS; Davies AM; Longmate J; Edelman MJ; Lara PN; Vokes EE; Villalona-Calero M; Gitlitz B; Reckamp K; Salgia R
  • Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy.
    Cancer Biol Ther Volume: 12 Page(s): 549 - 555
    09/15/2011 Authors: Xu C-X; Zhao L; Yue P; Fang G; Tao H; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
    Cancer Volume: 117 Page(s): 4049 - 4059
    09/01/2011 Authors: Kauh J; Chanel-Vos C; Escuin D; Fanucchi MP; Harvey RD; Saba N; Shin DM; Gal A; Pan L; Kutner M
  • A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, In Combination With Docetaxel in Subjects With Advanced Solid Tumour Malignancies
    Volume: 47 Page(s): S153 - S153
    09/01/2011 Authors: Harvey RD; Lewis CM; Kauh JS; Owonikoko TK; Akintayo A; Karol M; Teofilovici F; Lufkin JM; Khuri FR; Ramalingam SS
  • Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression.
    Cancer Res Volume: 71 Page(s): 5245 - 5254
    08/01/2011 Authors: Dhandapani L; Yue P; Ramalingam SS; Khuri FR; Sun S-Y
  • ROLE OF HDAC INHIBITION IN THE REVERSAL OF EPIGENETIC GENE SILENCING IN LUNG CARCINOGENESIS.
    JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S677 - S677
    06/01/2011 Authors: Brodie SA; El-Kommos A; Ramalingam S; Khuri FR; Brandes JC
  • ANALYSIS OF MTOR SIGNALING PATHWAY BIOMARKERS IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH EVEROLIMUS AND DOCETAXEL IN A PHASE II CLINICAL TRIAL.
    JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S1039 - S1040
    06/01/2011 Authors: Owonikoko TK; Ramalingam S; Subramanian J; Sica G; Chen Z; Behera M; Rogerio J; Saba N; Tighiouart M; Gal A
  • CHEMOTHERAPY FIRST LINE AND AT RECURRENCE
    JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S188 - S189
    06/01/2011 Authors: Ramalingam S
  • GASTROINTESTINAL TOXICITY OF THE PAN-HER TYROSINE KINASE INHIBITOR (TKI) PF299804: ASSESSMENT BY PATIENT-REPORTED OUTCOMES IN 2ND/3RD-LINE AND REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC)
    JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S1184 - S1185
    06/01/2011 Authors: Campbell AK; Blackhal FH; Gadgeel SM; Janne PA; Park K; Mundayat R; Letrent SP; Boyer M; O'Connell J; Ramalingam S
  • A PHASE IB WINDOW OF OPPORTUNITY CLINICAL STUDY WITH EVEROLIMUS IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)
    JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S967 - S968
    06/01/2011 Authors: Owonikoko TK; Force S; Sica G; Bechara R; Harvey RD; Sun S-Y; Saba N; Rogerio J; Gal A; Kono S
  • OVERALL SURVIVAL (OS) RESULTS OF A RANDOMIZED PHASE 2 TRIAL OF PF299804 VERSUS ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AFTER FAILURE OF CHEMOTHERAPY
    JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S318 - S319
    06/01/2011 Authors: Boyer M; Blackhall FH; Barrios CH; Frank RC; Heo DS; Park K; Rosell R; Talbot DC; Taylor IC; Liang J
  • DERMATOLOGIC ADVERSE EVENTS OF THE PAN-HER TYROSINE KINASE INHIBITOR (TKI) PF299804: ASSESSMENT BY PATIENT-REPORTED OUTCOMES IN 2ND/3RD-LINE AND REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC)
    JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S1185 - S1186
    06/01/2011 Authors: Campbell AK; Boyer M; Giaccone G; Janne PA; Kim D-W; Park K; Ramalingam S; Reckamp KL; Mundayat R; Letrent SP
  • R1507, A MONOCLONAL ANTIBODY TO INSULIN-LIKE GROWTH FACTOR RECEPTOR-1 (IGF-1R), IN COMBINATION WITH ERLOTINIB FOR ADVANCED STAGE NON-SMALL CELL LUNG CANCER (NSCLC): A PLACEBO-CONTROLLED, RANDOMIZED PHASE II STUDY
    JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S605 - S605
    06/01/2011 Authors: Ramalingam S; Spigel D; Steins M; Engelman J; Novello S; Eberhardt W; Schneider C; Crino L; Janne PA; Liu L
  • Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
    J Liposome Res Volume: 21 Page(s): 158 - 165
    06/01/2011 Authors: Zamboni WC; Maruca LJ; Strychor S; Zamboni BA; Ramalingam S; Edwards RP; Kim J; Bang Y; Lee H; Friedland DM
  • Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.
    J Clin Oncol Volume: 29 Page(s): e14569
    05/20/2011 Authors: Saba NF; Kim HM; El-Rayes BF; Kono SA; Ramalingam SS; Owonikoko TK; Landry JC; Miller DL; Shin DM; Khuri FR
  • Comparison of native and adaptive immunity profiles of healthy volunteers and patients with well-differentiated thyroid cancer.
    J Clin Oncol Volume: 29 Page(s): 5585
    05/20/2011 Authors: Hossain S; Bhimani C; Chen Z; Ramalingam SS; Shin DM; Cohen C; Khuri FR; Waller E; Owonikoko TK
  • Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis.
    J Clin Oncol Volume: 29 Page(s): 7553
    05/20/2011 Authors: Behera M; Owonikoko TK; Chen Z; Kono SA; Khuri FR; Belani CP; Ramalingam SS
  • Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC.
    J Clin Oncol Volume: 29 Page(s): 7602
    05/20/2011 Authors: Owonikoko TK; Behera M; Tran HN; Chen Z; Chowdry RP; Saba NF; Ramalingam SS; Khuri FR
  • Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study.
    J Clin Oncol Volume: 29 Page(s): e13601
    05/20/2011 Authors: Khuri FR; Owonikoko TK; Subramanian J; Sica G; Behera M; Saba NF; Chen Z; Tighiouart M; Shin DM; Sun S
  • Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC).
    Volume: 29
    05/20/2011 Authors: Kotsakis AP; Ramalingam SS; Tarhini AA; Heron DE; Smith R; Friedland D; Petro DP; Raez LE; Brahmer JR; Greenberger JS
  • Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Saba NF; Kim HM; El-Rayes BF; Kono SA; Ramalingam SS; Owonikoko TK; Landry JC; Miller DL; Shin DM; Khuri FR
  • Salvage tyrosine kinase inhibitor therapy for differentiated and medullary thyroid cancer.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Chowdry RP; Bhimani C; Ramalingam SS; Khuri FR; Owonikoko TK
  • Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Sarantopoulos J; Lenz H; LoRusso P; Shibata S; Kummar S; Mulkerin D; Ramanathan RK; Mita MM; O'Rourke P; Remick SC
  • Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Behera M; Owonikoko TK; Chen Z; Kono SA; Khuri FR; Belani CP; Ramalingam SS
  • Comparison of native and adaptive immunity profiles of healthy volunteers and patients with well-differentiated thyroid cancer.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Hossain S; Bhimani C; Chen Z; Ramalingam SS; Shin DM; Cohen C; Khuri FR; Waller E; Owonikoko TK
  • Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Owonikoko TK; Behera M; Tran HN; Chen Z; Chowdry RP; Saba NF; Ramalingam SS; Khuri FR
  • A randomized phase III study of maintenance therapy with bevacizumab (B), pemetrexed (Pm), or a combination of bevacizumab and pemetrexed (BPm) following carboplatin, paclitaxel and bevacizumab (PCB) for advanced nonsquamous
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Dahlberg SE; Ramalingam SS; Belani CP; Schiller JH
  • Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC).
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Ramalingam SS; Spigel DR; Steins M; Engelman JA; Schneider C; Novello S; Eberhardt WE; Crino L; Janne PA; Liu L
  • Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504).
    J Clin Oncol Volume: 29 Page(s): 1709 - 1714
    05/01/2011 Authors: Ramalingam SS; Lee J-W; Belani CP; Aisner SC; Kolesar J; Howe C; Velasco MR; Schiller JH
  • Elevated eukaryotic translation initiation factor 4E (eIF4E) is involved in erlotinib resistance
    CANCER RESEARCH Volume: 71
    04/15/2011 Authors: Li Y; Koo J; Fan S; Yue P; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • Profiling counter-regulatory and cytotoxic immune pathways with cellular biomarkers in thyroid cancer patients
    CANCER RESEARCH Volume: 71
    04/15/2011 Authors: Hossain MS; Bhimani C; Chen Z; Shin D; Ramalingam SS; Khuri FR; Edmund WK; Owonikoko TK
  • Preclinical evaluation of Poly (ADP) Ribose Polymerase (PARP) enzyme inhibitor, ABT-888, in combination with cytotoxic agents in small cell lung cancer (SCLC)
    CANCER RESEARCH Volume: 71
    04/15/2011 Authors: Owonikoko TK; Zhang G; Yue P; Ramalingam S; Khuri F; Sun S-Y
  • Profiling counter-regulatory and cytotoxic immune pathways with cellular biomarkers in thyroid cancer patients
    CANCER RESEARCH Volume: 71
    04/15/2011 Authors: Hossain MS; Bhimani C; Chen Z; Shin D; Ramalingam SS; Khuri FR; Edmund WK; Owonikoko TK
  • A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer.
    Hum Gene Ther Volume: 22 Page(s): 336 - 342
    03/01/2011 Authors: Tarhini AA; Belani CP; Luketich JD; Argiris A; Ramalingam SS; Gooding W; Pennathur A; Petro D; Kane K; Liggitt D
  • A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
    Cancer Chemother Pharmacol Volume: 67 Page(s): 447 - 454
    02/01/2011 Authors: Holen KD; Belani CP; Wilding G; Ramalingam S; Volkman JL; Ramanathan RK; Vasist LS; Bowen CJ; Hodge JP; Dar MM
  • The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
    PLoS One Volume: 6 Page(s): e20899
    01/01/2011 Authors: Xu C-X; Li Y; Yue P; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • Lung cancer: New biological insights and recent therapeutic advances.
    CA Cancer J Clin Volume: 61 Page(s): 91 - 112
    01/01/2011 Authors: Ramalingam SS; Owonikoko TK; Khuri FR
  • Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis.
    Oncology Volume: 81 Page(s): 12 - 20
    01/01/2011 Authors: Saba NF; Goodman M; Ward K; Flowers C; Ramalingam S; Owonikoko T; Chen A; Grist W; Wadsworth T; Beitler JJ
  • Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
    Clin Lung Cancer Volume: 12 Page(s): 33 - 37
    01/01/2011 Authors: Lara PN; Longmate J; Reckamp K; Gitlitz B; Argiris A; Ramalingam S; Belani CP; Mack PC; Lau DHM; Koczywas M
  • Histone deacetylase, proteasome, and heat shock protein inhibitors for the treatment of lung cancer.
    J Thorac Oncol Volume: 5 Page(s): S458 - S460
    12/01/2010 Authors: Ramalingam SS
  • Lung cancer in the elderly: what's age got to do with it?
    Oncology (Williston Park) Volume: 24 Page(s): 1120 - 1129
    11/15/2010 Authors: Owonikoko TK; Ramalingam SS; Khuri FR
  • Lung cancer in HIV-positive patients.
    J Thorac Oncol Volume: 5 Page(s): 1864 - 1871
    11/01/2010 Authors: Pakkala S; Ramalingam SS
  • Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
    J Clin Oncol Volume: 28 Page(s): 4507 - 4512
    10/10/2010 Authors: Ramalingam SS; Kummar S; Sarantopoulos J; Shibata S; LoRusso P; Yerk M; Holleran J; Lin Y; Beumer JH; Harvey RD
  • RANDOMIZED PHASE 2 STUDY OF PF299804, AN IRREVERSIBLE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR, VERSUS (V) ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AFTER CHEMOTHERAPY (CT) FAILURE: QUANTITATIVE AND QUALITATIVE BENEFITS
    Volume: 21 Page(s): 122 - 123
    10/01/2010 Authors: Ramalingam SS; Boyer MJ; Park K; Barrios C; Krzakowski M; Taylor I; Liang JQ; O'Connell JP; Campbell AK; Blackhall F
  • Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
    Cancer Volume: 116 Page(s): 3903 - 3909
    08/15/2010 Authors: Ramalingam SS; Harvey RD; Saba N; Owonikoko TK; Kauh J; Shin DM; Sun S-Y; Strychor S; Tighiouart M; Egorin MJ
  • Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
    J Thorac Oncol Volume: 5 Page(s): 1279 - 1284
    08/01/2010 Authors: Ramalingam SS; Belani CP; Mack PC; Vokes EE; Longmate J; Govindan R; Koczywas M; Ivy SP; Gandara DR
  • What is the role of maintenance therapy in the treatment of non-small cell lung cancer?
    Ther Adv Med Oncol Volume: 2 Page(s): 229 - 235
    07/01/2010 Authors: Jiang Y; Owonikoko TK; Ramalingam SS; Khuri FR; Belani CP
  • Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Lancet Oncol Volume: 11 Page(s): 500 - 501
    06/01/2010 Authors: Stinchcombe TE; Ramalingam SS
  • Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC)
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Belani CP; Waterhouse DM; Ghazal H; Ramalingam SS; Bordoni R; Greenberg R; Levine RM; Waples JM; Jiang Y; Reznikoff G
  • Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504)
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Ramalingam SS; Lee J; Belani CP; Aisner SC; Kolesar J; Howe CW; Velasco MR; Schiller JH
  • Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Kauh JS; Harvey RD; Lawson DH; Owonikoko TK; Tighiouart M; Ramalingam SS; Shin DM; Lewis CM; El-Rayes BF; Khuri FR
  • Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Harvey RD; Kauh JS; Ramalingam SS; Lewis CM; Chen Z; Lonial S; Blount IC; Shin DM; Khuri FR; Owanikoko TK
  • Survival impact of newly approved therapeutic agents in patients with advanced non-small cell lung cancer (NSCLC): A SEER-Medicare database analysis.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Owonikoko TK; Ramalingam SS; Behera M; Brandes JC; Saba NF; Bhimani C; Harichand-Herdt S; Shin DM; Khuri FR; Ragin C
  • HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Pakkala S; Chen Z; Rimland D; Owonikoko TK; Gunthel C; Brandes JC; Saba NF; Curran WJ; Khuri FR; Ramalingam SS
  • Phase I study of vorinostat for patients with advanced solid tumors and hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI #8057)
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Egorin MJ; Kummar S; Sarantopoulos J; Shibata S; LoRusso P; Yerk M; Lin Y; Ivy SP; Belani CP; Ramalingam SS
  • A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase (MnSOD) plasmid liposome (PL) protection in patients with locally advanced stage III non-small cell lung cancer.
    Volume: 28
    05/20/2010 Authors: Schillo RE; Tarhini AA; Belani CP; Luketich JD; Argiris A; Ramalingam SS; Liggitt D; Championsmith T; Epperly MW; Greenberger JS
  • THE BIOLOGICAL SIGNIFICANCE OF TARGETED THERAPIES: THE DEVELOPMENT OF MTOR INHIBITORS
    JOURNAL OF THORACIC ONCOLOGY Volume: 5 Page(s): S27 - S27
    05/01/2010 Authors: Khuri FR; Ramalingam SS; Owonikoko TK; Sun S-Y; Fu H
  • Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus.
    Clin Cancer Res Volume: 16 Page(s): 2496 - 2504
    05/01/2010 Authors: Owonikoko TK; Ramalingam SS; Belani CP
  • Histone deacetylase (HDAC) enzyme inhibition potentiates taxanes and doxorubicin activity in thyroid cancer cell lines
    CANCER RESEARCH Volume: 70
    04/01/2010 Authors: Owonikoko TK; Zhang G; Ramalingam SS; Khuri FR; Sun S-Y
  • Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.
    J Clin Oncol Volume: 28 Page(s): 1520 - 1526
    03/20/2010 Authors: Ramanathan RK; Egorin MJ; Erlichman C; Remick SC; Ramalingam SS; Naret C; Holleran JL; TenEyck CJ; Ivy SP; Belani CP
  • Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope.
    Curr Opin Oncol Volume: 22 Page(s): 79 - 85
    03/01/2010 Authors: Ramalingam SS; Belani CP
  • Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.
    Cancer Volume: 116 Page(s): 1344 - 1349
    03/01/2010 Authors: Ramalingam SS; Foster J; Gooding W; Evans T; Sulecki M; Belani CP
  • Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.
    Int J Cancer Volume: 126 Page(s): 743 - 755
    02/01/2010 Authors: Owonikoko TK; Ramalingam SS; Kanterewicz B; Balius TE; Belani CP; Hershberger PA
  • A Phase I Study Demonstrating Manganese Superoxide Dismutase Plasmid Liposome Complex (MnSOD-PL) Reduction of Esophagitis following Standard Chemoradiation in Surgically Unresectable Stage III NSCLC
    Volume: 78 Page(s): S201 - S201
    01/01/2010 Authors: Greenberger JS; Belani CP; Leuketich JD; Argiris A; Ramalingam SS; Gooding W; Pennathur A; Petro D; Epperly MW; Tarhini AA
  • Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.
    J Clin Oncol Volume: 28 Page(s): 56 - 62
    01/01/2010 Authors: Ramalingam SS; Maitland ML; Frankel P; Argiris AE; Koczywas M; Gitlitz B; Thomas S; Espinoza-Delgado I; Vokes EE; Gandara DR
  • Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women.
    Semin Oncol Volume: 36 Page(s): 572 - 580
    12/01/2009 Authors: Harichand-Herdt S; Ramalingam SS
  • Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm.
    Cancer Volume: 115 Page(s): 5143 - 5154
    11/15/2009 Authors: Mok TSK; Ramalingam SS
  • PI3 Kinase, mTOR, and AKT Pathways
    JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S1059 - S1060
    11/01/2009 Authors: Ramalingam SS; Khuri FR
  • PI3 kinase, mTOR, and AKT pathways.
    J Thorac Oncol Volume: 4 Page(s): S1059 - S1060
    11/01/2009 Authors: Ramalingam SS; Khuri FR
  • Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
    Clin Pharmacol Ther Volume: 86 Page(s): 519 - 526
    11/01/2009 Authors: Zamboni WC; Strychor S; Maruca L; Ramalingam S; Zamboni BA; Wu H; Friedland DM; Edwards RP; Stoller RG; Belani CP
  • Induction trial of RAD001 in operable lung cancer
    JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S43 - S44
    09/01/2009 Authors: Khuri FR; Ramalingam S; Fu H; Sun S-Y
  • Preoperative therapy for early-stage NSCLC: opportunities and challenges.
    Oncology (Williston Park) Volume: 23 Page(s): 886 - 892
    09/01/2009 Authors: Owonikoko TK; Khuri FR; Ramalingam SS
  • Phase 2 study of ABT-869 in combination with Carboplatin/Paclitaxel (CP) in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC): lead-in cohort results
    JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S706 - S706
    09/01/2009 Authors: Ramalingam S; Owonikoko T; Khuri F; Saba N; Wallace J; Qian J; Gupta N; Ricker J; Carlson D
  • Preoperative Therapy for Early-Stage NSCLC: Opportunities and Challenges OWONIKOKO Article Reviewed
    ONCOLOGY-NEW YORK Volume: 23 Page(s): 886 - 892
    09/01/2009 Authors: Owonikoko TK; Khuri FR; Ramalingam SS
  • Randomized, double-blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small-cell lung cancer (NSCLC)
    Volume: 7 Page(s): 507 - 507
    09/01/2009 Authors: Belani C; Ramalingam S; Kalemkerian G; Mok T; Rosell R; Ahn MJ; Sun L; Gates M; Lubiniecki GM; Govindan R
  • A phase I study of everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory non-small cell lung cancer
    JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S594 - S595
    09/01/2009 Authors: Owonikoko TK; Ramalingam SS; Harvey D; Saba NF; Kauh J; Shin DM; Sun S-Y; Browning K; Tighiouart M; Khuri FR
  • Randomized, double-blind, phase II study of carboplatin and paclitaxel with either vorinostat, a histone deacetylase inhibitor (HDAC), or placebo for first line therapy of advanced non-small cell lung cancer (NCI 7863)
    JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S382 - S383
    09/01/2009 Authors: Ramalingam SS; Maitland M; Frankel P; Argiris A; Thomas S; Gitlitz B; Koczywas M; Espinoza-Delgado I; Vokes EE; Gandara DR
  • Notable progression free survival (PFS) and disease control rate (DCR) with the halichondrin B analogue eribulin mesylate in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with a taxane: a California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored phase II trial
    JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S450 - S450
    09/01/2009 Authors: Gitlitz BJ; Davies AM; Belani CP; Athanassios A; Ramalingam SS; Hoffman PC; Koczywas M; Groshen SG; Gandara DR
  • Targeting the IGF-1R in lung cancer prevention and therapy
    JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S189 - S190
    09/01/2009 Authors: Owonikoko TK; Ramalingam S; Sun S-Y; Khuri FR
  • Angiogenesis in lung cancer: predictive plasma biomarker profiles
    JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S21 - S22
    09/01/2009 Authors: Ramalingam SS
  • Multi-center phase II study of cetuximab in combination with thoracic radiotherapy followed by consolidation chemotherapy in patients with unresectable stage III non-small cell lung cancer (NSCLC): A preliminary report
    JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S786 - S787
    09/01/2009 Authors: Ramalingam SS; Kotsakis AP; Heron D; Tahini AA; Burton SA; Smith R; Gooding W; Friedland D; Petro D; Flaugh R
  • Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues.
    Cancer Biol Ther Volume: 8 Page(s): 1463 - 1469
    08/01/2009 Authors: Fan S; Ramalingam SS; Kauh J; Xu Z; Khuri FR; Sun S-Y
  • Duration of chemotherapy for metastatic non-small-cell lung cancer: more may be better after all.
    J Clin Oncol Volume: 27 Page(s): 3265 - 3267
    07/10/2009 Authors: Schiller JH; Ramalingam SS
  • Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium.
    Volume: 4 Page(s): 930 - 935
    07/01/2009 Authors: Camidge R; Gaspar L; Goss G; Kelly K; Ramalingam S; Reckamp K; Simon G; Tsao M; West HJ; Herbst R
  • The role of cetuximab in the management of non-small-cell lung cancer.
    Clin Lung Cancer Volume: 10 Page(s): 230 - 238
    07/01/2009 Authors: Owonikoko TK; Sun S-Y; Ramalingam SS
  • Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study
    Volume: 27
    05/20/2009 Authors: Khuri FR; Harvey RD; Saba NF; Owonikoko TK; Kauh J; Shin DM; Sun SY; Browning KM; Tighiouart M; Ramalingam SS
  • Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors.
    J Clin Oncol Volume: 27 Page(s): 2545
    05/20/2009 Authors: Wu H; Ramanathan RK; Srychor S; Zamboni BA; Ramalingam S; Edwards RP; Friedland DM; Stoller RG; Belani CP; Zamboni WC
  • Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study.
    J Clin Oncol Volume: 27 Page(s): 8060
    05/20/2009 Authors: Khuri FR; Harvey RD; Saba NF; Owonikoko TK; Kauh J; Shin DM; Sun SY; Browning KM; Tighiouart M; Ramalingam SS
  • Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)
    Volume: 27
    05/20/2009 Authors: Ramalingam SS; Maitland M; Frankel P; Argiris AE; Koczywas M; Gitlitz B; Espinoza-Delgado I; Vokes EE; Gandara DR; Belani CP
  • Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors
    Volume: 27
    05/20/2009 Authors: Wu H; Ramanathan RK; Srychor S; Zamboni BA; Ramalingam S; Edwards RP; Friedland DM; Stoller RG; Belani CP; Zamboni WC
  • A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. A California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial
    Volume: 27
    05/20/2009 Authors: Gitlitz BJ; Davies AM; Belani CP; Argiris A; Ramalingam SS; Hoffman PC; Koczwas M; Groshen SG; Gandara DR
  • The histone deacetylase inhibitor, vorinostat, increases carboplatin and paclitaxel activity in non-small cell lung cancer cells.
    CANCER RESEARCH Volume: 69
    05/01/2009 Authors: Owonikoko T; Ramalingam S; Kanterewicz B; Balius T; Belani C; Hershberger P
  • Erlotinib enhances RAD001\#8217;s anticancer activity in vivo involving abrogation of mTOR inhibition-induced eIF4E phosphorylation
    Volume: 69
    05/01/2009 Authors: Fan S; Wang X; Yue P; Kauh J; Ramalingam S; Khuri F; Sun S-Y
  • The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer.
    Oncologist Volume: 14 Page(s): 412 - 424
    04/01/2009 Authors: Ramalingam SS; Khuri FR
  • Diallyl trisulfide selectively causes Bax- and Bak-mediated apoptosis in human lung cancer cells.
    Environ Mol Mutagen Volume: 50 Page(s): 201 - 212
    04/01/2009 Authors: Xiao D; Zeng Y; Hahm E-R; Kim Y-A; Ramalingam S; Singh SV
  • Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
    Clin Lung Cancer Volume: 10 Suppl 1 Page(s): S17 - S23
    03/01/2009 Authors: Pakkala S; Ramalingam SS
  • Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
    Clin Cancer Res Volume: 15 Page(s): 1466 - 1472
    02/15/2009 Authors: Zamboni WC; Ramalingam S; Friedland DM; Edwards RP; Stoller RG; Strychor S; Maruca L; Zamboni BA; Belani CP; Ramanathan RK
  • Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
    Clin Ther Volume: 31 Pt 2 Page(s): 2444 - 2458
    01/01/2009 Authors: Venkatakrishnan K; Rader M; Ramanathan RK; Ramalingam S; Chen E; Riordan W; Trepicchio W; Cooper M; Karol M; von Moltke L
  • Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
    J Thorac Oncol Volume: 4 Page(s): 97 - 101
    01/01/2009 Authors: Ramalingam SS; Belani CP; Ruel C; Frankel P; Gitlitz B; Koczywas M; Espinoza-Delgado I; Gandara D
  • The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC).
    Curr Treat Options Oncol Volume: 9 Page(s): 313 - 325
    12/01/2008 Authors: Owonikoko TK; Ramalingam S
  • Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
    Cancer Biol Ther Volume: 7 Page(s): 1952 - 1958
    12/01/2008 Authors: Wang X; Hawk N; Yue P; Kauh J; Ramalingam SS; Fu H; Khuri FR; Sun S-Y
  • Minimal progress, potential promise in small-cell lung cancer.
    Oncology (Williston Park) Volume: 22 Page(s): 1495 - 1496
    11/30/2008 Authors: Owonikoko T; Ramalingam S
  • Management of Small-Cell Lung Cancer: Incremental Changes but Hope for the Future The Hann/Rudin Article Reviewed
    ONCOLOGY-NEW YORK Volume: 22 Page(s): 1495 - 1496
    11/30/2008 Authors: Owonikoko T; Ramalingam S
  • Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.
    Cancer Volume: 113 Page(s): 2512 - 2517
    11/01/2008 Authors: Belani CP; Schreeder MT; Steis RG; Guidice RA; Marsland TA; Butler EH; Ramalingam SS
  • Recent advances in the treatment of malignant pleural mesothelioma.
    J Thorac Oncol Volume: 3 Page(s): 1056 - 1064
    09/01/2008 Authors: Ramalingam SS; Belani CP
  • Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Cancer Volume: 113 Page(s): 542 - 546
    08/01/2008 Authors: Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
  • A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
    Clin Cancer Res Volume: 14 Page(s): 3456 - 3461
    06/01/2008 Authors: Ramalingam SS; Egorin MJ; Ramanathan RK; Remick SC; Sikorski RP; Lagattuta TF; Chatta GS; Friedland DM; Stoller RG; Potter DM
  • Gene expression profiling of non-small cell lung cancer.
    Lung Cancer Volume: 60 Page(s): 313 - 324
    06/01/2008 Authors: Singhal S; Miller D; Ramalingam S; Sun S-Y
  • Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097)
    JOURNAL OF CLINICAL ONCOLOGY Volume: 26
    05/20/2008 Authors: Ramalingam SS; Mack PC; Vokes EE; Longmate J; Govindan R; Koczywas M; Ivy SP; Belani CP; Gandara DR
  • Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results.
    Clin Lung Cancer Volume: 9 Page(s): 141 - 143
    05/01/2008 Authors: Lara PN; Ramalingam SS
  • Management of a patient with stage IIIA (N2) NSCLC.
    Oncology (Williston Park) Volume: 22 Page(s): 553 - 557
    04/30/2008 Authors: Carlson K; Fowler BZ; Miller DL; Gal A; Ramalingam S
  • Small cell lung cancer in elderly patients: a review.
    J Natl Compr Canc Netw Volume: 6 Page(s): 333 - 344
    03/01/2008 Authors: Owonikoko TK; Ramalingam S
  • Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
    J Thorac Oncol Volume: 3 Page(s): 258 - 264
    03/01/2008 Authors: Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
  • Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Volume: 26 Page(s): 468 - 473
    01/20/2008 Authors: Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
  • Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
    J Clin Oncol Volume: 26 Page(s): 60 - 65
    01/01/2008 Authors: Ramalingam SS; Dahlberg SE; Langer CJ; Gray R; Belani CP; Brahmer JR; Sandler AB; Schiller JH; Johnson DH; Eastern Cooperative Oncology Group
  • Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Semin Thorac Cardiovasc Surg Volume: 20 Page(s): 217 - 223
    01/01/2008 Authors: Harichand-Herdt S; Ramalingam SS
  • Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
    Oncologist Volume: 13 Suppl 1 Page(s): 5 - 13
    01/01/2008 Authors: Ramalingam S; Belani C
  • Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database.
    J Clin Oncol Volume: 25 Page(s): 5570 - 5577
    12/10/2007 Authors: Owonikoko TK; Ragin CC; Belani CP; Oton AB; Gooding WE; Taioli E; Ramalingam SS
  • Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study
    JOURNAL OF THORACIC ONCOLOGY Volume: 2 Page(s): S468 - S468
    08/01/2007 Authors: Ramalingam SS; Dahlberg SE; Langer CJ; Gray R; Belani CP; Brahmer JR; Sandler A; Schiller JH; Johnson DH
  • Targeted therapy for non-small cell lung cancer: beyond EGFR and VEGF
    JOURNAL OF THORACIC ONCOLOGY Volume: 2 Page(s): S220 - S221
    08/01/2007 Authors: Ramalingam SS
  • Phase II study of irinotecan and paclitaxel for patients with recurrent small cell lung cancer (SCLC)
    Volume: 25
    06/20/2007 Authors: Owonikoko TK; Ramalingam S; Forster J; Shuai Y; Evans T; Gooding WE; Sulecki M; Belani CP
  • Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
    Clin Cancer Res Volume: 13 Page(s): 3605 - 3610
    06/15/2007 Authors: Ramalingam SS; Parise RA; Ramanathan RK; Lagattuta TF; Musguire LA; Stoller RG; Potter DM; Argiris AE; Zwiebel JA; Egorin MJ
  • Role of bevacizumab for the treatment of non-small-cell lung cancer.
    Future Oncol Volume: 3 Page(s): 131 - 139
    04/01/2007 Authors: Ramalingam S; Belani CP
  • Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
    Clin Cancer Res Volume: 13 Page(s): 1769 - 1774
    03/15/2007 Authors: Ramanathan RK; Egorin MJ; Eiseman JL; Ramalingam S; Friedland D; Agarwala SS; Ivy SP; Potter DM; Chatta G; Zuhowski EG
  • Recent advances in targeted therapy for non-small cell lung cancer.
    Expert Opin Ther Targets Volume: 11 Page(s): 245 - 257
    02/01/2007 Authors: Ramalingam S; Belani CP
  • Radiosurgery for the treatment of spinal lung metastases.
    Cancer Volume: 107 Page(s): 2653 - 2661
    12/01/2006 Authors: Gerszten PC; Burton SA; Belani CP; Ramalingam S; Friedland DM; Ozhasoglu C; Quinn AE; McCue KJ; Welch WC
  • An open-label study to characterize the pharmacokinetic (pk) parameters of erlotinib in patients with advanced solid tumors with adequate or moderately impaired hepatic function
    EJC SUPPLEMENTS Volume: 4 Page(s): 126 - 127
    11/01/2006 Authors: O'Bryant C; Eckhardt S; Hariharan S; Leong S; Belani C; Ramanathan R; Boinpally R; Gibbs A; Witt K; Ramalingam S
  • A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum.
    J Chromatogr B Analyt Technol Biomed Life Sci Volume: 840 Page(s): 108 - 115
    08/18/2006 Authors: Parise RA; Holleran JL; Beumer JH; Ramalingam S; Egorin MJ
  • Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in pati nts with advanced solid tumors.
    Volume: 24 Page(s): 82S - 82S
    06/20/2006 Authors: Zamboni WC; Friedland DM; Ramalingam S; Edwards RP; Stoller RG; Belani CP; Strychor S; Ou YC; Tonda ME; Ramanathan RK
  • Lung cancer in patients >= 80 years of age: Analysis of the national surveillance, epidemiology and end results (SEER) database.
    Volume: 24 Page(s): 403S - 403S
    06/20/2006 Authors: Owonikoko TK; Belani C; Cai C; Oton A; Potter D; Ramalingam S
  • A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC.
    Volume: 24 Page(s): 391S - 391S
    06/20/2006 Authors: Belani CP; Ramalingam S; Al-Janadi A; Eskander E; Ghazal H; Schwatzberg L; Elliott M; Shahin S; Dreiling L
  • Phase I, pharmacokinetic (PK), & pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, (17DMAG, NSC 707545) in patients with advanced solid tumors.
    Volume: 24 Page(s): 126S - 126S
    06/20/2006 Authors: Egorin MJ; Belani CP; Remick SC; Erlichman C; Teneyck CJ; Holleran JL; Ivy SP; Ramalingam S; Naret CL; Ramanathan RK
  • Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor.
    Volume: 24 Page(s): 79S - 79S
    06/20/2006 Authors: Holen KD; Belani CP; Wilding G; Ramalingam S; Heideman JL; Ramanathan RK; Bowen CJ; Williams DD; Hodge JP; Dar MM
  • Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
    Oncologist Volume: 11 Page(s): 655 - 665
    06/01/2006 Authors: Ramalingam S; Sandler AB
  • Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.
    Am J Clin Pathol Volume: 125 Page(s): 860 - 865
    06/01/2006 Authors: Dacic S; Flanagan M; Cieply K; Ramalingam S; Luketich J; Belani C; Yousem SA
  • Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial.
    J Thorac Oncol Volume: 1 Page(s): 240 - 244
    03/01/2006 Authors: Ramalingam S; Barstis J; Perry MC; La Rocca RV; Nattam SR; Rinaldi D; Clark R; Mills GM; Belani CP
  • First-line chemotherapy for advanced-stage non-small-cell lung cancer: focus on docetaxel.
    Clin Lung Cancer Volume: 7 Suppl 3 Page(s): S77 - S82
    12/01/2005 Authors: Ramalingam S
  • Molecularly-targeted therapies for non-small cell lung cancer.
    Expert Opin Pharmacother Volume: 6 Page(s): 2667 - 2679
    12/01/2005 Authors: Ramalingam S; Belani CP
  • Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small-cell lung carcinoma treated with 3-dimensional conformal radiation therapy with or without concurrent chemotherapy.
    Clin Lung Cancer Volume: 7 Page(s): 100 - 106
    09/01/2005 Authors: Wolski MJ; Bhatnagar A; Flickinger JC; Belani CP; Ramalingam S; Greenberger JS
  • Phase III randomized trial comparing weekly vs. standard schedules of paclitaxel (P) plus carboplatin (C) for advanced non-small cell lung cancer (NSCLC): Analyses of elderly patients
    Volume: 49 Page(s): S32 - S32
    07/01/2005 Authors: Belani C; Ramalingam S; Perry M; LaRocca R; Rinaldi D; Gable P; Tester W
  • Meta-analysis of weekly paclitaxel as maintenance therapy for advanced non-small cell lung cancer (NSCLC) patients following intitial chemotherapy
    Volume: 49 Page(s): S33 - S33
    07/01/2005 Authors: Belani C; Barstis J; LaRocca R; Tester W; Gable P; Perry M; Ramalingam S
  • Correlation between epidermal growth factor receptor (EGFR) protein expression (PE) and gene amplification (GA) in non-small cell lung carcinoma (NSCLC)
    Volume: 49 Page(s): S72 - S72
    07/01/2005 Authors: Ramalingam S; Dacic S; Flanagan M; Cleply K; Luketich J; Yousem S; Belani C
  • Molecular predictors of sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor: confusion or clarity?
    Clin Lung Cancer Volume: 7 Page(s): 8
    07/01/2005 Authors: Belani CP; Ramalingam S
  • Analysis of elderly (>= 65 yrs) patients' participation on early phase I clinical trials at two NCI-designated Comprehensive Cancer Centers
    Volume: 23 Page(s): 762S - 762S
    06/01/2005 Authors: Savvides P; Egorin MJ; Gerson S; Ramanathan RK; Berger NA; Ramalingam S; Hoppel C; Belani CP; Remick S; Chatta GS
  • Phase I and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors.
    Volume: 23 Page(s): 145S - 145S
    06/01/2005 Authors: Marshall JL; Ramalingam S; Hwang JJ; Ramanathan R; Malik S; Egorin M; Hannah A; Cropp GF; Johnson RG; Belani C
  • Phase I and pharmacokinetic (PK) study of STEALTH liposomal CKO-602 (S-CKD602) in patients with advanced solid tumors.
    Volume: 23 Page(s): 152S - 152S
    06/01/2005 Authors: Zamboni WC; Ramalingam S; Friedland DM; Belani CP; Stoller RG; Modi NB; Nath RP; Tonda ME; Strychor S; Ramanathan RK
  • Outcome of elderly (>= 70 years) non-small cell lung cancer (NSCLC) patients on a multicenter, phase III randomized trial comparing weekly vs. standard schedules of paclitaxel (P) plus carboplatin (C).
    Volume: 23 Page(s): 657S - 657S
    06/01/2005 Authors: Ramalingam S; Perry MC; Larocca RV; Rinaldi DA; Gable P; Tester WJ; Belani CP
  • Phase I study to determine tolerability and pharmacolkinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor.
    Volume: 23 Page(s): 137S - 137S
    06/01/2005 Authors: Holen KD; Belani CP; Wilding G; Ramalingam S; Volkman JL; Ramanathan RK; Bowen CJ; Williams DD; Dar MM; Ho PTC
  • Correlation between epidermal growth factor receptor (EGFR) protein expression (PE) and gene amplification (GA) in non-small cell lung carcinoma (NSCLC).
    Volume: 23 Page(s): 640S - 640S
    06/01/2005 Authors: Dacic S; Ramalingam S; Flanagan M; Cieply K; Luketich JD; Belani CP; Yousem S
  • Phase I study (twice weekly schedule) of 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced refractory tumors.
    Volume: 23 Page(s): 204S - 204S
    06/01/2005 Authors: Ramanathan RK; Belani CP; Friedland D; Ramalingam S; Agarwala SS; Ivy P; Potter D; Chatta G; Zuhowski E; Egorin MJ
  • Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
    Clin Cancer Res Volume: 11 Page(s): 3385 - 3391
    05/01/2005 Authors: Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S
  • Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.
    Ann Oncol Volume: 16 Page(s): 780 - 785
    05/01/2005 Authors: Mohamed MK; Ramalingam S; Lin Y; Gooding W; Belani CP
  • Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
    Cancer Chemother Pharmacol Volume: 55 Page(s): 354 - 360
    04/01/2005 Authors: Ramanathan RK; Ramalingam S; Egorin MJ; Belani CP; Potter DM; Fakih M; Jung LL; Strychor S; Jacobs SA; Friedland DM
  • Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer.
    Clin Lung Cancer Volume: 6 Page(s): 267 - 268
    03/01/2005 Authors: Belani CP; Ramalingam S
  • Exploring the future of non-small cell lung cancer treatment.
    Manag Care Volume: 14 Page(s): 9 - 13
    02/01/2005 Authors: Ramalingam S
  • Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
    Clin Lung Cancer Volume: 6 Page(s): 203 - 204
    01/01/2005 Authors: Belani CP; Ramalingam S
  • Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.
    Pharmacotherapy Volume: 24 Page(s): 1232 - 1235
    09/01/2004 Authors: Ramalingam S; Lagattuta TF; Egorin MJ; Hayes MJ; Ramanathan RK
  • Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer.
    Clin Lung Cancer Volume: 6 Page(s): 79 - 82
    09/01/2004
  • Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors.
    Clin Lung Cancer Volume: 6 Page(s): 74 - 76
    09/01/2004
  • Paclitaxel for non-small cell lung cancer.
    Expert Opin Pharmacother Volume: 5 Page(s): 1771 - 1780
    08/01/2004 Authors: Ramalingam S; Belani CP
  • Skin rash and good performance status (PS) predict improved survival with gefitinib for patients with advanced non-small cell lung cancer (NSCLC).
    Volume: 22 Page(s): 640S - 640S
    07/15/2004 Authors: Mohamed MK; Ramalingam S; Lin Y; Gooding WE; Cronin W; Eckardt JR; Belani CP
  • Carboplatin/gemcitabine combination in advanced NSCLC.
    Oncology (Williston Park) Volume: 18 Page(s): 21 - 26
    07/01/2004 Authors: Ramalingam S; Belani CP
  • Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study.
    Cancer Chemother Pharmacol Volume: 53 Page(s): 439 - 444
    05/01/2004 Authors: Ramalingam S; Dobbs TW; Einzig AI; Wojtowicz-Praga S; Cascino M; Bonomi P; Belani CP
  • Smoking cessation and treatment outcome.
    Clin Lung Cancer Volume: 5 Page(s): 264
    03/01/2004 Authors: Belani CP; Ramalingam S
  • State-of-the-art chemotherapy for advanced non-small cell lung cancer.
    Semin Oncol Volume: 31 Page(s): 68 - 74
    02/01/2004 Authors: Ramalingam S; Belani CP
  • Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
    Volume: 5 Page(s): 142 - 147
    11/01/2003
  • 2003 highlights from: 10th World Congress on Lung Cancer.
    Volume: 5 Page(s): 78 - 82
    09/01/2003 Authors: Tyagi F; Lee D
  • Meaningful survival in lung cancer patients.
    Semin Oncol Volume: 29 Page(s): 125 - 131
    02/01/2002 Authors: Ramalingam S; Belani CP
  • Meaningful survival in lung cancer patients
    SEMINARS IN ONCOLOGY Volume: 29 Page(s): 125 - 131
    02/01/2002 Authors: Ramalingam S; Belani CP
  • Lung cancer in patients < 50 years of age: the experience of an academic multidisciplinary program.
    Chest Volume: 115 Page(s): 1232 - 1236
    05/01/1999 Authors: Gadgeel SM; Ramalingam S; Cummings G; Kraut MJ; Wozniak AJ; Gaspar LE; Kalemkerian GP
  • Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database.
    J Clin Oncol Volume: 16 Page(s): 651 - 657
    02/01/1998 Authors: Ramalingam S; Pawlish K; Gadgeel S; Demers R; Kalemkerian GP
  • Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines.
    J Natl Cancer Inst Volume: 87 Page(s): 1674 - 1680
    11/15/1995 Authors: Kalemkerian GP; Slusher R; Ramalingam S; Gadgeel S; Mabry M
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2024 Emory University
  • Privacy Policy
  • Emergency Information